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ABSTRACT
This study describes the optimization of expression of the bacterial luciferase
enzyme in mammalian cells. Previous attempts to express this heterodimeric enzyme
complex in mammalian cells have been met with only modest success. In this research
effort, several vector formats were evaluated to fully determine the optimal format for
the expression of these genes. It was determined that the bacterial luciferase enzyme
produced optimal bioluminescence in mammalian cells when the genes were cloned and
expressed as a bicistronic transcript fused with an internal ribosomal entry site (IRES).
To optimize the enzyme expression further, a novel approach to codon optimize
the genes was performed. To accomplish this task, completely synthetic versions of the
codon optimized sequences were generated. This codon optimization, led to an increase
in bioluminescence levels greater than two orders of magnitude versus the wild type
genes.
Additionally, the availability of the FMNH2 substrate was evaluated and
determined to be a limiting substrate for the reaction. In an attempt to alleviate this
limitation, a flavin oxidoreductase gene (frp) from Vibrio harveyi was cloned and
expressed along with the codon optimized luxA and luxB genes. Although the
expression of this enzyme enhanced the bioluminescence significantly, FMNH2 remains
the limiting substrate for optimal bioluminescence.
To produce a usable reporter cell line, the reporter must remain stable within the
cells for long periods of time. The overall stability of the engineered cells was assessed
to determine the persistence of the reporter for long-term monitoring applications.
These data revealed that the luciferase genes were stable in HEK293 cells for more than
v

forty passages (five months) in culture in the absence of antibiotic, indicating that these
cell lines would be stable enough for relatively long term monitoring projects and
applications.
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CHAPTER 1
INTRODUCTION
Background and Research Objectives
Bacterial luciferase is a powerful reporter protein system since it allows for the
development of real-time autonomous sensors that the invasive manipulations required
by other reporter proteins do not permit. Mammalian cell lines expressing reporter
proteins have been widely used in both basic and applied research for the investigation
of a variety of cellular functions. These applications include, but are not limited to,
promoter analysis (Guignard et al., 1998; Zhang et al., 1997), identification of
transcription factors (Ichiki et al., 1998; Schwechheimer et al., 1998), discovery of
genes that are potential targets for disease (Watson et al., 1998) evaluation of cross talk
mechanisms (Naylor, 1999), and in vivo sensing of tumor and/or disease progression
(Contag et al., 1998). However, current mammalian bioreporter technology is limited
due to its inability to function as a stand-alone, real-time reporter in vivo. Current
methodologies that use firefly luciferase (Luc) and green fluorescent protein (GFP)
reporter systems in mammalian cells require lysis and substrate addition or exogenous
excitation, respectively, to produce a measurable response. Consequently, these cells
cannot serve as continuous on-line monitoring devices. Bacterial luciferase is unique in
that it is the only bioreporter system available that generates its own substrate, thus
eliminating the need for cell destruction or exogenous substrate addition.
Extensive work has been published using the bacterial lux system in prokaryotic
organisms for the development of whole cell biosensors (Simpson et al., 1998; Sayler et
1

al., 2001; Ripp et al., 2000; Corbiser et al., 1999; Kohler et al., 2000; King et al., 1990,
and VanDyk et al., 2001), advancements in biocomputing applications (Simpson et al.,
2001) and in vivo imaging models (Contag et al., 1998 and Francis et al., 2001).
Recently, a lux-based yeast reporter cell line has been developed for the detection of
estrogenic compounds (Gupta et al., 2003). This research was the first successful
attempt to express the complete lux operon required for autonomous bioluminescence in
a eukaryotic organism. Unfortunately, this technology has yet to be successfully
implemented into mammalian cells. Several attempts by various groups have been made
to express bacterial luciferase enzyme in mammalian cells. These efforts have been met
with only modest success as numerous obstacles have been encountered preventing
efficient expression of the lux proteins. A major effort and the first step required to
realize the ultimate potential of this technology is to achieve efficient expression of the
heterodimeric luciferase (luxA and luxB) protein.
The bacterial luciferase enzyme is a heterodimeric protein complex made up of
an α and β subunit encoded by the genes luxA and luxB, respectively. Because it is not
possible to express multiple genes as a polycistronic operon in eukaryotes, alternate
expression platforms are needed to obtain optimal thermostability and proper folding
which should aid in obtaining an adequate bioluminescent signal from mammalian cells.
Furthermore, the availability of the co-factors required for the lux reaction including
FMNH2 and O2 in mammalian cells has been suspected to be inadequate and levels need
to be evaluated. Other strategies for bioluminescence optimization and possible gene
amplification have not been previously pursued and the potential is unknown. This
avenue of research may result in a mammalian cell line able to produce the
2

bioluminescent levels required for sensitive monitoring of target analytes. Also, for an
autonomously driven bioluminescent mammalian cell line to realize its full
technological potential, the expression system must remain stable for long periods of
time without the need for selective pressure. The stability of mammalian cell lines
harboring the luciferase protein remains a question and needs to be evaluated. In
response to these questions, the following hypotheses are tested in this research:

•

Hypothesis 1: Expression of the bacterial luciferase (lux) subunits as individual
proteins rather than as a monomeric translational fusion results in efficient
folding and thermostability resulting in a higher bioluminescent signal in
mammalian cells.

•

Hypothesis 2: Codon optimization of the bacterial luciferase (lux) genes is
required to significantly enhance translation of the message and ultimately result
in greater bioluminescence levels from mammalian cells harboring these
optimized genes.

•

Hypothesis 3: Stably integrated constructs will be persistent in the absence of
selective pressure for long periods of time.

•

Hypothesis 4: Mammalian cells possess or can be engineered to express
adequate available concentrations of the required co-factor FMNH2 for efficient
bioluminescence
3

Literature Review
Reporter Gene Technology
Reporter genes are defined as genes that produce a measurable phenotype that
can be distinguished from other proteins within a cell (Alam and Cook, 1990). The use
of reporter genes for applied technologies requires that the signal be easily detected and
respond rapidly, possess a linear response to the target analyte for quantification and
produce a reproducible signal (Naylor, 1999 and Wood, 1995). Several reporter
proteins have been shown to be valuable tools for advancing both basic and applied
research. Examples of such basic applications include the development of reporter
fusions for the identification and analysis of promoter regions (Guignard et al., 1998;
Zhang et al., 1997), identification of transcription factors and induction/repression
schemes (Ichiki et al., 1998; Schwechheimer et al., 1998), as well as the discovery of
genes as potential targets for disease (Watson et al., 1998) and evaluation of cross talk
and signal transduction mechanisms (Naylor, 1999). Furthermore, reporter gene fusions
have been utilized for the creation of whole cell biosensors for environmental
monitoring (King et al., 1990; Ripp et al., 2000 and Kohler et al., 2000), advancement
of biocomputing applications (Simpson et al., 2001) and in vivo imaging of disease
onset and progression (Francis et al., 2001) as well as drug efficacy screening (Contag
et al., 1998).
Reporter genes can be used to study any pathway that is controlled on a
transcriptional level. The signals produced are responses to alterations in either gene
regulation or expression within the cell (Wood, 1995). Eukaryotic reporter systems
require receptor proteins for sensing and shuttling of analyte compounds. These
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analytes can be extracellular signals that are either detected on the cell surface and
trigger intracellular signal transduction pathways or bind an intracellular receptor which
can subsequently bind to specific response elements resulting in transcriptional
activation (Naylor, 1999). In either case, by fusing reporter proteins to promoter
elements within the target pathway, when promoter induction occurs, the reporter
protein is generated and a detectible phenotypic change occurs within the cell (Figure
1). This reporter signal is then measured and provides a simple way to determine if and
when a particular analyte affects gene expression (Levitzki, 1996). In prokaryotic
reporter cell schemes, generally the target analyte can bind directly to the promoter or
repressor element and induce transcription directly (Figure 2) (Kohler et al., 2000).
Nevertheless, in either case the ultimate outcome is the same and a detectable and often
times quantifiable signal is produced.

Reporter Genes and Proteins
Several reporter proteins have been shown to be valuable tools in various areas
of research. In order for a reporter protein to be useful, the generated signal must have
a low endogenous background level in the host cell and produce an easily detectable
response. Choice of the optimal reporter protein for individual applications is essential
for success. There are several criteria that should be considered in the selection process
of a reporter gene. (1) The reporter protein should be absent from the host to prevent
complications in distinguishing signal from background noise. (2) The assay for signal
detection should either be established or easily measured in a rapid, simple, and cost-
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Figure 1. Schematic representation of a generalized eukaryotic bioreporter cell.
Response elements (RE) are specific for the target analyte.
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Figure 2. Schematic diagram of a generalized prokaryotic bioreporter cell. The
promoter region is specific for the target analyte.
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effective manor. (3) In order to analyze induction of both small and large changes in
transcriptional activation, the reporter should have a large linear dynamic range for its
response (4) The expression of the reporter gene must not effect the overall physiology
of the cell (Ausubel et al., 1997). Each reporter protein identified to date has distinct
advantages and disadvantages for application. Table 1 summarizes some of these
differences between a few of the more commonly used reporter proteins available.
There are two main classes of reporter assays available, in vitro and whole-cell
bioassays. In vitro reporter applications refer to the protocols in which the
transcriptional activation is quantified in cell lysates or in the media from excreted
proteins. The measurement can be a direct quantification of the protein or an indirect
response to enzymatic or immunological stimulation (Alam and Cook, 1990). Although
these methodologies may be useful under certain circumstances, in vivo or whole cell
assays provide more reliable data for studies comparing promoter strengths, enhancer
regions and determining other cell requirements. Of all of the known reporter proteins,
the bacterial luciferase (lux) has the distinct advantage in that it is the only bioreporter
system available able to make its own substrate and generate an autonomous signal.
This property has made the bacterial bioluminescence reporter system an invaluable
tool for the creation of whole cell biosensors for remote sensing in prokaryotic
organisms (Sayler et al., 2001). Unfortunately, the one caveat in this technology to date
is that it has not been efficiently expressed in mammalian cells limiting its full potential
(Meighen, 1991 and Naylor, 1999).
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Table 1. Comparison of commonly used reporter proteins used for sensing
applications.
Reporter
Advantage
Disadvantage
Chloramphenicol
acetyltransferase (CAT)
β-galactosidase
Firefly luciferase (LUC)
Green Fluorescent Protein
(GFP)
Bacterial luciferase (lux)

No endogenous activity.
Automated detection
(ELISA)
Stable, Simple colorimetric
and chemiluminescent
assay available.
High specific activity, no
endogenous activity, easily
detectable
Autofluorescent
Mutants with altered
spectral qualities available.
Broad dynamic range,
easily measured, no
exogenous substrate
addition required.
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Requires the addition of
substrate and separation of
substrate and product.
Endogenous activity
(mammalian cell). Requires
the addition of substrate.
Requires addition of
substrate (luciferin), O2 and
ATP.
Moderate sensitivity.
Background fluorescence
may interfere. Requires
exogenous excitation
Requires O2 only
expressed in prokaryotes

Bacterial Bioluminescence
Organisms able to generate light have intrigued researchers for centuries.
Species able to produce bioluminescence are diverse, ranging from fireflies and
mushrooms to dinoflagellates and bacteria (Harvey, 1952). The luciferase enzymes
involved in the catalysis of the bioluminescence reaction are also evolutionarily very
diverse with the only one true commonality being that they all require O2 as a co-factor
(Fisher et al., 1996).
Bioluminescent bacteria are the most abundant of the light emitting organisms
(Meighen, 1991). They can be found in a high abundance in marine, freshwater and
terrestrial environments (Hastings et al., 1985). Most bioluminescent bacteria have
been classified into three genera: Vibrio, Photobacterium and Photorhabdus (formerly
Xenorhabdus). Organisms belonging to the first two genera generally can be found in
marine environments. These organisms have been identified as free-living planktonic
bacteria and symbionts with a variety of fish and squid species (Wilson and Hastings,
1998). The Photorhabdus genus contains strains that can colonize terrestrial organisms
and tend to be found acting in symbiosis with worms and caterpillars (Farmer et al.,
1989 and Colepicolo et al., 1989).

Biochemistry of Bacterial Bioluminescence
In all bioluminescent organisms, the enzymes that catalyze the luminescent
reaction are referred to as luciferases, while the required substrates are luciferins
(Wilson and Hastings, 1998). Further, this light producing reaction requires molecular
O2, the reducing power of FMNH2 and the energy of ATP as co-factors and substrates.
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The bacterial luciferase enzyme is a heterodimeric protein encoded by the luxA
and luxB genes. The heterodimeric complex forms a 77 kDa enzyme comprised of α
(40 kDa) and β (37 kDa) subunit polypeptides. Because the subunits are related (>30%
amino acid homology) they are thought to be products of a gene duplication event
(Baldwin et al., 1979). The complete luciferase enzyme is a flavin monooxygenase that
binds a reduced flavin molecule as a specific substrate. However, only the α subunit
carries the active center (Fisher et al., 1995). A specific role of for the β subunit has not
become clear, but its presence is essential for a high quantum yield reaction (Baldwin et
al., 1995). Nevertheless, the β subunit has been shown to have some impact on the
enzyme’s thermostability (Meighen et al., 1971; Cline and Hastings, 1972 and Szittner
and Meighen, 1990), binding of FMNH2 (Cline, 1973; Meighen and Bartlett, 1980;
Welch and Baldwin, 1981 and Watanabe et al., 1982) as well as efficient binding of
aldehyde (Tu and Henkin, 1983).
All bacterial luciferases studied to date catalyze the same overall reaction:
FMNH2 + O2 + RCHO Æ FMN + RCOOH + H2O + hv (λmax = 490nm)

The natural aldehyde for the reaction is thought to be tetradecanal in most
species of luminescent bacteria, however, the more thermostable forms of luciferase
(Vibrio harveyi and Photorhabdus luminescens) tend to produce higher
bioluminescence in the presence of dodecanal and decanal (Schmidt et al., 1989). The
general 1:1 stoichiometry of the luciferase subunits is conserved throughout all species
of bioluminescent bacteria known (Meighen, 1991). However, the amino acid sequence
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of each polypeptide is somewhat diverse. Certain motifs within the luciferase enzyme
are conserved throughout. There is a 60-85% identity between amino acid sequences of
the α subunit of reported various Vibrio, Photobacterium and Photorhabdus species
while the β subunit is less conserved with a 50-65% identity (Szittner and Meighen,
1990). The higher conservation of the α subunit sequence may be a direct reflection for
the need to conserve the active center and catalytic properties of luciferase (Meighen et
al., 1971).
Although the aldehyde substrate is not necessary for the luciferase reaction
itself, its presence significantly increases the light output kinetics (Volkova et al., 1999).
The genes required for synthesis of aldehydes are catalyzed by a multienzyme fatty acid
reductase and synthase (Rodriduez et al., 1983). These genes are all located within the
lux operon of all bioluminescent bacteria. Generally, the reductase (luxC) and
transferase (luxD) are located upstream of the luxA and luxB luciferase genes while the
synthase (luxE) gene is located immediately downstream. The primary reaction
catalyzed by this system is the reduction of fatty acids by the reductase and synthase
enzymes. The synthase acts to activate the fatty acid, which results in a fatty acyl-AMP
intermediate that remains bound to the enzyme. The acyl group is then transferred to
the synthase and then further transferred to the reductase, where it becomes reduced by
NAD(P)H to the corresponding aldehyde. The transferase subunit is responsible for the
transfer of activated fatty acyl groups. The fatty acid is then recycled. Each
multienzyme complex responsible for this reaction has been found to consist of a
central tetramer of reductase subunits bound to one synthase and one weakly associated
transferase subunit (Li et al., 2000).
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To produce light, the bioluminescence reaction appears to go through several
intermediate steps. With a stoichiometry of 1:1:1, the α and β subunits bind with a
reduced flavin molecule (FMNH2) to form a C4a hydroxyflavin. As this hydroxyflavin
becomes dehydrated to FMN, a blue-green light is emitted (Baldwin et al., 1979). A
schematic diagram of the overall reaction is shown in Figure 3. This enzymatic reaction
has a relatively slow turnover rate.
The luciferase subunits have been shown to fold independently and interact
during the folding process. They then form an active heterodimeric complex following
isomerization (Ziegler et al., 1991). However, because of the relatedness of the two
subunits, if they are present individually (in the absence of the other subunit) they tend
to form inactive homodimers that cannot refold into the active heterodimeric form
(Waddle et al, 1987 and Ziegler et al., 1991). Because of this complex stoichiometric
requirement for folding, there is a lag time of at least three to four minutes to complete
an active enzyme after translation of the subunit polypeptides (Ziegler et al., 1993). A
schematic diagram of the folding pattern of the luciferase subunits is shown in Figure 4.

Thermostability of Bacterial Luciferase
Bacterial luciferase (lux) genes cloned from various species of luminescent
bacteria have been used to create a myriad of reporter constructs. Given that the lux
operons from V. fischeri and V. harveyi were the first to be cloned (Engebrecht et al.,
1983 and Cohn et al., 1983), the vast majority of these clones are derived from these
sequences. However, just as selection of the appropriate reporter for individual
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Figure 3. Biochemistry of the bacterial bioluminescence reaction. (Figure Courtesy of A. Heitzer.)
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Figure 4. Schematic representation of the folding of an active luciferase (αβ). luxA
and luxB represent the individual genes, u denotes the unfolded form of
the polypeptides, i denotes the inactive form before dimerization, and x
denotes the homodimeric form that can no longer form an active
luciferase. Figure adapted from Zeigler et al., 1993.
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applications is important, the selection of the appropriate luciferase is equally critical.
A key difference between luciferase enzymes from different species is their overall
thermostability in vivo. The luciferase from V. fischeri has been shown to be heat
labile at temperatures above 30°C losing almost all catalytic properties at 37°C
(Meighen, 1991). The V. harveyi luciferase remains relatively stable at 37°C and
luciferase enzymes from P. luminescens are quite stable at 42°C (Szittner and
Meighen, 1990). Furthermore, the luciferase enzyme from P. luminescens is
optimally bioluminescent at 37°C. For selection of the application appropriate
enzyme, the optimal growth temperature for the host should be considered. For the
ultimate expression of the bacterial luciferase in mammalian cells, P. luminescens
would appear to be the appropriate choice and therefore, is the enzyme that was
chosen in this research.

Use of the Bacterial Luciferase (luxCDABE) Reporter System
Various lux-based reporter systems have been constructed mostly by the
insertion of a specific promoter in front of the lux cassette on either a plasmid or
transposon and then mobilizing the plasmid into the appropriate strain of bacteria.
The various constructs that have been designed are too numerous to completely
review in this document. Briefly, whole cell bioreporters have been generated to
monitor the catabolic genes involved in degradation pathways including but not
limited to; naphthalene (Burlage et al., 1990), toluene (Applegate et al., 1997), and mtoluate (deLorenzo et al., 1993). Van Dyk et al. (1995) used lux fusions to monitor
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heat shock gene expression and then later expanded this technology to monitor
genome wide expression patterns in E. coli (Van Dyk et al., 2001). Lux-based
reporters have also been used to monitor DNA damage (Vollmer et al., 1997),
oxidative stressors (Wallace et al., 1994) and in the creation of countless whole-cell
biosensors for monitoring compounds like nitrate (Prest et al., 1997), arsenic (Cai et
al., 1997), nickel (Tibazarwa et al., 2000), lead (Corbiser et al., 1996), 2,4-D (Hay et
al, 2000) and iron (Khang et al., 1997). Lux fusions have been further used for the in
vivo monitoring of pathogenic infection in whole mouse models (Contag et al., 1995;
Francis et al., 2000 and Francis et al., 2001).

Advantages and Disadvantages of Using Bacterial Luciferase as a Reporter
Use of the bacterial luciferase gene system has several advantages over other
bioreporter systems available. First, the absence of background luminescence in a
nonluminescent host makes this a very attractive system because the lower end of the
signal detection is only limited by the noise within the detector itself. With the
development of new, more sensitive detectors and noise reduction schemes, very low
concentrations of luciferase activity can be detected and quantified. Secondly, the
light intensity has been shown to be a direct measurement of the amount of luciferase
present (Meighen, 1991). This linear detection range is very wide relative to other
reporter proteins available (Meighen, 1991). Furthermore, the luminescent signal
can be detected within a matter of seconds making the assay relatively quick and easy
for the user.
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The ability to directly measure in vivo gene function without the disruption of
the cell or loss of cell viability is perhaps the most obvious advantage of the bacterial
luciferase enzyme system. This property has made the lux system sought out by
many for various research applications. As a result, numerous prokaryotic
biosensors have been developed. These sensors have been employed in a variety of
applications ranging from environmental pollutant monitoring (Sayler et al., 2001;
Ripp et al., 2000; Corbiser et al., 1999; Kohler et al., 2000; King et al., 1990) to
visualizing infections in vivo (Francis et al., 2001). The biggest limitation to date is
the inability to efficiently express the lux system in eukaryotic organisms. Recently,
it was shown that the complete lux operon from P. luminescens can be expressed in
the yeast S. cerevisiae as proof in principle for the further application into mammalian
cells (Gupta et al., 2003).
However, the exact interpretation of light levels from intact cells is
complicated because the intensity depends not only on luciferase concentrations
within the cell, but also the availability of the aldehyde and FMNH2 substrates. As
this system is moved into higher eukaryotes this measurement may become more
complicated (Meighen, 1991).

Expression of Bacterial Luciferase in Mammalian Cells
Unlike polycistronic expression of multiple genes often found in bacterial
systems, eukaryotic gene expression requires that each individual gene be preceded
by its own promoter. This has limited the expression of the lux genes in eukaryotes to
this point. To overcome this, several researchers have generated a monocistronic
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version of the V. harveyi luciferase protein by creating a translational fusion of the
individual subunits. This fusion protein allows for the expression of both genes from
a single promoter element. Unfortunately, these fusion proteins have not produced
adequate bioluminescence in vivo to generate a reliable mammalian sensor for gene
expression analysis. This loss of activity has been attributed to improper folding and
low thermostability of the fusion (Kirchner et al., 1989; Olsson et al., 1989;
Almashanu et al., 1990; Escher et al., 1989; Costa, 1991; Pazzagli et al., 1992;
Gelmini et al., 1993). Bioluminescence levels were significantly increased if the host
cells were grown at lower temperatures (Escher et al., 1989; Costa et al., 1991 and
Almashanu et al., 1990). Based on these data, it was determined that the fusion was
unable to properly fold into its active heterodimeric form at 37°C. This was thought
to be caused, in part, by the short polylinker region that separates the two subunits. It
was hypothesized that a short linker between the two genes may impose an unnatural
strain on the dimerization process and limit the amount of active heterodimer able to
form. To overcome this limitation, several attempts have been made to alter this
polylinker region and allow for a more natural folding of the two subunits. The
number of linker codons tested has ranged from one to twenty-two. The relative
activities (expressed in E. coli) of the enzyme are lowest with a short (one amino
acid) linker ranging from 0.04% (Boylan et al., 1989) to 19% (Almashanu et al.,
1990). The highest activities were obtained with a ten amino acid polylinker, which
produced 90% activity when grown at 23°C but only 8% at 37°C. None of the Vibrio
harveyi fusion proteins reported to date have shown the ability to remain stable at the
optimal mammalian growth temperature, 37°C.
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Interestingly, if cells, prokaryotic or eukaryotic, harboring the lux fusion
genes were grown at 37°C and then cooled to 23°C, a significant increase in
bioluminescence levels were shown to occur (Costa, 1991 and Escher et al., 1989).
On the other hand if chloramphenicol was added to the cells prior to the cooling step,
the bioluminescence remained low (Esther et al., 1989). These data indicated that the
light levels produced in the absence of the antibiotic were a result of de novo
synthesis and suggest a problem in folding of the protein at higher temperatures that
can not be recovered after folding is complete (Esther et al., 1989). These data
further support the model of luxA and luxB folding proposed earlier by Ziegler et al.
(1991).
Koncz et al. (1987) reported the expression of the heterodimeric bacterial
luciferase protein from V. harveyi as individual proteins expressed in a dual promoter
vector format. The expression levels, although difficult to compare were said to be
adequate for monitoring chimeric genes in plant extracts (Koncz et al., 1987). These
data also showed for the first time that individual subunits of the protein could be
transcribed and translated separately and subsequently assemble to form a functional
luciferase enzyme in a eukaryotic cell.

Internal Ribosomal Entry Sites (IRES)
In prokaryotes, translation of multiple adjacent genes within a single operon is
common. In these cases, the entire operon is transcribed as a single mRNA regulated
by the upstream promoter region. The translation of the mRNA is then initiated by
direct complementary base pairing between the 16S rRNA and mRNA Shine20

Dalgarno sequence. Upon binding, the 30S subunit is brought into an internal
position around the start codon (AUG) where translation of the protein begins.
Translation of several proteins from one mRNA is possible (Jackson, 2000). This
type of translation scheme is referred to as polycistronic translation.
Until recently, it was believed that eukaryotic translation was limited to cap
dependent initiation. This mechanism involves a methyl-7-G(5′)pppN structure (cap)
at the 5′ end of the mRNA that is recognized by a protein complex initiation factor to
begin translation (Hershey and Merrick, 2000). This initiation complex scans the
mRNA for the first AUG triplet downstream of the terminal 5′ cap usually within 50
to 100 bases where translation begins (Hennecke, 2001). In this type of initiation, the
simultaneous translation of multiple proteins from one mRNA is not possible and
monocistronic translation is the only option. Typically, each open reading frame is
transcribed and translated independently from its own promoter.
More recently, alternative translation mechanisms have been identified that
have been shown to initiate translation in a cap-independent manor in eukaryotic
organisms and their viral pathogens. These alternative initiation schemes were first
identified within the genomes of poliovirus and encephalomyocarditis virus (EMCV)
(Jackson, 1988 and Jang et al., 1988). These viral sequences are naturally uncapped
at their 5′ ends. They possess several complex features that would be predicted to
impair efficient ribosome binding (Vagner, 2001). Nevertheless, protein translation
was shown to be initiated at these sites, both in vitro and in vivo after viral infection

21

(Martinez-Salas et al., 2001). Furthermore, these sequences, termed internal
ribosomal entry sites (IRES) were found in all genera of picnovirus (Vagner, 2001).
IRES elements can be defined as specific nucleotide sequences that allow for
ribosomal entry and translation initiation directly at the start codon (AUG) rather than
requiring scanning from the 5′ end, cap structure, of the mRNA (Pestova et al., 2001
and Kozac, 2001). IRES activity is based on the secondary structure of the mRNA
and has been shown to be extremely sensitive to even point mutations that may alter
the integrity of this structure (Haller and Semler, 1992). IRES elements from various
sources, however, have been shown to lack conservation of primary sequences
(Pestova et al., 1991). Known IRES elements also vary greatly in their overall length,
ranging from 200nt in insect RNA viruses (Wilson et al., 2000) to as large as 600nt in
picnovirus IRES elements (Nicholson et al., 1991). Along with these variations in
nucleotide sequence and size, IRES elements have been shown to have varying
mechanisms from translation initiation (Martinez-Salas, 1999). However, certain
secondary structures remain constant and have been shown to be important for the
initial physical contact with the 40S ribosomal subunit for translation initiation.
Examples of these specific regions include, double stranded mRNA segments and
hairpin loop structures (Honda et al., 1996 and Honda et al., 1999).
The IRES element isolated from EMCV has been shown to initiate translation
by ribosomal binding at codons close to the 3′ border of the IRES sequence (Kalinski
et al., 1990). Unlike binding to the ribosomes to a Shine-Dalgarno (linear) sequence,
IRES binding to the 40S subunit is determined by several noncontiguous sequences
(Pestova et al., 2001). Whether the IRES and 18S rRNA physically bind is still yet
22

to be determined. Once the ribosome binds an elF (elongation) initiation factor
stimulates the formation of the 48S complex and forms internal loops on the IRES
sequence (Jubin, 2000 and Pestova et al., 1996). Then, in an ATP dependent manor,
translation begins directly at the AUG start codon.
Most IRES elements identified to date, represent an evolutionary survival
scheme for viruses upon infection. Once the virus infects the host cell, the cap
dependent translation machinery is shut down and only the viral proteins are made
(Vagner, 2001). Interestingly, several eukaryotic cellular IRES elements have also
been identified. The first cellular IRES was a 220nt 5′ untranslated region (UTR) of
the immunoglobulin heavy chain binding protein (BiP). This protein was shown to be
highly translated after viral infection and thus in a cap-independent manor (Macejak
and Scarnow, 1991). Other cellular IRES elements have since been identified and
shown to be related to various stress responses. For example, anti-apoptotic genes
have been shown to use IRES elements for translation initiation of proteins, like
Apaf-1 (Coldwell et al., 2000). Furthermore, translation initiation factors have been
shown to become translated in this fashion, as well including DAP5 (Henis-Korenblit
et al., 2000) and ELF4G (Johannes and Sarnow, 1998). It has been hypothesized that
translation from IRES elements may have been selected for as a last stitch effort to
survive harsh conditions by providing a failsafe method to ensure synthesis of certain
proteins under specific physiological conditions (Pestova et al., 2001). A list of viral
and cellular IRES elements that have been identified to date are listed in Table 2.
Several IRES elements have been used to create bicistronic expression vectors
for the co-expression of multiple genes from the same promoter (Wong et al., 2002
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Table 2. Examples of viral and cellular IRES elements identified to date.
Virus/gene Type
Viral RNAs
Picnoviruses

Flavivirus
Pestivirus
Retrovirus
Lentivirus
Insect RNA virus
Cellular mRNAs
Translation initiation
factors

Virus/gene

Reference

Poliovirus (PV)

Pelletier and Sonenberg,
1988
Jang et al., 1988

Encephalomyocarditis
virus (EMCV)
Foot and mouth disease
virus (FMDV)
Hepatitis C virus (HCV)
Classical Swine fever virus
Murine leukemia virus
Simian immunodeficiency
virus
Cricket paralysis virus
ElF4G
DAP5

Miscellaneous

Initiation factor G4
c-Myc
NF-kB-repressing factor
Vascular endothelial
growth factor
Fibroblast growth factor
Platelet-derived growth
factor B
Antennapedia
X-linked inhibitor of
apoptosis
Apaf-1
BiP

Yeast

p150

Transcription factors
Growth Factors

Homeotic genes
Survival Proteins
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Kuhn et al., 1990
Reynolds et al., 1995
Pestova et al., 1998
Berlioz and Darlix, 1995
Ohlmann et al., 2000
Wilson et al, 2000
Johannes and Sarnow,
1998
Henis-Korenblit et al.,
2000
Wong et al., 2002
Stoneley et al., 2000
Oumard et al., 2000
Huez et al., 1998
Creancier et al., 2000
Bernstein et al., 1997
Oh et al., 1992
Holick and Korneluk,
2000
Coldwell et al., 2000
Macejak and Sarnow,
1991
Zhou et al., 2001

and deFelipe, 2002). These new expression vectors have gained much attention due
to their potential impact as valuable tools for drug and gene delivery vectors for
multi-drug combined therapies for treating diseases such as cancer and AIDS
(deFelipe, 2002). Consequently, for the expression of multigene enzyme systems like
bacterial luciferase in eukaryotes, IRES based bicistronic vectors may prove to be an
invaluable tool.
Several IRES elements have been tested for implementation into this format
and improved vector development. Some IRES elements, like the IRES isolated from
poliovirus, are vulnerable to adjacent gene placement (Mosser et al., 2000). The
EMCV IRES element has been shown to be immune to these types of effects and
upstream genes have little effect on the downstream gene expression (Gorski and
Jones, 1999). This property has made the EMCV IRES the most frequent choice for
creating reliable, high expression bicistronic vectors (Meilke et al., 2000 and Harries
et al., 2000). However, by expressing two genes in a promoter-gene1-IRES-gene2
format, the expression of the second gene has been shown to possess lower overall
expression levels ranging from 6-100% activity when compared to the first gene
(Mizuguchi et al., 2000). This has been regarded as typical expression levels from
these vectors and therefore, to determine optimal expression, several clones must be
tested (Clontech Corporation, personal communication).
New IRES elements are being frequently discovered and better options for optimal
expression of multiple genes will become available. Wong et al., 2002 report that a
newly isolated IRES element from eukaryotic initiation factor G4 produces more than
100 fold higher overall expression of the genes that follow it compared to
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other IRES elements. This element possesses enhancer abilities as well as acting as a
ribosomal entry site. By using this IRES element or others identified in the future, it
will be possible to create bicistronic and possibly polycistronic eukaryotic expression
vectors with enhanced expression of each gene from a single promoter.

Codon Usage
The standard term “universal genetic code” comes from the fact that there are
64 possible codons coding for only 20 amino acids. Although the genetic code is
degenerate, the alternate synonymous codons are not used with equal frequency
(Sharp et al., 1988). In fact, it has been shown that in multivariate analysis, that each
species has a major trend in codon usage among genes (Schultz and Yarus, 1996).
This trend has also been shown to differ from highly expressed versus lower
expressed genes within the same species (Aota and Ikemura, 1986 and Sharp et al.,
1986). Several more distinct patterns in codon usage become apparent when genes
are sorted into the top and bottom 10% of protein activity within the cell (Sharp et al.,
1988). Within these general trends, it has been shown that there is not only a
selective difference but also a preference for certain codons in highly expressed
proteins (Sharp et al., 1993). The genes that encode for these proteins have a highly
biased codon usage pattern with a higher frequency of optimal codons used and a
lower frequency or absence all together of the other possible codons (Grantham et al.,
1981; Ikemura, 1985 and Sharp et al., 1993). Lowly expressed genes have been
shown to possess a more random pattern of codon usage (Hoekema et al., 1987). In
fact, Gouy and Gauter (1982) showed that the frequency of optimal codons in a
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particular gene was highly correlated with its expression in E. coli. The same
scenario was seen with genes expressed from S. cerevisiae (Sharp and Cowe, 1991).
However, it should be noted that a gene is not necessarily expressed at a low
level simply because it is made up of low frequency codons (Kurland, 1991). Codon
usage is not the only factor involved in gene expression. Several other factors have
profound impacts on the expression levels of genes in all organisms. Non-inhibitory
flanking sequences that surround the gene and optimal ribosomal binding sites are
critical (Nassal et al., 1987). Nevertheless, codon bias does play a key role in the
expression efficiency in all species tested to date (Amicis and Marchetti, 2000).
The question has arisen, to whether or not this increase in gene expression is
due to a more efficient translation of the protein or some other factor. The answer to
this questions still remains unclear, however, evidence is building that it may be a
combination of factors. It has been shown, that optimal codons are codons to which
the species in question possesses an overabundance of that particular tRNA molecule.
Furthermore, these optimal codons are translated faster than their lower frequency
counterparts (Sorensen et al., 1989), which is thought to lead to a more efficient
translation (Anderson and Kurland, 1990). However, the speed of overall protein
translation has not been shown to be significantly affected (Kurland, 1991).
Other hypotheses for codon optimization having a direct impact on protein
expression have been set forth including a reduction of cis acting inhibitory elements
(AU rich regions) (Kofman et al., 2003a) and an overall increase in mRNA stability
(Kofman et al., 2003b). Kofman et al. (2003b) also proposes that there may be an
inefficient processing and transport from the nucleus of mRNAs possessing lower
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frequency codons in eukaryotes. This idea was supported by the fact that if the genes
were expressed on a plasmid (in the cytoplasm) the activity of the protein was
somewhat recovered.
It is unclear to this point if codon usage has a specific regulatory function in
cells. Rare codons are present more frequently in the 5′ end of lowly expressed genes
in E. coli (Goldman et al., 1995). It is not known, however, if the optimization of
only 5′ sequences would be enough to significantly enhance expression to reach
maximal protein activity (Vervoort et al., 2000).
Codon optimization is the term given to a synthetic creation of a gene
sequence to possess the optimal codon usage patterns for the host organism. Several
examples of codon optimization have been recently published. These optimized
proteins have been primarily designed for expression in mammalian hosts, as
mammalian expression of foreign genes is often times limited (Narum et al., 2001).
Some codon optimization schemes have also been designed to optimize human genes
for expression in yeast or bacteria to provide for a simpler protocol for investigation
or to generate large quantities of individual proteins (Baev et al., 2001).
Disbrow et al. (2003) and Arregui et al. (2003) have used codon optimization to
optimize the expression of the poorly expressed E5 and E7 proteins from human
papillomaviruses (HPV) that have been shown to have early transformation activity
on infected cells. They have shown that codon optimization was able to increase
expression as much as 100 fold versus the wild type. This overexpression of the
protein resulted in cell death to much of the population expressing the codon
optimized protein. Based on this increase in cell mortality, they further hypothesized
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that the virus may have selectively evolved to use a different coding pattern from the
host as a way to survive in vivo for longer periods of time (Arregui et al., 2003).
Other groups have used codon optimization to increase expression of viral or bacterial
proteins for the efficient generation of antibodies. The amount of DNA required to
produce a high titer of antibody is significantly reduced if the codon usage patterns of
the genes are optimized (Narum et al., 2001 and Deml et al., 2001).
Codon optimization has also been used to increase the efficiency of reporter proteins
for expression in mammalian cells. Zhang et al., 2002 optimized the green
fluorescent protein (GFP) from Aequrea victoria for enhanced expression in
mammalian cells. This enhanced GFP gene, EGFP, was shown to make the protein
35 times brighter than the wild type version (Zhang et al., 2002). This same idea has
been used to optimize the expression of Renilla luciferase proteins in mammalian
cells (Gruber and Wood, 2000). In both of these instances, the reporter protein
became a stronger reporter for gene expression and reliable monitoring formats.
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CHAPTER 2
DETERMINING AN OPTIMAL EXPRESSION FORMAT FOR EXPRESSION OF
THE BACTERIAL LUCIFERASE GENES (luxA AND luxB)
Introduction
Mammalian cell lines expressing reporter proteins are commonly used in both
basic and applied research. Current methodologies that depend on firefly luciferase
(Luc) and green fluorescent protein (GFP) reporter constructs in mammalian cells are
limited due to the required cell lysis, substrate addition and/or exogenous excitation to
evoke a measurable response. Consequently, these reporter constructs cannot be
implemented into continuous, real-time, on-line monitoring devices or strategies.
Bacterial luciferase is unique in that it is the only bioreporter system available that
generates its own substrate, thus allowing for autonomous signal generation.
Unfortunately, the bacterial luciferase system’s potential has not been realized in
mammalian cells because of difficulties encountered with efficient expression of this
multi-enzyme system.
Unlike polycistronic expression of multiple genes often found in bacterial
systems, eukaryotic gene expression generally requires that each individual gene be
preceded by its own promoter. This has limited the expression of the lux genes in
eukaryotes to this point. In an attempt to overcome this, several researchers have
generated a monocistronic version of the V. harveyi luciferase protein by creating a
translational fusion of the individual subunits. Unfortunately, these efforts have been
met with only modest successes. The loss of bioluminescence activity has been
attributed to improper folding and low thermostability of the fusion protein (Kirchner et
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al., 1989; Olsson et al., 1989; Almashanu et al., 1990; Esther et al., 1989; Costa, 1991;
Pazzagli et al., 1992; Gelmini et al., 1993). None of the fusion proteins reported to date
have shown the ability to remain stable at the optimal mammalian growth temperature,
37°C.
Koncz et al. (1987) reported the successful expression of the heterodimeric
bacterial luciferase protein from V. harveyi as individual proteins expressed in a dual
promoter vector format. The expression levels, although difficult to compare were said
to be adequate for monitoring chimeric genes in plant extracts (Koncz et al., 1987).
These data also showed for the first time that individual subunits of the protein could be
transcribed and translated separately and subsequently assemble to form a functional
luciferase enzyme in a eukaryotic cell. Gupta et al. (2003) showed that by linking the
lux genes transcriptionally with IRES elements, the complete lux operon could be
efficiently expressed in the yeast, S. cerevisiae. However, no one expression format
has been shown to be the optimal choice for expression of the bacterial luciferase genes
in mammalian cells and therefore no mammalian reporter systems are currently
available that utilize this uniquely powerful reporter system. Therefore, further research
is needed to identify the optimal expression format for the heterodimeric luciferase
protein in mammalian cells. In this research effort the specific objectives are:
•

To construct and evaluate the overall bioluminescence potential from a
constitutively expressed luxAB fusion protein, a dual promoter vector
harboring both the luxA and luxB genes, expression from co-transfected
plasmids harboring the luxA and luxB genes independently and

31

expression from a transcriptionally fused luxA and luxB that are
independently translated via an IRES element.
•

To establish if episomal expression of the lux genes provides a higher
bioluminescent signal than constructs integrated into the host’s
chromosome.

•

To determine the stability of an episomal plasmid in mammalian cell
lines without selective pressure.

•

To evaluate if FMNH2 is a limiting substrate for efficient
bioluminescence in mammalian cells.

Materials and Methods
Cell Culture and Plasmid Maintenance
All relevant constructs and strains, bacterial and mammalian, used in this study
are outlined in Table 3. E. coli cells were routinely grown in Luria Bertani (LB) (Fisher
Scientific, Pittsburgh, PA) broth containing the appropriate antibiotic selection with
continuous shaking (200rpm) at 37°C. Kanamycin and Ampicillin were used at a final
concentration of 50µg/ml and 100 µg/ml, respectively.
All cell culture reagents and media were obtained from Sigma Aldrich, (St.
Louis, MO) unless otherwise stated. Mammalian cells were grown in the appropriate
complete growth media containing 10% heat-inactivated horse or fetal bovine serum,
0.01mM non-essential amino acids and 0.1mM sodium pyruvate in a Dubelco’s
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Table 3. Strains and plasmids used in the determination of the optimal expression
format for bacterial luciferase in mammalian cells.
Plasmid/Strain
Designation
Strains
E. coli

Relevant Genotype/ Characteristics

Source

DH5α

Φ80dlacZ∆M15, recA1, endA1, gyrA96, thi-1,
hsdR17 (rK-, mK+), supE44, relA1, deoR,
∆(lacZYA-argF)U169

Gibco, BRL

TOP 10

F-, mcrA ∆(mrr-hsdRMS-mcrBC) Φ80/lacZ
∆lacX74 deoR recA1 araD139 ∆(ara-leu) 7697
ga/K rpsL endA1 nupG

Invitrogen

HEK293

Permanent line of primary human embryonal
kidney transformed by sheared human
adenovirus type 5 (Ad 5) DNA. ATCC# CRL1573

ATCC

COS-7

Monkey Kidney cells transformed with an origin
defective mutant of SV40 which codes for wildtype T antigen. ATCC# CRL-1651

ATCC

HeLa

Human cervical cancer cell line ATCC# CCL-2

ATCC

Mammalian Cell Lines

Plasmids
pCR2.1-TOPO

TOPO TA cloning vector for easy cloning of
PCR products generated with 3′ A overhangs
Kmr, Ampr

Invitrogen

pCR4-TOPO

TOPO TA cloning vector for easy cloning of
PCR products generated with 3′ A overhangs
designed for sequencing Kmr, Ampr

Invitrogen

pcDNA3.1

Mammalian expression vector, constitutive
CMV promoter, contains a Neomycin G418
antibiotic selection and a ColEI and Ampr for
replication in E. coli

Invitrogen

pCEP4

Mammalian episomally maintained expression
vector, constitutive CMV promoter, Hygromycin
antibiotic selection marker and a ColEI and
Ampr for replication in E. coli

Invitrogen

pREP9

Mammalian episomally maintained expression
vector, constitutive RSV promoter, Neomycin
G418 antibiotic selection marker and a ColEI
and Ampr for replication in E. coli

Invitrogen
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Table 3. Continued

Plasmid/Strain
Designation

pIRES2-DsRed2

pIRES

Relevant Genotype/ Characteristics
Mammalian expression vector containing the
internal ribosomal entry site (IRES) of the
encephalomyocarditis virus between the multicloning site and a DsRed reporter protein, a
constitutive CMV promoter, Neomycin G418
antibiotic selection marker and a pUC ori and
Kmr for replication in E.coli
Mammalian expression vector containing the
internal ribosomal entry site (IRES) of the
encephalomyocarditis virus between two multicloning sites which allows for the expression of
two genes under the control of a single
constitutive CMV promoter, Neomycin G418
antibiotic selection marker and a pUC ori and
Kmr for replication in E.coli

Source

Clontech

Clontech

pCR4PLluxCDABE

pCR4 harboring a 6.1 kb luxCDABE cassette
from Photorhabdus luminescens

This Study

pCR4luxA

pCR4 TA cloning vector harboring the luxA
from Photorhabdus luminescens

This Study

pCR4luxB

pCR4 TA cloning vector harboring the luxB
from Photorhabdus luminescens

This Study

pCR2luxA

pCR2.1 TA cloning vector harboring the luxA
from Photorhabdus luminescens

This Study

pCR2luxB

pCR2.1 TA cloning vector harboring the luxB
from Photorhabdus luminescens

This Study

pCRluxAf

pCR2.1 TA cloning vector harboring the luxA
from Photorhabdus luminescens amplified with
the reverse fusion primer

This Study

pCRluxBf

pCR2.1 TA cloning vector harboring the luxB
from Photorhabdus luminescens amplified with
the luxB forward fusion primer

This Study

pCRluxABf

pCR2.1 TA cloning vector harboring the luxAB
generated by ligating the luxAf and luxBf
together

This Study

pcDNABf

pcDNA3.1 harboring the luxABf

This Study
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Table 3. Continued

Plasmid/Strain
Designation

Relevant Genotype/ Characteristics

Source

pcDNABfKoz

pcDNA3.1 harboring the luxABf with the Kozac
sequence modification

This Study

pcDNluxA

pcDNA3.1 harboring the luxA from
P. luminescens

This Study

pCEPluxA

pCEP4 harboring luxA from P.luminescens

This Study

pREPluxB

pREP9 harboring luxB from P.luminescens

This Study

pCRSVluxBpA

pCR4 harboring the RSV promoter, luxB and the
SV40 pA with introduced ClaI and BglII sites on
both the 5′ and 3′ ends of the gene

This Study

pREPABf

pREP9 harboring luxAB fusion from
P.luminescens

This Study

pCEPluxARluxB

pCEP4 harboring the luxA cloned into the MCS
and the RSV-luxB-SV40pA into a unique ClaI
restriction site within the vector

This Study

pcDNA3.1 harboring luxA cloned into the MCS
and the RSV-luxB-SV40pA into a unique BglII
restriction site within the vector

This Study

pluxAIEGFP

pIRES-EGFP harboring the luxA from P.
luminescens

This Study

pluxBIDsRed

pIRES-DsRed harboring the luxB from P.
luminescens

This Study

pCR4NotIluxA

pCR4 harboring the luxA from P. luminescens
with introduced NotI sites on both the 5′ and 3′
ends of the gene

This Study

pluxAIRES3

pIRES harboring the luxA from P. luminescens
cloned into the MCS(A)

This Study

pluxAIRESluxB

pIRES harboring the luxA cloned into the
MCS(A) and luxB cloned into MCS(B) from P.
luminescens

This Study

pcDNARB
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minimal essential media base (DMEM) (M4655). Cells were routinely grown at 37°C
in a 5% CO2 atmosphere to confluency and split every three to four days by
trypsinization at a 1:4 ratio into fresh complete growth media. Appropriate
concentrations of antibiotic were used to maintain constructs after transfection
according to susceptibility kill curve analysis. Kill curves were completed for each cell
line and lot of antibiotic. A range of typical concentrations used for each antibiotic is
found in Table 4.

Antibiotic Kill Curves
Kill curve experiments were performed to determine the antibiotic susceptibility
for each cell line to each lot of antibiotic. Cells were plated into six well tissue culture
plates and grown to 50-60% confluency. Varying concentrations of antibiotic were
mixed into each well along with one control well (no antibiotic). The plates were
incubated at 37°C in a 5% CO2 atmosphere for seven to ten days with the media being
refreshed every three days. Cells were checked daily by microscopic analysis and
changes in cell morphology and viability were recorded. The minimum concentration
of antibiotic that was toxic to the cells within eight days was used for selection of stable
cell lines (Table 4).

Construction of a luxA- luxB Fusion Protein
To create a monocistronic version of the heterodimeric luciferase protein
encoded by the luxA and luxB genes, a translational fusion of the two polypeptides was
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Table 4. Concentrations of antibiotics used for each cell line based on results of kill
curves.
Antibiotic
Neomycin G418
Zeocin
Hygromycin

HEK293
450-650µg/ml
250-400µg/ml
400-600µg/ml

COS-7
400-700µg/ml
Not Tested
Not Tested

37

HeLa
500-750µg/ml
Not Tested
Not Tested

constructed. Synthetic oligonucleotides were designed to fuse the 3′ end of the luxA to
the 5′ end of the luxB. Both oligonucleotide sequences were complementary to
sequences at the 3′ end of the luxA, the intergenic region between the luxA and luxB,
and the start codon of luxB. These oligos were synthesized with the following
modifications: luxA Reverse Primer: the luxA stop codon (TAG) was removed by
substituting a Cytosine nucleotide for the Guanine resulting in a tyrosine codon, a single
base addition of Guanine was also added to place the luxB in the same reading frame to
create a fusion protein, further, a Guanine was substituted to generate an AvrII
restriction site at the 3′ end of the luxA. luxB Forward Primer: the primer was the
exact complement of the luxA reverse primer. The luxA and luxB genes were
individually amplified using Taq polymerase (to generate 3′ A overhangs) and TA
cloned into the pCR2.1 TOPO cloning vector (Invitrogen Corporation, Carlsbad, CA) to
construct pCRluxAf and pCRluxBf. These plasmids were then digested with EcoRI
and AvrII and the products were gel purified by electroelution (Sambrook et al., 1999).
The fragments were then ligated in equal molar concentrations for 2 h. The ligation
product (1 µl) was then used as template for a PCR reaction using the outermost luxA
forward and luxB reverse primer pair to generate a luxAB fusion. The resultant PCR
products of the correct size were TA TOPO cloned into the pCR2.1 TOPO cloning
vector to generate pCRluxABf. The construct was then digested with AvrII and EcoRI
restriction enzymes and sequenced to ensure its integrity. The sequence of the wild
type and modified intergenic region of the fusion are shown in Figure 5.
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luxA stop

luxB start

tat tag cta agg aga aag a*a atg aaa ttt
Tyr Stop

Met

AvrII

Base substitution

base addition

Lys

Phe

luxB start

tat tac cta ggg aga aag aga atg aaa ttt
Tyr

Tyr Leu

Gly

Arg

Lys

luxAB unfused

Arg

Met

Lys

luxAB fused

Phe

Figure 5. Sequence of the wild type luxAB and luxABf. Introduced AvrII site is in
the shaded area. Base substitutions and base additions are noted and *
represents the absence of the base in the wild type luxAB.
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Episomal Expression
For the expression fusion protein as an episome, the luxABf was cloned into the
pREP9 mammalian expression vector (Clontech Corporation, Palo Alto, CA). To create
this clone, the luxABf insert was cleaved from pCRABf with KpnI and XhoI restriction
sites located within the vector and then ligated into the pREP9 vector that had been
digested with the same enzymes. The ligation of these two fragments generated
pREPABf (Figure 6A).
Chromosomal Expression
The luxAB fusion was cleaved from pCRABf via 3′ and 5′ EcoRI sites and nondirectionally cloned into pcDNA3.1 to generate pcDNABf (Figure 6B) for
chromosomal insertion and expression in mammalian cells.
To facilitate high levels of expression in eukaryotes, Kozac sequences are often
inserted at the 5′ ends of genes. To accomplish this addition to the luxAB fusion a luxA
forward primer was modified to insert a Kozac sequence by substituting an Adenine at
the –3 position and a Guanine at the +4 position around the start site of the luxA. The
luxAB fusion was then amplified from the pCRABf plasmid construct and the resultant
PCR product was subsequently TA cloned into pCR2.1 to generate pCRABfKoz. This
insert was then cleaved by EcoRI and cloned into the pcDNA3.1 mammalian expression
vector to create pcDNABfKoz.

40

A

CMV

pcDNABf
luxABf
Neo G418
SV40 pA

PCMV

B

OriP

EBNA-1
luxABf

pREPABf

Neo G418
SV40pA

Figure 6. Diagram of vector plasmids for the expression of the luxAB fusion in
mammalian cells. pcDNABf construct provides chromosomal expression and
neomycin G418 selection. B. pREPABf construct allows for episomal
expression and neomycin G418 selection.
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Construction of a Dual Promoter Vector for Expression of luxA and luxB
Episomal Expression
Pasting pieces from pCEP4 and pREP9 episomal mammalian expression vectors
together generated a dual promoter vector that allowed for the expression of both genes
(luxA and luxB) from their own promoters. First, luxA was cleaved from pCRluxA with
introduced 5′ NheI and a 3′ XhoI sites and cloned into pCEP4 to generate pCEPluxA.
The luxB gene was then cloned into pREP9 to generate pREPluxB using the same clone
strategy described above for cloning luxA into pCEP4. Oligonucleotide primers were
designed and synthesized to amplify the RSV promoter region of pREP9, luxB gene,
and the SV40 ployA region from pREPluxB with the introduction of 5′ and 3′ ClaIBglII restriction sites. The resultant PCR product was then TA TOPO cloned into pCR4
TOPO (Invitrogen Corporation, Carlsbad, CA) to generate pCRSVluxBpA. This
construct was then cleaved via ClaI and the insert cloned into a complementary site on
pCEPluxA to generate pCEPluxARluxB (Figure 7A).
Chromosomal Expression
To chromosomally express both the luxA and luxB from individual promoters
with only one selection marker required, a dual promoter vector was constructed. This
expression vector was generated on the plasmid backbone of the pcDNA3.1 mammalian
expression vector (Invitrogen Corporation, Carlsbad, CA). First, the luxA gene was
cleaved from pCRluxA with EcoRI and nondirectionally ligated into pcDNA3.1. The
clones were then checked for insert presence and orientation by restriction digestion and
sequencing to generate pcDNluxA. Once verified the RSV, luxB and SV40 polyA
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A

CMV

luxA

Neo G418

pcDNARB

PRSV

SV40 pA

luxB

SV40 pA

SV40 pA

B

luxA

OriP
PCMV

EBNA-1

pCEPluxARluxB

Hygromycin
SV40 pA
luxB

PRSV

Figure 7. Diagram of vector plasmids for the expression of luxA and luxB from
individual promoters within the same vector in mammalian cells. A.
pcDNARB construct allows for chromosomal expression and hygromycin
selection. B. pCEPluxARluxB construct provides episomal expression
and neomycin G418 selection.
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region were cleaved from pCRSVluxBpA via a unique 5′ and 3′ BglII sites and cloned
into pcDNluxA to generate pcDNARB (Figure 7B).

Construction of GFP vectors for co-transfection Experiments
Episomal Expression
Co-transfection of each gene (luxA and luxB) on separate plasmids would allow
the proteins to be expressed independently. For episomal expression, the pREP9 and
pCEP4 (both from Clontech Corporation, Palo Alto, CA) expression vectors were used.
The luxA and luxB genes were cloned into these vectors as previously described to
generate pCEPluxA (Figure 8A) and pREPluxB (Figure 8B).
Chromosomal Expression
Separate EGFP and DsRed reporter vectors were constructed to allow for cotransfection of luxA and luxB genes on separate plasmids and integration within the
host’s chromosome. luxA was cloned into pIRES-EGFP and luxB was cloned into
pIRES2-DsRed2 (both from Clontech Corporation, Palo Alto, CA). These reporter
vectors were chosen to allow for the monitoring of co-transfection efficiency and
plasmid maintenance. Each plasmid contains a GFP variant reporter gene under the
translational control of an encephalomyocarditis virus (EMCV) internal ribosomal entry
site (IRES) that immediately follows the multi-cloning site within the vector. To
generate these constructs, each vector was digested with EcoRI and the luxA or luxB
was cleaved from pCRluxA or pCRluxB using the same enzyme. The vector and
inserts were then ligated via the complementary ends to generate pluxAIEGFP (Figure
9A) and pluxBIDsRed (Figure 9B).
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PCMV

A

luxA

pluxA-EGFP

IRES

EGFP

Kan/Neo

PCMV

B
luxB

pluxB-DsRed

IRES

DsRed

Kan/Neo

Figure 8. Diagram of vector plasmids for the expression of luxA and luxB from
individual plasmids along with a GFP reporter protein in mammalian
cells. A. pluxA-EGFP expresses the luxA gene and an EGFP reporter
protein from a single bi-cistronic transcript. B. pluxB-DsRed construct
expresses the luxB gene and a DsRed reporter protein from a single bicistronic transcript.
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A

SV40 pA

luxA

OriP
PCMV

EBNA-1

pCEPluxA

Hygromycin

B

PRSV
luxB

OriP

EBNA-1

SV40 pA

pREPluxB

Neo G418

Figure 9. Diagram of vector plasmids for the expression of luxA and
luxB from individual plasmids in mammalian cells. A.
pCEPluxA allows for expression of the luxA gene as an
episome with hygromycin selection. B. pREPluxB construct
allows fro the expression of the luxB gene as an episome with
neomycin G418 selection.
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Construction of a Bi-cistronic Vector to Express luxA and luxB
To co-express both luxA and luxB genes from a single promoter, the pIRES
mammalian expression vector was chosen (Clontech Corporation, Palo Alto, CA). This
expression vector contains two multi-cloning sites separated by an internal ribosomal
entry site (IRES) from encephalomyocarditis virus (EMCV). The IRES element allows
for the expression of two genes (one cloned into each multi-cloning site) from a single
constitutive CMV promoter. To create this construct, the luxA gene from P.
luminescens was amplified from pCR4PLluxCDABE plasmid that harbors the complete
luxCDABE cassette (Table 3) with the introduction of unique NotI restriction sites on
both the 5′ and 3′ ends of the luxA gene. The resultant PCR product was TA TOPO
cloned into pCR4 TOPO to generate pCR4NotIluxA. The luxA gene was then cloned
into the MCS(A) of pIRES via the unique NotI restriction sites to generate pluxAIRES3.
Once this construct was confirmed by sequencing, the plasmid was purified using the
Wizard midi-prep plasmid purification kit according to the manufacturer’s instructions
(Promega Corporation, Madison, WI). The luxB gene was cleaved via a 5′ XbaI and 3′
SpeI site from pCRluxB and cloned into the XbaI site within the MCS(B) of
pluxAIRES3 to generate pluxAIRESB (Figure 10).

Ligation Reactions
Plasmid vectors and inserts were digested (2-6 h) with the appropriate enzymes
(Promega Corporation, Madison, WI). Linearized vectors were dephosphorylated using
a calf intestine alkaline phosphatase enzyme according to the manufacturer’s
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PCMV

luxA

pAIRESB

IRES
Kan/Neo
luxB

Figure 10. Diagram of vector construct for the expression of luxA and luxB
as a single bi-cistronic transcript, pAIRESB.
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instructions (Promega Corporation, Madison, WI). Both vector and insert DNA were
gel purified from 1% agarose gels using the Geneclean gel extraction kit (Bio101,
Carlsbad, CA). The recovered DNA was then quantified using a Dyna Quant 200
fluorometer (Hoefer Pharmacia Biotech Incorporated, San Francisco, CA) and ligations
were set up as 20µl reactions using a 3:1 molar ratio of insert to vector DNA. The
ligation reactions were then incubated at 17°C overnight.

Electroporation
Electrocompetent cells were prepared as outlined by the manufacturer (BTX,
San Diego, CA). Electroporations were performed using the BTX Electroporator 600
with the following conditions: 40µl cells, 1-2µl ligation mixture (above), a 2.5kV pulse
for 4.7ms using a 2mm gap cuvette. After the pulse, cells were immediately
resuspended in 1ml of sterile LB and allowed to recover for 1 h at 37°C (200 rpm).
Cells were then plated on selective media containing the appropriate antibiotic.

Selection of Bacterial Clones
Resistant colonies were picked after 24 h and expanded to patches on grid
plates. To test for proper insert presence and orientation, rapid boil plasmid mini-preps
(Promega Corporation, Madison, WI) were done followed by the digestion of the
plasmid with the appropriate restriction enzyme mixture according to the
manufacturer’s instructions (Promega Corporation, Madison, WI). Products were run
on 1% agarose gels to determine if the banding pattern indicated the insert presence and
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proper orientation. Upon identifying correct clones, the plasmids were further purified
using the Wizard midiprep plasmid purification system according to the manufacture’s
protocol (Promega Corporation, Madison, WI) and sequenced.

Sequencing
All constructs were sequenced to ensure their integrity. Sequencing was done in
the University of Tennessee Molecular Biology Service Facility using an Applied
Biosystems 3100 Genetic Analyzer sequencer (Foster City, CA).

Determination of Thermostability of the luxAB Fusion Protein
To determine the thermostability of the luxAB fusion protein, E. coli cells
harboring the pCRABf construct were grown at 23°C, 30°C and 37°C overnight with
50 µg Kanomycin/ml in LB. The bioluminescence levels for each temperature
condition were taken in triplicate. Bioluminescence measurements were done using the
FB14 luminometer (Zylux Corporation, Pforzheim, Germany) at a 1 s integration and
reported as relative light units (RLU). To normalize the data each bioluminescence
reading was divided by absorbance O.D.600 for the culture and reported as relative
bioluminescence.

Transfection of Mammalian Cells
Transfection of all cell lines was done in six well poly-D-lysine coated tissue
culture plates (Fisher Scientific, Pittsburgh, PA). Cells were split from stock cultures
and inoculated into each well at approximately 1X105 cells per well in complete growth
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media. The plate was then placed at 37°C in a 5% CO2 atmosphere for 1-2 days until
the cells became 80-90% confluent. The day of transfection, the medium was refreshed.
DNA for transfections was purified from 100ml overnight E. coli cultures using the
Wizard Purefection plasmid purification kit to remove endotoxins according to the
manufacturer’s instructions (Promega Corporation, Madison, WI). For chromosomal
integration, the plasmid DNA was linearized before transfection to increase proper
integration. For episomal expression, plasmids were transfected as circular DNA.
HEK293 Cells
Purified plasmid DNA (3.2 µg) was mixed into 200 µl of serum free DMEM in
a 1.5 ml tube. In a second tube, 8 µl of Lipofectamine 2000 reagent (Invitrogen
Corporation, Carlsbad, CA) was added to 200 µl of serum free DMEM. The
lipofectamine mixture was added to the DNA mixture within 5 min and incubated at
room temperature for 20 min. The entire mixture (400 µl total) was added directly to
the appropriate well on the plate and rocked back and forth to ensure adequate mixing.
Twenty-four hours post transfection, the complexes were removed and the media was
replaced with fresh complete growth media supplemented with the appropriate
antibiotic for selection.
COS-7 Cells
Purified plasmid (1.5 µg) was mixed with 100 µl of serum free DMEM in a 1.5
ml tube. In a second tube, 5 µl of lipofectin (Invitrogen Corporation, Carlsbad, CA)
was mixed with 100 µl of serum free DMEM. The two mixtures were then mixed
together and incubated at room temperature for 45 min. After incubation, 0.8 ml of
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serum free DMEM was added to the mixture and then directly placed on the cells in the
plate that had been previously rinsed two times with serum free DMEM to remove any
residual serum. The complexes were incubated on the cells for 5 h at 37°C in a 5% CO2
atmosphere. After incubation DMEM supplemented with 20% fetal calf serum was
added. Forty-eight hours after transfection, complete DMEM plus antibiotic was
applied to the cells for selection.
HeLa Cells
Purified plasmid DNA (1.6 µg) was added to 200 µl of serum free DMEM along
with 10 µl of the PLUS Reagent (Invitrogen Corporation, Carlsbad, CA) and incubated
at room temperature for 15 min. In a second tube 1 µl of Lipofectin (Invitrogen
Corporation, Carlsbad, CA) reagent was added to 50 µl of serum free DMEM and
incubated at room temperature for 30 min. The two tubes were then mixed gently and
incubated further for 15 min. The growth media was removed from the cells and
replaced with serum free DMEM and the DNA-Lipofectin complexes were added
directly to the wells and gently mixed. The plates were then incubated at 37°C in a 5%
CO2 atmosphere for 3 to 5 h. After incubation, 15% fetal bovine serum was added to
each well. Twenty-four hours post transfection, growth media supplemented with the
appropriate antibiotic was applied to the cells for selection.

Selection of Mammalian Cell Clones
Twenty-four to forty-eight hours post transfection, selective medium was added
to all wells and refreshed every three to four days. Within two weeks all control cells
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were dead and the transected cells were forming small colonies on the plate surface.
Colonies were separated from the rest of the well by placing a sterile chamber around
the cell mass and sealing it with silicon (Fisher Scientific, Pittsburgh, PA). The media
could then be removed and each colony could be trypsinized and transferred to
individual tissue culture flasks. To accomplish this, after washing with a PBS solution,
200 µl of a 1X Trypsin-EDTA solution (Sigma Aldrich, St. Louis, MO) was added
directly to the chamber and incubated at 37°C for 3 to 5 min. The trypsin-EDTA
solution was then replaced with complete growth media and the cells were transferred
to a 25cm2 tissue culture flask for propagation. Each clone was given a number and
expanded to individual cell lines. Each line was split and maintained as described
earlier with the addition of selective media. At between nine and twenty cell lines were
propagated in this manner for each plasmid tested.

Bioluminescence Assays from Mammalian Cells
To determine bioluminescence potential from each cell line clone, total proteins
were extracted and in vitro enzyme (bioluminescence) assays performed. To extract the
proteins, the cells were trypsinized from the plate or flask surface using standard
protocols and resuspended into 2.0 ml Sarstedt tubes (Fisher Scientific, Pittsburgh, PA).
The cells were then spun down and washed two times in sterile phosphate buffered
saline (PBS) to remove any residual medium (Sigma Aldrich, St. Louis, MO). Cell
pellets were then resuspended into 1 ml 0.1M potassium phosphate buffer pH 7.8 and
disrupted by three consecutive cycles of freeze (30 s liquid N2) thaw (5 min at 37°C)
extraction. After disruption, the cell debris was pelleted by spinning the samples at
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14,000Xg for 5 min and the supernatant was used in the bioluminescence assay. To
determine light intensity, the protein extract was mixed with 0.1 mM NAD(P)H, 4 µM
FMN, 0.2% (w/v) BSA, 0.002% (w/v) n-decanal. Bioluminescence was measured
using the FB14 luminometer (Zylux Corporation, Pforzheim, Germany) at a 1 s
integration and reported as relative light units (RLU). To determine if FMNH2 was a
limiting factor for the bioluminescence reaction, a flavin oxidoreductase enzyme (1U)
isolated from V. harveyi (Roche Scientific, Indianapolis, IN) was added to the
bioluminescence assay and the light levels were measured again for comparison (Table
5).
Bioluminescence signals were normalized between samples and cell lines by
dividing the RLU measurement by the total protein and reporting the bioluminescence
as RLU/µg total protein. Protein concentrations were determined using the Coomassie
Plus protein assay according to the manufacture’s instructions (Biorad, Hercules, CA).

In Vitro Transcription/Translation
To determine if the lux genes could be generated in vitro in rabbit reticulocyte
lysate (mammalian translation machinery), pCR2.1 TOPO vectors harboring luxA, luxB
and luxABf were transcribed and translated. First, the plasmid DNA containing the
genes was digested at a unique SpeI restriction site at the 3′ end of the gene within the
vector. This digestion linearized the plasmid and allowed for the generation of run-off
transcript from the vector derived T7 promoter. Each gene was transcribed via T7
polymerase using the RiboMax large-scale transcription system (Promega Corporation,
Madison, WI). Three individual transcription reactions were set up along with
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Table 5. Final constructs transfected into mammalian cell lines.
Plasmid
pcDNABf
pcDNABfKoz
pREPABf
pCEPluxA
pREPluxB
pluxA-EGFP
pluxB-DsRed
pCEPluxARluxB
pcDNARB
pluxAIRESluxB

Expression

Cell Line Tested

Chromosomal
Chromosomal
Episomal
Episomal
Episomal
Chromosomal
Chromosomal
Episomal
Chromosomal
Chromosomal

HEK293, HeLa, COS-7
HEK293, HeLa, COS-7

HEK293
HEK293
HEK293
HEK293
HEK293
HEK293
HEK293
HEK293
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Selection
Marker
G418
G418
G418
Hygromycin
G418
G418, EGFP
G418, DsRed
Hygromycin
G418
G418

a positive T7 control and a negative control containing no template DNA. Each
reaction was set up according to the manufacturer’s protocol and then incubated at 37°C
for 1 h. Transcripts were quantified by absorbance (260/280) measurements (Beckman
Coulter, Fullerton, CA). Ten micrograms per ml of total RNA transcript was then
added to 50 µl (total volume) rabbit reticulocyte lysate translation reactions. Each
reaction was gently mixed on ice according to the manufacturer’s protocol for 35S
labeled protein generation and then incubated at 30°C for 90 min (Promega
Corporation, Madison, WI). Once translation was complete, 15 µl of each reaction was
loaded onto a 12% SDS-PAGE mini-gel and run at 30mA for 1 h. The gel was removed
and dried at 60°C with vacuum pressure using a model 443 Slab Dryer (BioRad,
Hercules, CA) onto 3MM filter paper (Fisher Scientific, Pittsburgh, PA). To visualize
the generated proteins, the gel was placed onto x-ray film overnight and specific activity
was measured upon film development.

Genomic DNA Isolation
Genomic DNA from each cell line clone was accomplished using the Wizard
genomic DNA extraction kit according to the manufacture’s protocols (Promega
Corporation, Madison, WI).

RNA Isolation and Blotting
At passage six post transfection, selected cell line clones were expanded to
75cm2 tissue culture flasks. When the cells became 80-95% confluent, the cells were
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trypsinized to remove the cells from the surface and transferred to 2.0 ml Sarstedt tubes
(Fisher Scientific, Pittsburgh, PA). Cells were spun down and washed two times in
PBS (Sigma Aldrich, St. Louis, MO). Total RNA was then isolated from the cells using
the RNeasy kit (Quiagen, Valencia, CA) according to the manufacturer’s instructions
for isolation of total RNA from mammalian cells. To remove any contaminating DNA,
the RNA was digested for 30 min with DNaseI (Promega Corporation, Madison, WI).
To remove the DNaseI enzyme, the clean-up procedure from the RNeasy kit was used
(Quiagen, Valencia, CA). Total RNA was then quantified using the Beckman DU-640
spectrophotometer absorbance at 260/280 (Beckman Coulter, Fullerton, CA).
RNA Slot Blotting
Ten micrograms of total RNA were loaded onto a BiotransTM nylon membrane
(ICN, Irvine, CA) using a Bioslot blot apparatus (Biorad, Hercules, CA) according to
the manufacturer’s protocol. A

32

P labeled probe was generated complementary to the

300 bp of the luxA or luxB gene from P. luminescens using standard PCR protocols with
the incorporation of a [32P] labeled dCTP nucleotide. The free nucleotides were
removed and the probe purified by column purification according to the manufacture’s
instructions (Stratagene, La Jolla, CA). The specific activity of each probe was
measured by scintillation counting (Beckman Coulter, Fullerton, CA). Before use, the
dsDNA probe was boiled for 10 minutes to denature the DNA and directly added to the
pre-hybridization solution (SLIME). The blot was incubated with the probe at 48°C
overnight. After probe hybridization, the blot was washed 4 times in 20X SSC to
remove any unbound activity. The wash temperatures were determined experimentally
to achieve optimal probe binding without excess background activity. The blot was air
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dried and then placed on a phosphorescence intensifier screen (Molecular Dynamics,
Piscataway, NJ). Specific activity was measured using the STORM 840
phosphoanalyzer and the data analyzed using the ImageQuant data analysis software
(Molecular Dynamics, Piscataway, NJ).

Protein Isolation and Western Blotting
To extract the proteins, cells were trypsinized from a plate or flask surface and
resuspended into 2.0 ml Sarstedt tubes (Fisher Scientific, Pittsburgh, PA). The cells
were then spun down and washed two times in sterile phosphate buffered saline (PBS)
to remove any residual media (Sigma Aldrich, St. Louis, MO). Cell pellets were
resuspended into 1 ml 0.1M potassium phosphate buffer pH 7.8 and disrupted by three
consecutive cycles of freeze (30 s liquid N2) thaw (5 min at 37°C) extraction. After
disruption, the cell debris was pelleted by spinning the samples at 14,000Xg for 5 min
and the supernatant was used as total soluble protein for Western blot analysis.
Protein concentrations were determined using the Coomassie Plus protein assay
according to the manufacturer’s instructions (Pierce, Rockford, IL). Equal amounts
(100 – 250 µg) of protein were loaded onto a 12% SDS-PAGE gel. Minigels were run
at 30 mA for approximately 2 h and larger slab gels were run at 30 mA overnight. The
proteins were then electroblot transferred to a PDVF membrane (Biorad, Hercules, CA)
using a semi-dry electroblotter according to the manufacture’s instructions (CBS
Scientific Company, Incorporated, Del Mar, CA). Blots were then blocked overnight in
5% nonfat dry milk and hybridized with a polyclonal antibody raised against a 16 amino
acid luxA polypeptide (′N′ - FDDSDQTRGYDFNKGC - ′C′) or a 16 amino acid luxB
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polypeptide (′N′ - CMILVNYNEDSNKAKQ - ′C′) (Genemed Synthesis, Incorporated,
San Francisco, CA). Antibodies were diluted in T-TBS (Tris Buffered Saline + 3%
Tween 20) at a 1:500 dilution and applied to the membrane at room temperature for 5 h
to overnight. The blot was then washed several times in T-TBS and incubated with a
Goat Anti-Rabbit second antibody that has been conjugated to alkaline phosphatase.
The blot was then developed according to the manufacture’s protocol (Biorad, Hercules,
CA).

Statistics
Statistical analysis of the data presented here was conducted using either the
JMP (SAS Institute, Incorporated, Pacific Grove, CA) or Microsoft Excel (Microsoft,
Seattle, WA ) statistical software packages. Graphs were made using Sigma Plot
software (SPSS, SAS Institute, Incorporated, Pacific Grove, CA) or Microsoft Excel
(Microsoft, Seattle, WA). All error bars on graphs indicate one standard deviation of
the mean from triplicate samples. Significant differences were determined using either
t-test or 1 way ANOVA analysis at a level of α=0.05.

Results
LuxAB Fusion Protein
Creation of the LuxAB Fusion
A LuxAB fusion protein from P. luminescens was generated by the elimination
of the stop codon at the 3′ end of the luxA gene and the addition of one base within the
intergenic region to place the two genes into the same reading frame. Although the
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fusion protein was functional, light levels were significantly lower (p = 0.05) when
expressed constitutively in E. coli. As shown in Figure 10, the LuxAB fusion protein
had bioluminescence activity levels only approximately 30% of the wild type unfused
LuxA and LuxB. The addition of a Kozak sequence further reduced the
bioluminescence level to approximately 5% of the wild type protein (Figure 11).

Thermostability of the LuxAB Fusion
To determine if temperature had an effect on the folding and activity of the
fusion protein, the fused and wild type versions of the luxAB constitutively expressed in
E. coli were grown as 100ml liquid cultures overnight at 23˚C, 30˚C and 37˚C.
Bioluminescence measurements were taken in triplicate and reported as specific
bioluminescence (RLU/O.D. 600). Results are shown in Table 6A. In E. coli, there was
no statistical difference (p = 0.05) between bioluminescence activities of cells grown at
varied temperatures. To further evaluate this in a eukaryote, the luxAB fusion construct
was cloned into a yeast expression vector (pYES-TOPO) and transformed into S.
cerevisiae. Surprisingly, contradictory to the data from E. coli, light levels significantly
decreased when the cells were grown at 37˚C (Table 6B).

In Vitro Expression
To mimic mammalian cell translation machinery, the luxA, luxB and luxAB
fusion genes were transcribed and translated in vitro. Although equal molar amounts of
RNA transcript were added to each translation reaction and equal volumes of the
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Figure 11. Bioluminescence values from E. coli cells harboring either
wild type luxA and luxB, the luxAB fusion protein, or the
luxAB fusion protein with the Kozac sequence modifications
grown at 37°C. Bioluminescence values were taken in
triplicate with the addition of 20 µl of a 1% n-decanal
emulsion. (a, b and c signify significant differences at p<0.05)
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Table 6. Effect of temperature on the LuxAB fusion protein’s activity. A. Light
emission from E. coli clones harboring the luxAB fusion genes when grown at
23°C, 30°C and 37°C. B. Specific bioluminescence of pYES2.1-TOPO with
luxAB fusion in S. cerevisiae grown on galactose inducing media at 30˚C and
37˚C.

A

Temperature

23°C

30°C

37°C

Specific
bioluminescence ± SD

1.56*107
±0.12*107

1.47*107
± 0.12*107

1.52*107
±0 .11*107

B

Temperature °C

(+) Aldehyde - Specific
bioluminescence
(light/O.D.) ± SD

30°C

64,534 (±1,545)

37°C

16,223 (±1,018)
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translation reaction were loaded onto the gel, the individual LuxA and LuxB proteins
were not detected while the LuxAB fusion protein was easily detectable (approximately
78 kDa) (Figure 12).

Expression in Mammalian Cell Lines
Three mammalian cell lines were chosen to evaluate the expression of the
LuxAB fusion protein. These cell lines included; HeLa, COS-7 and HEK293. To
determine if the plasmid was present within each cell type after antibiotic selection of
clones, PCR was performed on the genomic DNA from each clone with a luxA specific
primer set. All cell line clones that resulted in a positive PCR product were further
investigated for luxA message (mRNA), protein and bioluminescence activity. All
clones tested had luxA mRNA levels higher than background vector controls, but the
levels varied greatly between cell lines and individual clones (data not shown). The
bioluminescence values obtained from cell extracts also varied between cell types and
clones. The exogenous addition of an oxidoreductase enzyme to produce FMNH2
increased the bioluminescence levels more than ten fold. These data suggest that
FMNH2 is a limiting substrate for the bioluminescence in mammalian cells. Figure 13
shows the average bioluminescence (RLU/mg total protein) from the brightest three
clones from each cell type harboring pcDNABf within its chromosome. HEK293 cells
consistently produced the highest bioluminescence levels, however these differences
were not statistically significant (p = 0.05). Polyclonal antibodies to peptide epitopes
within the LuxA and LuxB proteins were obtained (Genemed Synthesis, San Francisco,
CA). Unfortunately, even though the bioluminescence levels were quantifiable the lux
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Figure 12. LuxA, LuxB and LuxAB fusion proteins translated in vitro in rabbit
reticulocyte lysate with the incorporation of 35S methionine. The
molecular weight marker is labeled with [14C] methylated protein.
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Figure 13. Relative bioluminescence (RLU/mg total protein) from
stably integrated pcluxABf harboring the luxAB fusion
gene. Bioluminescence was measured from cell extracts
upon the addition of 0.002% n-decanal and FMNH2.
Bioluminescence reported as an average of the top three
clones from each cell line.
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protein levels were not adequate for detection by immunoblot analysis.

LuxAB Fusion with Kozac Modifications
Although the Kozac sequence modifications on the 5′ end of the luxA gene was
shown to drastically diminish bioluminescence levels in E. coli (Figure 11), the Kozac
sequence is a mammalian ribosomal binding site and therefore to evaluate its true
effectiveness the construct was tested in HEK293 cells. Stable cell lines harboring
pcDNABfKoz were obtained and tested for bioluminescence activity. The light levels
were significantly reduced (>90%) compared to HEK293 cells expressing the fusion
protein without the Kozac modifications (Figure 14).

Alternative Expression Formats
Although detectable bioluminescence levels were obtained from mammalian cell
lines harboring the LuxAB fusion protein, these levels were not sufficient for the
creation of a reliable biosensor. Therefore, other expression formats were evaluated.
The bioluminescence activity from the LuxAB fusion protein in HEK293 cells was
compared to the expression of the individual luxA and luxB genes on either a single
plasmid in a dual promoter format or by co-transfecting cells with separate plasmids
carrying the genes. Stable cell lines expressing the lux genes in a dual promoter or cotransfected format were obtained. Furthermore, each vector format (fusion, dual
promoter and co-transfection) was evaluated when the constructs were maintained as
episomal plasmids or were integrated into the host’s chromosome. The average
bioluminescence levels (RLU/mg total protein) of the three brightest clones for each
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Figure 14. Relative bioluminescence (RLU/mg total protein) from stably
integrated pcluxABf harboring the luxAB fusion gene or
pcluxABfKoz harboring the luxAB fusion with the Kozac
modification. Bioluminescence was measured from cell
extracts upon the addition of 0.002% n-decanal and FMNH2.
Bioluminescence reported as an average of the top three clones
from each cell line.
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construct tested are shown in Figure 15. When the constructs were expressed as
episomes within the nucleus of the cells, the bioluminescence was on average higher for
the LuxAB fusion protein and for co-transfected plasmids. However, these differences
were not statistically significant (p<0.05). The episomally expressed dual promoter
plasmid carrying luxA and luxB genes (pCEPARB, Figure 6B) resulted in a significantly
lower bioluminescence level than its integrated counterpart (pcDNARB, Figure 6A).
This reduced amount of bioluminescence from cells episomally expressing
pCEPluxARluxB was surprising. Further experiments were conducted in an attempt to
identify the expression problems with this construct.
Since the Lux proteins were not detectable by immunoblot, mRNA levels were
evaluated. RNA slot blot analysis revealed that clone DE4 had significantly higher
amounts of luxA message compared to the luxB message. The other two clones tested
harboring the construct (DE8 and DE9) had the exact opposite trend for message
quantities (Figure 16). The backbone vector for this construct had only minimal
hybridization with either the luxA or luxB probes.

Stability of Constructs in Mammalian Cells
To evaluate the stability of each construct in the absence of antibiotic selection, each
HEK293 cell line clone was grown in complete growth media without antibiotic for
twenty passages. The bioluminescence levels were obtained every fifth passage for
comparison. In general, all clones were stable for at least five passages after the
antibiotic removal. However, the constructs that were maintained as episomes began to
decline in bioluminescence activity by passage ten. The co-transfected cell line
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Figure 15. Relative bioluminescence (RLU/mg total protein) from either chromosomally integrated or
episomal plasmids expressing luxA and luxB as a fusion protein (black), on one plasmid with
separate promoters (red) or co-transfected on separate plasmids (green).
69

B

A
DE4
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(Episomal)
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pCEPluxARluxB
(Episomal)

DE9
pCEP4
(NC)

pCEP4
(NC)

Figure 16. RNA slot blot analysis of HEK293 clones harboring the
pCEPluxARluxB construct as an episome. A. Probed with a
300 bp region of the luxA gene from P. luminescens. B. Probed
with a 300 bp region of the luxB from P. luminescens. A
negative vector control (NC) of pCEP4 was added to determine
background hybridization levels.
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harboring two plasmids both maintained episomally had the fastest bioluminescence
decline rate. The bioluminescence levels from this cell line declined approximately
10% per generation. The constructs that were integrated into the host’s chromosome
remained relatively stable throughout the twenty passage (approximately 2.5 months)
evaluation (Figure 17).

Bicistronic Expression
To evaluate the expression of the luxA and luxB genes as a single bicistronic
transcript, an IRES element from EMCV virus was used to transcriptionally fuse the
two genes together (Figure 9). From each of the nine stable cell line clones obtained
harboring this construct, the bioluminescence (RLU/mg total protein) was at least an
order of magnitude greater than the average levels obtained from the brightest clones
with any of the other expression formats tested (Figure 18). On average, there was no
significant difference between bioluminescence levels obtained from HEK293 cells
expressing the luxAB fusion, the luxA and luxB in a dual promoter format or as cotransfected separate plasmids. However, the bioluminescence levels from HEK293
cells harboring the luxA and luxB as a single bicistronic transcript consistently produced
significantly higher light levels (Figure 19).
Because the Lux proteins were not detectable from stable cell lines, mRNA from
the three brightest clones from each construct was isolated and probed with a [32P]
labeled probe complementary to the luxA sequence. luxA mRNA was detectable from
every cell line tested above background vector control levels (Figure 20). However, the
amount of transcript (determined as intensity values from autoradiougraphy) varied
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Figure 17. Relative bioluminescence levels (RLU/mg total protein) from stable HEK293 cell line clones
grown in the absence of antibiotic. Solid lines indicate bioluminescence from cell lines that
the constructs integrated into the host chromosome. Dashed lines indicate clones expressing
the genes episomally.
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Figure 18. Bioluminescence levels (RLU/mg total protein) from stable HEK293 cell line clones expressing the
luxA and luxB as a bicistronic transcript via an IRES element. The negative control is an HEK293
line transfected with the pIRES vector only.
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Figure 19. Relative bioluminescence levels (RLU/mg total protein) from stable HEK293 cell line clones
expressing luxAB fusion (black), luxA and luxB from a dual promoter vector (red), cotransfection of the luxA and luxB on separate plasmids (green) or as a bicistronic transcript
via an IRES element (yellow).
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Figure 20. RNA slot blot analysis of HEK293 clones expressing the luxA and luxB genes either as a fusion
protein, on separate plasmids (co-transfected), within the same plasmid but with separate promoters
(dual promoter) or a transcriptional fusion linked with an IRES element. Negative vector controls
(NC) were added to determine background hybridization levels. Plasmid (pcDNABf) DNA was
added as a positive control (PC).
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greatly between cell lines and clones and did not correlate with the bioluminescence
levels obtained (R2=0.15) (Figure 21).

Discussion
Previous work by Escher et al. (1989) showed that the luxAB fusion, using genes
from Vibrio harveyi, was stable at elevated temperatures if initially expressed in E. coli
at 23°C. However, when the fused protein was grown and expressed at 37°C there was
a greater than 99% reduction in light. These data suggest that the fused luxAB does not
fold properly at elevated temperatures. The luciferase from P. luminescens has a higher
thermal stability (t1/2 >3 h at 45°C) than V. harveyi (t1/2 5 min. at 45°C) (Meighen,
1991). Therefore, a translational fusion generated from the P. luminescens luxA and
luxB genes was generated and evaluated. Although the luxAB fusion was functional in
E. coli, bioluminescence activity was significantly reduced (70%) compared to the wild
type unfused genes (Figure 11). In the unfused luxAB the α and β subunits are
individually translated and are free to fold into their specific conformation (Tu and
Mager, 1995). Therefore, the reduction in bioluminescence may be due to steric
hindrance involved in the way the subunits form the heterodimer when expressed as a
protein monomer. The addition of a Kozak sequence further reduced the
bioluminescence level to approximately 5% of the wild type protein. Nevertheless, the
Kozac sequence is a mammalian ribosomal binding site and therefore to evaluate its
true effectiveness the construct was tested in HEK293 cells. The light levels were
significantly reduced (>90%) compared to HEK293 cells expressing the fusion protein
without the Kozac modifications (Figure 13). The addition of a Kozak sequence (G at
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Figure 21. Relative bioluminescence (RLU/mg total protein) versus average
intensity values from RNA slot blot analysis of each clone.
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the +4 position) specifically changes the second amino acid of luxA from Lysine to
Glutamic acid. These two amino acids have opposite net charges, which could result in
a modification of the protein's secondary structure ultimately altering the protein's
function resulting in decreased bioluminescence.
To determine temperature effect on the folding of the fusion protein, the fused
and unfused versions of the luxAB were grown at 23˚C, 30˚C and 37˚C. In E. coli, there
was not a statistical difference (p < 0.05) associated with temperature on
bioluminescence as seen by Escher et al. This suggested that the folding problems in the
V. harveyi LuxAB fusion protein were not present in the P. luminescens LuxAB fusion
protein. However, when the fusion construct was expressed in the yeast, S. cerevisiae
the bioluminescence levels significantly decreased as temperature increased to 37˚C
(Table 6B). The differences seen in these two systems may be a result of the bacterial
system’s ability to transcribe the luxB independently due to the ribosomal binding site
and luxB start codon still present in the fusion. When the fusion is expressed in the
yeast system, the luxB is no longer independently expressed resulting in a true fusion
protein that is unable to properly fold at 37˚C. The independent expression of the luxB
in bacteria may have resulted in the unfused LuxB subunit forming the heterodimeric
conformation with the LuxA within the LuxAB fusion resulting in the unaffected
bioluminescence observed when the construct was expressed in E. coli.
In an attempt to mimic mammalian translation machinery, in vitro transcription
and translation of the luxA, luxB and luxAB fusion were performed in a rabbit
reticulocyte lysate system. Although the 77kDa fusion protein was easily detected, the
individual proteins, LuxA and LuxB, were not. This result was unexpected because
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equal amounts of RNA transcript were added to each translation reaction. These data
suggest that the formation of the heterodimeric (α and β subunit) complex may be
required for not only efficient bioluminescence activity, but also for the overall stability
of the protein.
Although detectable amounts of bioluminescence were obtained from
mammalian cell lines harboring the LuxAB fusion protein, these levels were not
sufficient for the creation of a reliable biosensor. Therefore, other expression formats
were evaluated in an attempt to optimize bioluminescence activity. It was thought that
by expressing the lux genes separately, the subunits would be able to form a more
natural heterodimeric conformation. Human embryonic kidney cells (HEK293) were
used for these evaluations. Cells were transfected with a dual promoter vector construct
that that was developed to constitutively express each gene from a separate promoter or
co-transfected with two plasmids each harboring either the luxA or luxB gene.
Furthermore, to evaluate the differences in protein expression from genes integrated in
the host’s chromosome versus those constructs maintained as episomal plasmids, each
expression format (fusion, dual promoter and co-transfection) was constructed on a
plasmid backbone able to replicate episomally in HEK cells. The bioluminescence
levels from stable cell lines harboring each expression variation were determined.
Although there were slight variations in activity the differences were not statistically
significant (p=0.05). The only exception was the reduced bioluminescence activity
obtained from cells harboring a dual promoter vector episomally (Figure 15). The low
light levels from these clones were somewhat surprising considering that the average
bioluminescence from the fusion protein and from cells co-transfected with two
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plasmids were slightly higher when the constructs were maintained as episomes. Upon
further analysis, it was determined that the mRNA levels from the individual lux genes
were not equal and therefore in this expression format, one promoter is inducing
transcription at a higher rate than the other. This type of promoter occlusion where the
transcription of one of the two promoters was significantly dampened has been seen
previously (Horlick et al., 2000). The unequal availability of one of the lux subunits at
a level over the other may prevent the proper formation of the heterodimeric active
luciferase protein and may result in inactive homodimer formation.
In order for a bacterial lux-based mammalian bioreporter to be useful, the
constructs need to remain stable in the absence of antibiotic selection for long periods of
time. Efficient maintenance and stability of foreign genes requires that the DNA
replicate once per cell cycle and be retained (integrated or episomally) in the nucleus.
Expression plasmids harboring the luxA and luxB genes in three individual expression
formats were created on both the traditional integration vectors and on Epstein-Barr
virus (ori-P) based episomal plasmid vectors. To determine the stability of these
constructs in HEK293 cells, the cell line clones were grown for twenty passages in
complete growth media without antibiotic. In general, all clones (chromosomal and
episomal) were stable for at least five passages after the antibiotic removal. However,
the constructs that were maintained as episomes began to lose bioluminescence activity
by passage ten with episomal co-transfected cells resulting in the fastest
bioluminescence decline rate (Figure 17). Although there was a significant decline in
bioluminescence activity from episomally based constructs over time, the light was not
completely lost from any of the cells lines. Therefore, this reduction in
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bioluminescence may be the result of natural plasmid loss and generation of a plasmid
equilibrium within the cells. Immediately following transfection the DNA molecules
within each cell can be very high and a natural decline in this concentration occurs to a
steady state for plasmid maintenance (Middleton and Sugen, 1994 and Horlick et
al.,1997). This number can vary, but the average is between 50 and 100 copies per cell
with the further loss of approximately 5% per generation in the absence of selection
(Yates and Guan, 1991). The constructs that were integrated into the host’s
chromosome remained relatively stable throughout the twenty passage (approximately
2.5 months) evaluation. These data indicate that integration of the lux genes within the
host’s chromosome may be the most suitable way to express the genes in mammalian
cells for long-term gene maintenance and stable bioluminescence activity.
In order to optimize the bioluminescence potential from mammalian cells the lux
genes need to be processed and expressed much in the way they are in bacteria. To
establish a more natural expression format for the heterodimeric luciferase protein, the
luxA and luxB genes were cloned into a bicistronic mammalian expression vector. This
vector was developed to allow for the expression of two genes of interest under the
control of a single constitutive promoter with the use of an internal ribosomal entry site
(IRES). IRES elements can be defined as specific nucleotide sequences that allow for
ribosomal entry and translation initiation directly at the start codon (AUG) rather than
requiring scanning from the 5′ end, cap structure, of the mRNA (Pestova et al., 2001
and Kozac, 2001). Since the lux genes are naturally found in a polycistronic operon, it
was thought that by expressing the genes in this format a more natural production and
formation of the heterodimer could be obtained. From each of the stable cell line
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clones obtained harboring lux genes expressed as a bicistronic transcript, the
bioluminescence (RLU/mg total protein) was at least an order of magnitude greater than
levels obtained with any of the other expression formats tested (Figure 18). On average,
there was no significant difference between bioluminescence levels obtained from
HEK293 cells expressing the luxAB fusion, the luxA and luxB in a dual promoter format
or as co-transfected separate plasmids. However, the bioluminescence levels from
HEK293 cells harboring the luxA and luxB as a single bicistronic transcript
constitutively produced significantly higher light levels (Figure 19).
Based on these data it was determined that of the four expression formats
evaluated that the bicistronic expression of the luxA and luxB genes was by far the best
choice. Furthermore, although in general, the bioluminescence levels were slightly less,
the stability of the construct when integrated into the host’s chromosome makes this a
more suitable choice for the development of bacterial lux-based mammalian biosensors.
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CHAPTER 3
CODON OPTIMIZATION OF THE BACTERIAL LUCIFERASE FOR EXPRESSION
IN MAMMALIAN CELLS

Introduction
The standard term “universal genetic code” comes from the fact that there are
sixty-four possible codons for only twenty amino acids. Although the genetic code is
degenerate, the alternate synonymous codons are not used with equal frequency (Sharp
et al., 1988). In fact, it has been shown that there is not only a selective difference, but
also a preference for certain codons in highly expressed genes (Sharp et al., 1993). This
obvious codon bias has been shown to play a key role in the gene expression efficiency
in all species tested to date (Amicis and Marchetti, 2000). Furthermore, codon usage
patterns are not conserved between organisms of different species. This is especially
true between genes from prokaryotes and eukaryotes.
An obvious first step in developing a mammalian cell line that utilizes the
potential benefits of the bacterial luciferase enzyme system is to optimize the expression
of the heterodimeric luciferase protein. The bioluminescence levels obtained through
the expression of the wild type genes in various expression formats, although promising
are not adequate for the development of reliable mammalian biosensors. Based on these
data, the lux genes need further optimization in order to realize their full potential as
mammalian reporter proteins.
Codon optimization is the term given to the synthetic creation of a gene
sequence to possess the optimal codon usage patterns for the host organism. Several
examples of successful codon optimization have been recently published. These
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optimized proteins have been primarily designed for increased expression in
mammalian hosts, as mammalian expression of foreign genes is often times limited
(Narum et al., 2001). Several reporter proteins have been codon optimized in an attempt
to increase expression in mammalian cells including the optimization of green
fluorescent protein (GFP) (Zhang et al., 2002) and Renilla luciferase (Gruber and
Wood, 2000) reporter genes. In both of these instances, codon optimization resulted in
these reporter proteins becoming stronger reporters for gene expression and reliable
monitoring tools in mammalian cells.
Based on this knowledge and the fact that further optimization is needed for the
efficient expression of the bacterial luciferase in mammalian cells, it is hypothesized
that by codon optimizing the luxA and luxB genes from P. luminescens that the
bioluminescence activity from mammalian cell lines harboring these genes would be
enhanced. The specific objectives of the this research are:

•

To evaluate the luxA and luxB gene sequences from P. luminescens for
codon usage pattern differences compared with optimal mammalian
codon usage.

•

To design a codon optimized sequence for the luxA and luxB genes to
potentially allow for enhanced expression in mammalian cells.

•

Compare the codon optimized sequences to the wild type genes using
prediction analysis programs for mammalian expression.

•

Synthesize complete codon optimized genes from oligonucleotides.
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•

To determine if codon optimization significantly improves the
expression of bacterial luciferase in mammalian cells.

•

To evaluate on what level of expression (transcription or translation) an
increase in activity is derived.

Materials and Methods
Cell Culture and Plasmid Maintenance
All relevant constructs and strains, bacterial and mammalian, used in this study
are outlined in Table 7. E. coli cells were routinely grown in Luria Bertani (LB) (Fisher
Scientific, Pittsburgh, PA) broth containing the appropriate antibiotic selection with
continuous shaking (200rpm) at 37°C. Kanamycin and Ampicillin were used at a final
concentration of 50µg/ml and 100 µg/ml, respectively.
All cell culture reagents and media were obtained from Sigma Aldrich, (St.
Louis, MO) unless otherwise stated. Mammalian cells were grown in the appropriate
complete growth media containing 10% heat-inactivated horse serum, 0.01mM nonessential amino acids and 0.1mM sodium pyruvate in a Dubelco’s minimal essential
media base (DMEM) (M4655). Cells were routinely grown at 37°C in a 5% CO2
atmosphere to confluency and split every three to four days by trypsinization at a 1:4
ratio and transfer into fresh complete growth media. Appropriate concentrations of
antibiotic were used to maintain constructs after transfection according to susceptibility
kill curve analysis. Kill curves were completed for each lot of antibiotic. The range of
typical concentrations used for the selection of HEK293 cell line clones was between
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Table 7. Strains and plasmids used in the determination of the optimal expression
format for bacterial luciferase in mammalian cells.
Plasmid/Strain
Designation
Strains
E. coli

Relevant Genotype/ Characteristics

Source

DH5α

Φ80dlacZ∆M15, recA1, endA1, gyrA96, thi-1,
hsdR17 (rK-, mK+), supE44, relA1, deoR,
∆(lacZYA-argF)U169

Gibco, BRL

TOP 10

F-, mcrA ∆(mrr-hsdRMS-mcrBC) Φ80/lacZ
∆lacX74 deoR recA1 araD139 ∆(ara-leu) 7697
ga/K rpsL endA1 nupG

Invitrogen

Mammalian Cells
Permanent line of primary human embryonal
kidney transformed by sheared human adenovirus
type 5 (Ad 5) DNA. ATCC# CRL-1573

ATCC

pCR2.1-TOPO

TOPO TA cloning vector for easy cloning of PCR
products generated with 3′ A overhangs Kmr,
Ampr

Invitrogen

pCR4-TOPO

TOPO TA cloning vector for easy cloning of PCR
products generated with 3′ A overhangs designed
for sequencing Kmr, Ampr

Invitrogen

HEK293

Plasmids

pIRES

Mammalian expression vector containing the
internal ribosomal entry site (IRES) of the
encephalomyocarditis virus between two multicloning sites which allows for the expression of
two genes under the control of a single constitutive
CMV promoter, Neomycin G418 antibiotic
selection marker and a pUC ori and Kmr for
replication in E.coli

Clontech

pCR4luxB

pCR4 TA cloning vector harboring the luxB from
Photorhabdus luminescens

This Study

pNotIluxA

pCR4 harboring the luxA from P. luminescens with
introduced NotI sites on both the 5′ and 3′ ends of
the gene

This Study

pWTAI3

pIRES harboring the luxA from P. luminescens
cloned into the MCS(A)

This Study
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Table 7. Continued
Plasmid/Strain
Designation

Relevant Genotype/ Characteristics

Source

pCOA#1

pCR4 vector harboring the codon optimized luxA
gene with errors at base 365 and 1003.

This Study

pCOA#11

pCR4 vector harboring the codon optimized luxA
gene with errors at bases 11, 28 and 365

This Study

pCOB#6

pCR4 vector harboring the codon optimized luxB
gene with errors at base 321 and 829.

This Study

pCOB#7

pCR4 vector harboring the codon optimized luxB
gene with errors at base 287 and 569.

This Study

pWTA-I-WTB

pIRES harboring the luxA (WTA) cloned into the
MCS(A) and luxB (WTB) cloned into MCS(B)
from P. luminescens

This Study

pCOA-I-WTB

pIRES harboring the codon optimized luxA (COA)
into the MCS (A) and wild type luxB (WTB) into
the MCS (B) from P. luminescens

This Study

pCOA-I-COB

pIRES harboring the codon optimized luxA (COA)
into the MCS (A) and codon optimized luxB
(COB) into the MCS (B) from P. luminescencs

This Study

WTA-I-WTB(1-20)

HEK293 cell lines stably transfected with the
pWTA-I-WTB plasmid and selected by G418.

This Study

COA-I-WTB(1-20)

HEK293 cell lines stably transfected with the
pCOA-I-WTB plasmid and selected by G418.

This Study

COA-I-COB(1-20)

HEK293 cell lines stably transfected with the
pCOA-I-COB plasmid and selected by G418.

This Study
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450µg and 650µg/ml.

Determining Codon Optimized Sequence of Photorhabdus luminescens luxA and

luxB Genes
To determine a codon optimized sequence for P. luminescens luxA and luxB
genes, the codon ratios within the wild type genes were analyzed and compared to
optimal codon usage patterns from highly expressed (top 10%) mammalian genes. The
optimal codon ratios were determined by information tabulated in Genbank. The
overall ratio for usage of each codon within the wild type genes was altered to more
closely match mammalian codon usage (Table 8A and 8B). In general, low frequency
codons were used rarely or not at all and higher frequency codons were used more
often. The codons were replaced within the wild type sequences in a random fashion.
The sequence was further analyzed for any potential splice sites or other regulatory
regions using the NetGene2 algorithm for prediction of potential acceptor and donor
splice sites (www.cbs.dtu.dk/cgi-bin/nph-webface?jobid=netgene2). Any potential
splice sites were removed. Transcription factor binding sites were also identified,
however, these sequences were too numerous to successfully eliminate. After the final
codon optimized sequence was determined, it was compared to the wild type sequence
using the Genescan prediction algorithm (http://genes.mit.edu) to evaluate the potential
expression of the new sequence versus the wild type.

88

Table 8. Codon usage of wild type versus codon optimized genes. (A) luxA (B) luxB
WTA= wild type luxA, WTB= wild type luxB, COA= codon optimized luxA
COB= codon optimized luxB.
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A
Amino Acid

Codon

WTA

COA

Amino Acid

Codon

WTA

COA

Phe

TTT
TTC
TTA
TTG
CTT
CTC
CTA
CTG
ATT
ATC
ATA
ATG
GTT
GTC
GTA
GTG
TCT
TCC
TCA
TCG
CCT
CCC
CCA
CCG
ACT
ACC
ACA
ACG
GCT
GCC
GCA
GCG

14
5
9
5
9
1
2
3
14
4
6
9
3
2
10
6
5
1
6
2
2
4
2
3
6
1
9
4
13
3
3
5

6
13
2
4
10
13
4
20
9
3
6
12
11
1
5
4
2
5
14
1
15
9
-

Tyr

TAT
TAC
TAA
TAG
CAT
CAC
CAA
CAG
AAT
AAC
AAA
AAG
GAT
GAC
GAA
GAG
TGT
TGC
TGA
TGG
CGT
CGC
CGA
CGG
AGT
AGC
AGA
AGG
GGT
GGC
GGA
GGG

12
5
0
1
10
1
11
3
14
6
17
6
15
8
13
9
4
4
0
6
4
5
2
2
3
1
2
0
7
5
9
5

5
12
1
3
8
6
8
5
15
4
19
6
17
2
20
3
5
6
9
3
1
5
3
4
11
5
6

Leu

Ile
Met
Val

Ser

Pro

Thr

Ala

Ter
His
Gln
Asn
Lys
Asp
Glu
Cys
ter
Trp
Arg

Ser
Arg
Gly
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Table 8. Continued
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B
Amino Acid

Codon

WTB

COB

Amino Acid

Codon

WTB

COB

Phe

TTT
TTC
TTA
TTG
CTT
CTC
CTA
CTG
ATT
ATC
ATA
ATG
GTT
GTC
GTA
GTG
TCT
TCC
TCA
TCG
CCT
CCC
CCA
CCG
ACT
ACC
ACA
ACG
GCT
GCC
GCA
GCG

13
5
9
6
3
2
2
3
13
5
8
8
13
3
4
1
3
1
4
0
6
1
3
1
4
2
6
4
8
3
4
5

5
13
3
2
18
5
21
8
3
7
11
8
7
2
2
4
12
14
6
-

Tyr

TAT
TAC
TAA
TAG
CAT
CAC
CAA
CAG
AAT
AAC
AAA
AAG
GAT
GAC
GAA
GAG
TGT
TGC
TGA
TGG
CGT
CGC
CGA
CGG
AGT
AGC
AGA
AGG
GGT
GGC
GGA
GGG

16
1
1
0
8
3
6
5
18
6
16
6
17
3
23
8
4
2
0
2
1
2
0
1
7
2
3
0
6
3
3
2

4
13
1
2
9
3
8
4
20
4
20
3
17
6
25
1
5
2
3
1
2
7
3
1
9
2
2

Leu

Ile
Met
Val

Ser

Pro

Thr

Ala

Ter
His
Gln
Asn
Lys
Asp
Glu
Cys
ter
Trp
Arg

Ser
Arg
Gly
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Synthesizing the Codon Optimized luxA and luxB Genes
Once the codon optimized sequence had been determined, oligonucleotides for
each gene were designed that covered the complete sequence (Table 9& 10). Each
oligo was designed with an 18 – 23 base pair overlap on the 5′ and 3′ ends with its
adjacent oligos. These overlapping regions were designed with Tm values of 53°C 56°C. Once the oligos were designed they were synthesized by Sigma Genosys (Sigma,
St. Louis, MO) and polyacrylamide gel (PAGE) purified to ensure full-length products.
Each oligonucleotide was placed into a PCR reaction with the following conditions;
internal oligos (0.25 pmol), the two outermost oligos (25 pmols), dNTP mixture (200
nm), 1X Pfu buffer, 1X Pfu Enhancer solution, MgCl2 (concentration determined
experimentally) and 1U of Pfu DNA polymerase (Stratagene, La Jolla, CA).
All PCR reactions were performed in 0.2 ml thin walled PCR tubes using a
PTC-225 DNA Engine (MJ Research, Waltham, MA). For gene synthesis the following
program was used; (1) initial denaturation 95°C for 5 min, (2) 30 cycles of 94°C for 1
min, 50°C for 1 min and 68°C for 2 min followed by (3) final extension 68°C for 10
min. Resultant PCR products were run on 1% agarose gels in 1X TBE. Unfortunately,
there were no detectable products of the correct size. As an alternative strategy, four
separate reactions were set up with four adjacent oligos in each reaction (Figure 22).
The two innermost primers were added at a final concentration of 0.25 pmols and the
two outermost oligos were used as both template and primers at a concentration of 25
pmols. Each piece was then amplified using the parameters outlined above with the
exception of the extension step was reduced from 2 min to 45 sec. The resultant PCR
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1st round
of PCR

2nd round
of PCR

Final
Product

Figure 22. Schematic diagram of the recursive PCR method used to construct the
synthetic luxA and luxB genes. Outside oligonucleotides were added at 25
pmol final concentration while the inside oligonucleotides were added at 0.25
pmol final concentration.
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Table 9. Oligonucleotide primer sequences used to synthesize the codon optimized
luxA gene.
Primer Name
Sequence 5′ to 3′
5′CGAAACCATGAAGTTCGGCAACTTCCTGCTCACATATCAGCC
COA1
TCCCCAGTTTTCCCAAACCGAGGTCATGAAGCGGCTGGTTA
(Sense)
AGCTCGGCCGCATCTC C 3′

COA2
(Antisense)

5′ AAGCAGCAGCGACATAAGGGTTACCAAGCAGGCCGAA
CTCGGTGAAGTGGTGCTCCAGCAGCCACACGGTGTCGAAAC
CGCACTCCTCGGAGATGCGGCCGAGCTTA 3′

COA3
(Sense)

5′ CCCTTATGTCGCTGCTGCTTATCTGCTCGGCGCCAC
CAAGAAACTGAACGTCGGCACTGCCGCTATCGTTCTC
CCCACCGCCCATCCAGTCCGCCAGCTT 3′

COA4
(Antisense)

5′ GAAGTCCTTGTTGTAAAGCCCGCGGCAGATGCCGAA
CCGAAAGCGCCCCT TGGACATTTGATCCAGCAAGTTC
ACGTCCTCAAGCTGGCGGACTGGATGG 3′

COA5
(Sense)

5′ CGGGCTTTACAACAAGGACTTCCGCGTGTTCGGCA
CCGACATGAACAACAGCCGCGCCCTGGCCGAGTGTT
GGTACGGGCTGATCAAGAATGGCATGA 3′

COA6
(Antisense)

5′ GAGCGCCACCTCTGCTGTAAGCGGCGGGGTTCACTT
TGACTTTGTGGAACTTGATGTGCTCATTGTCGGCTTCC
ATGTATCCCTCGGTCATGCCATTCTTGATCAGCC 3′

COA7
(Sense)

5′ ACAGCAGAGGTGGCGCTCCTGTTTATGTGGTGGCTG
AGTCAGCTAGTACCACTGAGTGGGCTGCTCAATTTGG
CCTCCCTATGATCCTGTCCTGGATCATCAACAC 3′

COA8
(Antisense)

5′ CAGGCAGTGGTCGATGTTATGAATGTCGTGCCCG
TACTCTTGAGCCACTTCGTTGTAAAGCTCGAGCTGG
GCCTTCTTCTCATTAGTG TTGATG ATCCAGGACAGG 3′

COA9
(Sense)
COA10
(Antisense)

5′ CATAACATCGACCACTGCCTGTCCTACATCACCTC
CGTGGACCACGACTCCATCAAGGCCAAGGAGATTTG
CCGGAAGTTTCTCGGGCATTGGTATGATAG 3′
5′ AACACGAAATCGCGCCACTGCCCCTTGTTGAAGTC
GTAACCTCTGGTCTGGTCGGAGTCGTCAAAGATAGTG
GTAGCATTCACG TAGCTAT CATACCAATGCCCGAG 3′
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Table 9. Continued
Sequence

Primer Name
COA11
(Sense)

COA12
(Antisense)
COA13
(Sense)
COA14
(Antisense)

5′ AGTGGCGCGATTTCGTGTTGAAAGGACACAAGG
ATACTAACAGACGCATCGACTACAGCTACGAGATCAA
TCCCGTGGGCACCCCTCAG GAGTGCATTGACATCATCC 3′
5′ ATGGAAGCGATGATCTCGTCCACGGTTCCGTTAGCCTCA
AATCCACAACAGATGTTGGAGATTCCGGTAGCATCAA
TGTCCTTTTGGATGATG TCAATGCACTCCTG 3′
5′ GACGAGATCATCGCTTCCATGAAGCTCTTCCAGTCCG
ATGTCA TGCCATTCCTCAAGGAGAAGCAACGCA
GCCTCCTGTACTAGGGATCC 3′

5′ GGATCCCTAGTACAGGAGGCTGC 3′
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Table 10. Oligonucleotide primer sequences used to synthesize the codon optimized
luxB gene.
Primer Name

Sequence 5′ to 3′

COB1
(Sense)

5 ′CGAAACCATGAAGTTCGGACTGTTCTTCCTTAACTTCATCA
ACTCCACCACTGTGCAGGAGCAAAGCATCGTGCGCATGCAG
GAGATCACCGAGTATGTGGAC 3′

COB2
(Antisense)

5 ′CACAGTCAGAGGAGCGCCGACAACGCCATTGTCGGAAAA
GTGGTTCTCGTACACCAGGATCTGCTCGAAGTTCAGCTTG
TCCACATAC TCGGTGATCTCC 3′

COB3
(Sense)
COB4
(Antisense)
COB5
(Sense)

5 ′ GGCGCTCCTCTGACTGTGTCCGGCTTCCTGCTCGGCCT
GACCGAGAAGATCAAAATTGGCTCCCTGAACCACATCAT
CACCACTCATCATCCTGTCGCCATCGCT 3′
5 ′ GTGCATCTCGTCCTTCTTCTCGCAATCGCTGAACCCC
AGGATGAATCTCCCCTCGCTCAGCTGATCCAGCAGGCA
AGCCTCCTCAGCGATGGCGACAGGATG 3′
5 ′GAGAAGAAGGACGAGATGCACTTTTTCAACCGCCCTGT
GGAATATCAGCAG CAACTGTTTGAAGAGTGCTACGAGAT
CATTAACGACGCTCTGACCACCGGCTACTGC 3′

COB6
(Antisense)

5 ′AGCGGTGACATACTTCCGAGGGCCGCCTGGGGTGTAA
GCGTGGGGGTTGACGGAGATTTTAGGGAAGCTGTAG
AAGTCATTGTCGGGGTTGCAGTAGCCGGTGGTCAG 3′

COB7
(Sense)

5 ′TCGGAAGTATGTCACCGCTACCAGTCATCACATCGTGG
AGTGGGCTGCCAAG AAAGGCATCCCTCTCATCTTTAAGT
GGGATGACTCCAACGACGTGAGATACGAGTA 3′

COB8
(Antisense)

5′ TAACCAGGATCATCAGCTGGTGGTCGATTTCGGACAG
GTCAACGTCATATTTGTCAGCCACGGCCTTGTATCTC
TCAGCGTACTCGTATCTCACGTCGTTGG 3′

COB9
(Sense)
COB10
(Antisense)

5′ CCAGCTGATGATCCTGGTTAACTACAACGAAGACAGC
AACAAGGCTAAG CAGGAGACCCGCGCCTTCATTAGCGA
CTACGTGCTTGAAATGCACCCTAAC 3′

5′ CCAGCTTAGCAGCAGTGATACACTCGGTGTAGTTTCCG
ACAGCGTTCTCGGCGATGATTTCCTCAAGCTTGTTCTCGA
AGTTCTCGTTAGGGTGCATTTCAAGCAC 3′
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Table 10. Continued
Sequence

Primer Name
COB11
(Sense)
COB12
(Antisense)

5′ TGTATCACTGCTGCTAAGCTGGCCATCGAGAAGTGCGGT
GCTAAGAGTGTCCTGCTGTCCTTTGAGCCAATGAATGAC
CTGATGAGCCAAAAGAACGTCAT 3′
5′ GGATCCTTAGGTGTACTCCATGTGGTACTTCTTAATATTG
TCGTCCACAATGTTGATGACGTTCTTTTGGCTCATCAG 3′
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products were then gel purified using the Geneclean gel extraction kit according to the
manufacturer’s instructions (Bio101, Carlsbad, CA). The extracted products were
quantified using a Dyna Quant 200 fluorometer (Hoefer Pharmacia Biotech
Incorporated, San Francisco, CA) and placed into a second PCR reaction at equal molar
concentrations (0.25 pmols). The two outermost (5′ and 3′) oligos were used as primers
at a final concentration of 25 pmols. After the second PCR reaction, the products of the
correct size were again gel purified as previously described. Because Pfu polymerase
produces blunt end products, 3′ A overhangs were added to allow for TA TOPO cloning
of the products. To accomplish this, the gel-extracted product was mixed with dATP
(200nM) 1X amplitaq buffer and 1U of Taq polymerase (Amersham Pharmacia, San
Francisco, CA) and placed at 72°C for 20 – 30 min. Immediately following the addition
of the A’s, the product was TA TOPO cloned into the pCR4 TOPO cloning vector
(Invitrogen Corporation, Carlsbad, CA). Resultant colonies were then checked for
insert by an EcoRI restriction digest and sequenced to ensure their integrity.

Site Directed Mutagenesis
Although the oligos were successfully joined into a double stranded synthetic
gene, several point mutations were determined by sequencing. A number of clones for
each gene were completely sequenced in an attempt to identify a flawless clone without
success. To correct these errors, site directed mutagenesis was done. First, for the
codon optimized luxA gene, two separate clones pCOA#1 and pCOA#11 were used as
template. Site directed mutagenesis primers were designed to introduce the necessary
changes. The complete luxA sequence was amplified in two separate sections (365 bp
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from pCOA#1 and 719bp from pCOA#11) that overlapped between the bases where the
necessary changes were required. Each segment was gel purified and then linked back
together by a second round of PCR as described for the original gene synthesis.
Subsequently, 3′ A overhangs were added and the product TA TOPO cloned into pCR4.
Upon sequencing, a construct with the correct sequence was identified and termed
pPA2. Site directed mutagenesis was also performed on the codon optimized luxB
sequence using overlapping primers designed to introduce the proper changes. The
complete luxB sequence was amplified in three segments (324 bp from pCOB#7, 340 bp
from pCOB#6 and 319 bp pCOB#7) from two separate clones (pCOB#7 and pCOB#6)
and subsequently linked by PCR as previously described. A construct of the correct
sequence was produced and termed pPB2.

Construction of a Bicistronic Expression Vector
To compare the expression of the codon optimized luxA and luxB genes to the
wild type, the pIRES vector was used (Clontech Corporation, Palo Alto, CA). This
expression vector contains two multi-cloning sites separated by an internal ribosomal
entry site (IRES) from encephalomyocarditis virus (EMCV). The IRES element allows
for the expression of two genes (one cloned into each multi-cloning site) from a single
constitutive CMV promoter. For comparison purposes, a wild type luxA and luxB
(pWTA-I-WTB) construct, a codon optimized luxA and wild type luxB (pCOA-I-WTB)
construct and a codon optimized luxA and codon optimized luxB (pCOA-I-COB)
construct were generated.
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pWTA-I-WTB
To create this construct, the luxA gene from P. luminescens was amplified from
pPLluxCDABE plasmid that harbors the complete luxCDABE cassette (Table 7) and
unique NotI restriction sites were introduced on both the 5′ and 3′ ends of the luxA gene.
The resultant PCR product was TA TOPO cloned into pCR4 TOPO to generate
pNotIluxA. The luxA gene was then cloned into the MCS(A) of pIRES via the unique
NotI restriction sites to generate pWTAI. Once this construct was confirmed by
sequencing, the plasmid was purified using the Wizard midi-prep plasmid purification
kit according to the manufacturer’s instructions (Promega Corporation, Madison, WI).
The luxB gene was cleaved via a 5′ XbaI and 3′ SpeI site from pCRluxB and cloned into
the XbaI site within the MCS(B) of pWTAI to generate pWTA-I-WTB (Figure 23A).
pCOA-I-WTB
To generate this construct, the codon optimized luxA gene (COA) was cleaved
from pPA2 via unique NotI restriction sites and cloned into the MCS(A) of the pIRES
vector (Clontech Corporation, Palo Alto, CA) to generate pCOAI. Once this construct
was confirmed by sequencing, the plasmid was purified using the Wizard midi-prep
plasmid purification kit according to the manufacturer’s instructions (Promega
Corporation, Madison, WI). The wild type luxB gene was cleaved via a 5′ XbaI and 3′
SpeI site from pCRluxB and cloned into the XbaI site within the MCS(B) of pCOAI to
generate pCOA-I-WTB (Figure 23B).
pCOA-I-COB
To generate this construct, the codon optimized luxB (COB) gene was cleaved
from pPB2 via introduced 5′ and 3′ XbaI sites and cloned into the MCS(B) from pCOAI
to create pCOA-I-COB (Figure 23C).
101

Figure 23. Schematic diagram of the final constructs used to compare the wild type
luxA and luxB to the codon optimized genes. A. Wild type luxA and wild
type luxB B. Codon optimized luxA and wild type luxB C. Codon optimized
luxA and codon optimized luxB.
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Ligation Reactions
Plasmid vectors and inserts were digested (2-6 h) with the appropriate enzymes
(Promega Corporation, Madison, WI). Linearized vectors were dephosphorylated using
a calf intestine alkaline phosphatase enzyme according for the manufacturer’s
instructions (Promega Corporation, Madison, WI). Both vector and insert DNA were
gel purified from 1% agarose gels using the Geneclean gel extraction kit (Bio101,
Carlsbad, CA). The recovered DNA was then quantified using a Dyna Quant 200
fluorometer (Hoefer Pharmacia Biotech Incorporated, San Francisco, CA) and ligations
were set up as 20µl reactions using a 3:1 molar ratio of insert to vector DNA. The
ligation reactions were then incubated at 17°C overnight.

Electroporation
Electrocompetent cells were prepared as outlined by the manufacturer (BTX,
San Diego, CA). Electroporations were performed using the BTX Electroporator 600
with the following conditions: 40µl cells, 1-2µl ligation mixture, a 2.5kV pulse for
4.7ms using a 2mm gap cuvette. After the pulse, cells were immediately resuspended in
1ml of sterile LB and allowed to recover for 1 h at 37°C (200 rpm). Cells were then
plated on selective media containing the appropriate antibiotic.

Selection of Bacterial Clones
Resistant colonies were picked after 24 h and expanded to patches on grid
plates. To test for proper insert presence and orientation, rapid boil plasmid mini-preps
(Promega Corporation, Madison, WI) were done followed by the digestion of the
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plasmid with the appropriate restriction enzyme mixture according to the
manufacturer’s instructions (Promega Corporation, Madison, WI). Products were run
on 1% agarose gels to determine if the banding pattern indicated the insert presence and
proper orientation. Upon identifying correct clones, the plasmids were further purified
using the Wizard midiprep plasmid purification system according to the manufacturer’s
protocol (Promega Corporation, Madison, WI) and sequenced.

Sequencing
All constructs were sequenced to ensure their integrity. Sequencing was done in
the University of Tennessee Molecular Biology Service Facility using an Applied
Biosystems 3100 Genetic Analyzer sequencer (Foster City, CA).

Transfection of Mammalian Cells
Transfection of mammalian cell lines was done in six well poly-D-lysine coated
tissue culture plates (Fisher Scientific, Pittsburgh, PA). Cells were split from stock
cultures and inoculated into each well at approximately 1X105 cells per well in
complete growth media. The plate was then placed at 37°C in a 5% CO2 atmosphere
for 1-2 days until the cells became 80-90% confluent. The day of transfection, the
media was refreshed. DNA for transfections was purified from 100ml overnight E. coli
cultures using the Wizard Purefection plasmid purification kit to remove endotoxins
according to the manufacturer’s instructions (Promega Corporation, Madison, WI). For
chromosomal integration, the plasmid DNA was linearized before transfection to
increase proper integration.
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HEK293 Cells
Purified plasmid DNA (3.2 µg) was mixed into 200 µl of serum free DMEM in
a 1.5 ml tube. In a second tube, 8 µl of Lipofectamine 2000 reagent (Invitrogen
Corporation, Carlsbad, CA) was added to 200 µl of serum free DMEM. The
lipofectamine mixture was added to the DNA mixture within 5 min and incubated at
room temperature for 20 min. The entire mixture (400 µl total) was added directly to
the appropriate well on the plate and rocked back and forth to ensure adequate mixing.
Twenty-four hours post transfection, the complexes were removed and the media was
replaced with fresh complete growth media supplemented with the appropriate
antibiotic for selection.

Selection of Mammalian Cell Clones
Twenty-four hours post transfection, selective media was added to all wells and
refreshed every three to four days. Within two weeks all control wells were dead and
the transfected cells were forming small colonies on the plate surface. Colonies were
separated from the rest of the well by placing a sterile chamber around the cell mass and
sealing it with silicon (Fisher Scientific, Pittsburgh, PA). The media could then be
removed and each colony could be trypsinized and transferred to individual tissue
culture flasks. To accomplish this, after washing with a PBS solution, 200 µl of a 1X
Trypsin-EDTA solution (Sigma Aldrich, St. Louis, MO) was added directly to the
chamber and incubated at 37°C for 3 to 5 min. The trypsin-EDTA solution was then
replaced with complete growth media and the cells were transferred to a 25cm2 tissue
culture flask for propagation. Each clone was given a number and expanded to
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individual cell lines. Each line was split and maintained as described earlier with the
addition of selective media. Twenty cell lines were propagated in this manner for each
plasmid tested.

Bioluminescence Assays from Mammalian Cells
To determine bioluminescence potential from each cell line clone, total proteins
were extracted and in vitro enzyme (bioluminescence) assays performed. To extract the
proteins, the cells were trypsinized from the plate or flask surface using standard
protocols and resuspended into 2.0 ml Sarstedt tubes (Fisher Scientific, Pittsburgh, PA).
The cells were then spun down and washed two times in sterile phosphate buffered
saline (PBS) to remove any residual media (Sigma Aldrich, St. Louis, MO). Cell pellets
were then resuspended into 1 ml 0.1M potassium phosphate buffer pH 7.8 and disrupted
by three consecutive cycles of freeze (30 s liquid N2) thaw (5 min at 37°C) extraction.
After disruption, the cell debris was pelleted by spinning the samples at 14,000Xg for 5
min and the supernatant was used in the bioluminescence assay. To determine light
intensity, the protein extract was mixed with 0.1 mM NAD(P)H, 4 µM FMN, 0.2%
(w/v) BSA, 0.002% (w/v) n-decanal. Bioluminescence was measured using the FB14
luminometer (Zylux Corporation, Pforzheim, Germany) at a 1 s integration and reported
as relative light units (RLU). To determine if FMNH2 was a limiting factor for the
bioluminescence reaction, a flavin oxidoreductase enzyme (1U) isolated from V.
harveyi (Roche Scientific, Indianapolis, IN) was added to the bioluminescence assay
and the light levels were measured again for comparison.
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Bioluminescence signals were normalized between samples and cell lines by
dividing the RLU measurement by the total protein and reporting the bioluminescence
as RLU/µg total protein. Protein concentrations were determined using the Coomassie
Plus protein assay according to the manufacture’s instructions (Biorad, Hercules, CA).

In Vitro Transcription/Translation
To determine if the lux genes could be translated in vitro in rabbit reticulocyte
lysate (mammalian translation machinery), pIRES vector harboring the wild type luxA
(WTA), and codon optimized luxA (COA) were transcribed and translated. First, the
plasmid DNA containing the genes was digested at a unique XbaI restriction site at the
3′ end of the gene within the vector. This digestion linearized the plasmid and allowed
for the generation of run-off transcript from the vector derived T7 promoter. Each gene
was transcribed via T7 polymerase using the RiboMax large-scale transcription system
(Promega Corporation, Madison, WI). Three individual transcription reactions were set
up along with a positive T7 control and a negative control containing no template DNA.
Each reaction was set up according to the manufacturer’s protocol and then incubated at
37°C for 1 h. Transcripts were quantified by absorbance (260/280) measurements
(Beckman Coulter, Fullerton, CA). Ten micrograms per ml of total RNA transcript was
then added to 50 µl (total volume) rabbit reticulocyte lysate translation reactions. Each
reaction was gently mixed on ice according to the manufacturer’s protocol for S35
labeled protein generation and then incubated at 30°C for 90 min (Promega
Corporation, Madison, WI). Once translation was complete, 15 µl of each reaction was
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loaded onto a 12% SDS-PAGE mini-gel and run at 30 mA for 1 h. The gel was
removed and dried at 60°C with vacuum pressure using a model 443 Slab Dryer
(BioRad, Hercules, CA) onto 3MM filter paper (Fisher Scientific, Pittsburgh, PA). To
visualize the generated proteins, the gel was placed onto an intensifier screen overnight
and specific activity was measured using the STORM 840 phosphoanalyzer (Molecular
Dynamics, Piscataway, NJ).

Genomic DNA Isolation and Southern Blotting
Genomic DNA from each clone was accomplished using the Wizard genomic
DNA extraction kit according to the manufacturer’s protocols (Promega Corporation,
Madison, WI). After isolation each preparation was quantified using a Dyna Quant 200
fluorometer (Hoefer Pharmacia Biotech Incorporated, San Francisco, CA). In two
separate reaction tubes restriction digestions were set up with 2.5µg of DNA each using
a BamHI restriction enzyme according to the manufacturer’s instructions (Promega
Corporation, Madison, WI). Digestions were carried out in a 37°C water bath for four
hours. After digestion the products were loaded and run on a 1% agarose gel at 30V for
6 hours. The gel was then stained with ethidium bromide and photographed before the
transfer. The gel was then soaked for 15 min in a depurination solution (250mM HCl)
and 30 min in a denaturation solution (0.5M NaOH and 1M NaCL), rinsed with dH2O
and then neutralized two times for 15 min in (0.5M Tris/ 1.5M NaCl) before a final
equalization in 20X SSC. The DNA was then transferred to BiotransTM nylon
membrane (ICN, Irvine, CA) using the Turbo blotter apparatus according to the
manufacturer’s instructions (Schleicher and Schuell, Keene, NH).
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Double stranded DNA probes were generated complementary to a 300 bp
portion of the codon optimized and wild type luxA genes using standard PCR protocols
with the incorporation of a [32P] labeled dCTP nucleotide. The probe was purified by
column purification according to the manufacturer’s instructions (Stratagene, La Jolla,
CA). The specific activity of the each probe was measured by scintillation counting
(Beckman Coulter, Fullerton, CA). Double stranded probes were boiled for 10 min to
denature the DNA and directly added in equal amounts of specific activity to each blot.
The blot was incubated with the probe at 65°C overnight. After probe hybridization, the
blot was washed 4 times in 20X SSC to remove any unbound activity. The wash
temperatures were determined experimentally to achieve optimal probe binding without
excess background activity. The blot was air dried and then placed on a
phosphorescence intensifier screen (Molecular Dynamics, Piscataway, NJ). Specific
activity was measured using the STORM 840 phosphoanalyzer and the data analyzed
using the ImageQuant data analysis software package (Molecular Dynamics,
Piscataway, NJ).

RNA Isolation and Blotting
At passage six, post transfection, selected cell line clones were expanded to
75cm2 tissue culture flasks. When the cells became 80-95% confluent, they were
trypsinized to remove the cells from the surface and transferred to 2.0 ml Sarstedt tubes
(Fisher Scientific, Pittsburgh, PA). Cells were spun down and washed two times in
sterile PBS (Sigma Aldrich, St. Louis, MO). Total RNA was then isolated from the
cells using the RNeasy kit (Quiagen, Valencia, CA) according to the manufacturer’s
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instructions for isolation of total RNA from mammalian cells. To remove any
contaminating DNA, the RNA was digested for 30 min with DNaseI (Promega
Corporation, Madison, WI). To remove the DNaseI enzyme, the clean-up procedure
from the RNeasy kit was used (Quiagen, Valencia, CA). Total RNA was then
quantified using the Beckman DU-640 spectrophotometer absorbance at 260/280
(Beckman Coulter, Fullerton, CA).
Northern Blotting
Ten micrograms of total RNA were loaded onto a 0.8% agarose formaldehyde
gel and run at 100V for 2 hrs. The gel was then stained in an ethidium bromide solution
and visualized. The RNA was then transferred to a BiotransTM nylon membrane (ICN,
Irvine, CA) using a semi-dry electroblot transfer apparatus according to the
manufacturer’s instructions (CBS Scientific, San Francisco, CA).
A 26 base pair oligonucleotide was designed to specifically hybridize to the
codon optimized and wild type luxA sequences. This oligonucleotide was then 3′ end
labeled with a γ [32P] dATP by T4 polynucleotide kinase according to the
manufacturer’s protocol (Promega Corporation, Madison, WI). The oligonucleotide
probe was then purified by column purification as outlined by the manufacturer
(Stratagene, La Jolla, CA). The specific activity of the probe was measured by
scintillation counting (Beckman Coulter, Fullerton, CA) and added directly to the blot.
Double stranded DNA probes were generated complementary to a 300 bp
portion of the codon optimized and wild type luxA genes using standard PCR protocols
with the incorporation of a [32P] labeled dCTP nucleotide. The probe was purified by
column purification according to the manufacturer’s instructions (Stratagene, La Jolla,
111

CA). The specific activity of the each probe was measured by scintillation counting
(Beckman Coulter, Fullerton, CA). Double stranded probes were boiled for 10 min to
denature the DNA and directly added in equal amounts of specific activity to each blot.
The blot was incubated with the probe at 50°C overnight. After probe
hybridization, the blot was washed 4 times in 20X SSC to remove any unbound activity.
The wash temperatures were determined experimentally to achieve optimal probe
binding without excess background activity. The blot was air dried and then placed on
a phosphorescence intensifier screen (Molecular Dynamics, Piscataway, NJ). Specific
activity was measured using the STORM 840 phosphoanalyzer and the data analyzed
using the ImageQuant data analysis software (Molecular Dynamics, Piscataway, NJ).

Protein Isolation and Western Blotting
To extract the proteins, cells were trypsinized from a plate or flask surface and
resuspended into 2.0 ml Sarstedt tubes (Fisher Scientific, Pittsburgh, PA). The cells
were then spun down and washed two times in sterile phosphate buffered saline (PBS)
to remove any residual media (Sigma Aldrich, St. Louis, MO). Cell pellets were
resuspended into 1 ml 0.1M potassium phosphate buffer pH 7.8 and disrupted by three
consecutive cycles of freeze (30 s liquid N2) thaw (5 min at 37°C) extraction. After
disruption, the cell debris was pelleted by spinning the samples at 14,000Xg for 5 min
and the supernatant was used as total soluble protein for Western blot analysis.
Protein concentrations were determined using the Coomassie Plus protein assay
according to the manufacturer’s instructions (Pierce, Rockford, IL). Equal amounts
(100 – 250 µg) of protein were loaded onto a 12% SDS-PAGE gel. Minigels were run
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at 30 mA for approximately 2 h and larger slab gels were run at 30 mA overnight. The
proteins were then electroblot transferred to PDVF membrane (Biorad, Hercules, CA)
using a semi-dry electroblotter according to the manufacturer’s instructions (CBS
Scientific Company, Incorporated, Del Mar, CA). Blots were then blocked overnight in
5% nonfat dry milk and hybridized with a polyclonal antibody raised against a 16 amino
acid luxA polypeptide (′N′ - FDDSDQTRGYDFNKGC - ′C′) or a 16 amino acid luxB
polypeptide (′N′ - CMILVNYNEDSNKAKQ - ′C′) (Genemed Synthesis, Incorporated,
San Francisco, CA). Antibodies were diluted in T-TBS (Tris Buffered Saline + 3%
Tween 20) at a 1:500 dilution and applied to the membrane at room temperature for 5 h
to overnight. The blot was then washed several times in T-TBS and incubated with a
Goat Anti-Rabbit second antibody that has been conjugated to alkaline phosphatase.
The blot was then developed according to the manufacturer’s protocol (Biorad,
Hercules, CA).

Statistics
Statistical analysis of the data presented here was conducted using either the
JMP (SAS Institute, Incorporated, Pacific Grove, CA) or Microsoft Excel (Microsoft,
Seattle, WA) statistical software packages. Graphs were made using Sigma Plot
software (SPSS, SAS Institute, Incorporated, Pacific Grove, CA) or Microsoft Excel
(Microsoft, Seattle, WA). All error bars on graphs indicate one standard deviation of
the mean. Significant differences were determined using either t-test or 1 way ANOVA
analysis at a level of α=0.05.
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Results

Determining a Codon Optimized Sequence of P. luminescens luxA and luxB for
Expression in Mammalian Cells
The ratio of codons in the wild type luxA and luxB nucleotide sequences was
compared to codon usage patterns of highly expressed (top 10%) mammalian genes
according to the Genbank sequence database. It was determined that the codon usage
patterns between P. luminescens and human genes were extremely different. Therefore,
to create an optimized version of the lux genes, the codon ratios were altered to more
closely follow codon usage patterns within the human genome. Higher frequency
codons were used more often while rare codons were eliminated from the sequence
entirely. Changes were made within the nucleotide sequence in a random fashion. This
codon optimized sequence was further analyzed for potential regions that may act as
target splice sites or other regulatory signals. The sequence was then modified until all
potential splice sites and the more obvious regulatory sequences were removed. A
comparison of the final codon optimized and wild type lux sequences was made. Once
the codon optimized sequence was finalized it was tested using the GENSCAN online
algorithm that predicts protein expression levels of gene sequences in human cells by
comparing the sequence to known highly expressed genes within the matrix specified
(http://genes.mit.edu). The results of this analysis were encouraging and a predicted a
significant increase in expression on both transcriptional and translational levels.
Further, although verification was not possible, GENSCAN predicted a cleavage of the
first twenty amino acids of the wild type LuxA protein when expressed in mammalian
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cells (Table 11). This cleavage was eliminated in the codon optimized sequence and a
full length product was predicted to form. A seqence alignment of the wild type and
codon optimized genes is shown in Figures 24 and 25. The wild type and codon
optimized luxA and luxB ratios for codon usage is shown in Table 8A and 8B.

Construction of the Codon Optimized luxA and luxB Genes
To evaluate the potential impact of codon optimization on the expression of the
bacterial luciferase genes in mammalian cells, codon optimized versions of each gene
were synthesized in vitro. To generate functional genes, single stranded
oligonucleotides (80-106 bp) were designed that spanned the entire gene sequence with
overlapping (18-23 bp) regions. Four oligonucleotides were placed into a single PCR
reaction to amplify segments of the genes individually (Figure 22). The two outside
oligonucleotides were used as both template and primers for the amplification reaction
and the internal oligos as template. Resultant PCR products of the appropriate size
were placed into a second PCR reaction and the fragments were then amplified to link
the pieces together using the two outermost oligonucleotides as primers (Figure 22).
Products of the correct size were again purified and TA TOPO cloned to generate pPA2
and pPB2. Complete sequence analysis was performed and revealed several introduced
errors that were subsequently corrected by site directed mutagenesis.
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Table 11. GENSCAN transcription and translation prediction scores for expression
of the luxA and luxB in a human host. (http://genes.mit.edu)

Gene

Type Begin End

Length I

T

CodRg

luxA(wt) 1
luxA(op) 1

61
1

1083
1083

1023
1083

45 42
66 42

791
1910

luxB(wt) 1
luxB(op) 1

1
1

984
984

984
984

51 38
66 41

585
1952

P

Trans.

0.7
0.88

67.01
181.78

0.97
0.99

I = initiation signal T = termination signal CodRg = Coding Region score
P = probability of an exon
Trans. = exon score
*Score interpretation: 0-50 = weak
50-100 = moderate
>100 = strong
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46.37
185.60

WTA
COA

1 atgaaatttggaaactttttgcttacataccaacctccccaattttctcaaacagaggta
||||| || || ||||| |||| ||||| || |||||||| ||||| ||||| |||||
1 atgaagttcggcaacttcctgctcacatatcagcctccccagttttcccaaaccgaggtc

WTA 61 atgaaacgtttggttaaattaggtcgcatctctgaggagtgtggttttgataccgtatgg
||||| || ||||||| | || |||||||| |||||||| ||||| || ||||| |||
COA 61 atgaagcggctggttaagctcggccgcatctccgaggagtgcggtttcgacaccgtgtgg
WTA121 ttactggagcatcatttcacggagtttggtttgcttggtaacccttatgtcgctgctgca
| |||||||| || ||||| ||||| || ||||||||||||||||||||||||||||
COA121 ctgctggagcaccacttcaccgagttcggcctgcttggtaacccttatgtcgctgctgct
WTA181 tatttacttggcgcgactaaaaaattgaatgtaggaactgccgctattgttcttcccaca
||| | || ||||| || || ||| |||| || || ||||||||||| ||||| |||||
COA181 tatctgctcggcgccaccaagaaactgaacgtcggcactgccgctatcgttctccccacc
WTA241 ggcccatccagtacgccaacttgaagatgtgaatttattggatcaaatgtcaaaaggacga
||||||||||| ||||| |||||| || ||||| || ||||||||||||| || || ||
COA241 ggcccatccagtccgccagcttgaggacgtgaacttgctggatcaaatgtccaaggggcgc
WTA301 tttcggtttggtatttgccgagggctttacaacaaggactttcgcgtattcggcacagat
|||||||| || || ||||| |||||||||||||||||||| ||||| |||||||| ||
COA301 tttcggttcggcatctgccgcgggctttacaacaaggacttccgcgtgttcggcaccgac
WTA361 atgaataacagtcgcgccttagcggaatgctggtacgggctgataaagaatggcatgaca
||||| ||||| |||||| | || || || |||||||||||||| ||||||||||||||
COA361 atgaacaacagccgcgccctggccgagtgttggtacgggctgatcaagaatggcatgacc
WTA421 gagggatatatggaagctgataatgaacatatcaagttccataaggtaaaagtaaacccc
|||||||| |||||||| || ||||| || ||||||||||| || || ||||| ||||||
COA421 gagggatacatggaagccgacaatgagcacatcaagttccacaaagtcaaagtgaacccc
WTA481 gcggcgtatagcagaggtggcgcaccggtttatgtggtggctgaatcagcttcgacgact
|| || || |||||||||||||| || ||||||||||||||||| ||||||
|| |||
COA481 gccgcttacagcagaggtggcgctcctgtttatgtggtggctgagtcagctagtaccact
WTA541 gagtgggctgctcaatttggcctaccgatgatattaagttggattataaatactaacgaa
||||||||||||||||||||||| || ||||| |
||||| || || ||||| ||
COA541 gagtgggctgctcaatttggcctccctatgatcctgtcctggatcatcaacactaatgag
WTA601 aagaaagcacaacttgagctttataatgaagtggctcaagaatatgggcacgatattcat
||||| || || || |||||||| || |||||||||||||| || |||||||| ||||||
COA601 aagaaggcccagctcgagctttacaacgaagtggctcaagagtacgggcacgacattcat
WTA661 aatatcgaccattgcttatcatatataacatctgtagatcatgactcaattaaagcgaaa
|| |||||||| ||| | || || || || || || || || ||||| || || || ||
COA661 aacatcgaccactgcctgtcctacatcacctccgtggaccacgactccatcaaggccaag

Figure 24. Wild type and codon optimized luxA sequence alignment.
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WTA721 gagatttgccggaaatttctggggcattggtatgattcttatgtgaatgctacgactatt
|||||||||||||| ||||| |||||||||||||||
|| ||||||||||| |||||
COA721 gagatttgccggaagtttctcgggcattggtatgatagctacgtgaatgctaccactatc
WTA781 tttgatgattcagaccaaacaagaggttatgatttcaataaagggcagtggcgtgacttt
||||| || || ||||| || |||||||| || ||||| || ||||||||||| || ||
COA781 tttgacgactccgaccagaccagaggttacgacttcaacaaggggcagtggcgcgatttc
WTA841 gtattaaaaggacataaagatactaatcgccgtattgattacagttacgaaatcaatccc
|| || |||||||| || |||||||| | || || || ||||| ||||| |||||||||
COA841 gtgttgaaaggacacaaggatactaacagacgcatcgactacagctacgagatcaatccc
WTA901 gtgggaacgccgcaggaatgtattgacataattcaaaaagacattgatgctacaggaata
||||| || || ||||| || |||||||| || ||||| |||||||||||||| |||||
COA901 gtgggcacccctcaggagtgcattgacatcatccaaaaggacattgatgctaccggaatc
WTA961 tcaaatatttgttgtggatttgaagctaatggaacagtagacgaaattattgcttccatg
|| || || |||||||||||||| ||||| ||||| || ||||| || || |||||||||
COA961 tccaacatctgttgtggatttgaggctaacggaaccgtggacgagatcatcgcttccatg
WTA1021 aagctcttccagtctgatgtcatgccatttcttaaagaaaaacaacgttcgctattatat
|||||||||||||| |||||||||||||| || || || || |||||
|| | ||
COA1021 aagctcttccagtccgatgtcatgccattcctcaaggagaagcaacgcagcctcctgtac
WTA1081 tag
|||
COA1081 tag

Figure 24. Continued
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WTB
COB

1 atgaaatttggattgttcttccttaacttcatcaattcaacaactgttcaagaacaaagt
||||| || ||| |||||||||||||||||||||| || || ||||| || || |||||
1 atgaagttcggactgttcttccttaacttcatcaactccaccactgtgcaggagcaaagc

WTB 61 atagttcgcatgcaggaaataacggagtatgttgataagttgaattttgaacagatttta
|| || ||||||||||| || || |||||||| || ||| |||| || || ||||| |
COB 61 atcgtgcgcatgcaggagatcaccgagtatgtggacaagctgaacttcgagcagatcctg
WTB121 gtgtatgaaaatcatttttcagataatggtgttgtcggcgctcctctgactgtttctggt
||||| || || || ||||| || ||||| ||||||||||||||||||||||| || ||
COB121 gtgtacgagaaccacttttccgacaatggcgttgtcggcgctcctctgactgtgtccggc
WTB181 tttctgctcggtttaacagagaaaattaaaattggttcattaaatcacatcattacaact
|| |||||||| | || ||||| || |||||||| || | || |||||||| || |||
COB181 ttcctgctcggcctgaccgagaagatcaaaattggctccctgaaccacatcatcaccact
WTB241 catcatcctgtcgccatagcggaggaagcttgcttattggatcagttaagtgaagggaga
||||||||||||||||| || ||||| |||||| | |||||||| | || || ||||||
COB241 catcatcctgtcgccatcgctgaggaggcttgcctgctggatcagctgagcgaggggaga
WTB301 tttattttagggtttagtgattgcgaaaaaaaagatgaaatgcatttttttaatcgcccg
|| || | ||||| || |||||||| || || || || ||||| ||||| || |||||
COB301 ttcatcctggggttcagcgattgcgagaagaaggacgagatgcactttttcaaccgccct
WTB361 gttgaatatcaacagcaactatttgaagagtgttatgaaatcattaacgatgctttaaca
|| |||||||| |||||||| ||||||||||| || || ||||||||||| ||| | ||
COB361 gtggaatatcagcagcaactgtttgaagagtgctacgagatcattaacgacgctctgacc
WTB421 acaggctattgtaatccagataacgatttttatagcttccctaaaatatctgtaaatccc
|| ||||| || || || || || || || || |||||||||||||| || || || |||
COB421 accggctactgcaaccccgacaatgacttctacagcttccctaaaatctccgtcaacccc
WTB481 catgcttatacgccaggcggacctcggaaatatgtaacagcaaccagtcatcatattgtt
|| ||||| || |||||||| |||||||| ||||| || || ||||||||||| || ||
COB481 cacgcttacaccccaggcggccctcggaagtatgtcaccgctaccagtcatcacatcgtg
WTB541 gagtgggcggccaaaaaaggtattcctctcatctttaagtgggatgattctaatgatgtt
|||||||| ||||| ||||| || ||||||||||||||||||||||| || || || ||
COB541 gagtgggctgccaagaaaggcatccctctcatctttaagtgggatgactccaacgacgtg
WTB601 agatatgaatatgctgaaagatataaagccgttgcggataaatatgacgttgacctatca
||||| || || ||||| ||||| || ||||| || || ||||||||||||||||| ||
COB601 agatacgagtacgctgagagatacaaggccgtggctgacaaatatgacgttgacctgtcc
WTB661 gagatagaccatcagttaatgatattagttaactataacgaagatagtaataaagctaaa
|| || ||||| ||| | ||||| | |||||||| |||||||| || || || |||||
COB661 gaaatcgaccaccagctgatgatcctggttaactacaacgaagacagcaacaaggctaag

Figure 25. Wild type and codon optimized luxB sequence alignment.
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WTB721 caagagacgcgtgcatttattagtgattatgttcttgaaatgcaccctaatgaaaatttc
|| ||||| || || || ||||| || || || ||||||||||||||||| || || |||
COB721 caggagacccgcgccttcattagcgactacgtgcttgaaatgcaccctaacgagaacttc
WTB781 gaaaataaacttgaagaaataattgcagaaaacgctgtcggaaattatacggagtgtata
|| || || ||||| ||||| || || || |||||||||||||| || || ||||||||
COB781 gagaacaagcttgaggaaatcatcgccgagaacgctgtcggaaactacaccgagtgtatc
WTB841 actgcggctaagttggcaattgaaaagtgtggtgcgaaaagtgtattgctgtcctttgaa
||||| |||||| |||| || || ||||| ||||| || ||||| |||||||||||||
COB841 actgctgctaagctggccatcgagaagtgcggtgctaagagtgtcctgctgtcctttgag
WTB901 ccaatgaatgatttgatgagccaaaaaaatgtaatcaatattgttgatgataatattaag
||||||||||| ||||||||||||| || || ||||| ||||| || || |||||||||
COB901 ccaatgaatgacctgatgagccaaaagaacgtcatcaacattgtggacgacaatattaag
WTB961 aagtaccacatggaatatacctaa
|||||||||||||| || ||||||
COB961 aagtaccacatggagtacacctaa

Figure 25. Continued
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In Vitro Transcription and Translation of the Wild Type and Codon Optimized
luxA
To quickly evaluate the translation efficiency in a mammalian cell system of the
codon optimized and wild type luxA genes, in vitro transcription and translation analysis
was performed. The pIRES expression vector contains a bacteriophage T7 promoter
region upstream of the MCS (A). This promoter was used to generate runoff transcripts
of the wild type and codon optimized luxA sequences. The transcript was then
translated in vitro using rabbit a reticulocyte lysate system that incorporates a 35S
methoinine into the polypeptide sequence and allows for easy detection. The codon
optimized LuxA protein (COA) was determined to be produced by this system
approximately twenty fold over the wild type LuxA protein (Figure 26).

In Vivo Expression of the Wild Type Versus Codon Optimized luxA and luxB
Genes
To evaluate the optimized genes in vivo, wild type and codon optimized versions
of the luxA and luxB were cloned into the pIRES mammalian expression vector to allow
for bicistronic expression of both genes with only one selection marker. Twenty
stable clones (HEK293 cells) were selected for each construct along with one negative
vector control. At passage three post transfection, each clone was tested in vitro for
bioluminescence upon the addition of n-decanal and FMNH2. These data revealed that
each clonal cell line varied in its bioluminescence levels (Figure 27). The average
bioluminescence from each gene combination is shown in Figure 28. Based on these
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MW Ladder
Marker
C14

COA
WTA

WTA
PA2

220 kD

NC
NC

Intensity Values
WTA = 1496
PA2
29,636
COA==29,636

97 kD
66 kD
45 kD

LuxA protein

30 kD

20 kD

Figure 26. In vitro translation products of the wild type luxA and codon optimized luxA
genes. Products were labeled by the incorporation of [35S] methionine.
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Figure 27. Bioluminescence measurements taken at passage three post transfection for
the twenty clones for each construct. A. WTA/WTB clones
B. COA/WTB clones C. COA/COB Clones.
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Figure 27. Continued
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Figure 28. Average bioluminescence from stably transfected HEK293 cell
lines. (20 clones tested for each clone type in triplicate).
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data, the two or three clones producing the highest bioluminescence levels were chosen
for further study. At passage six, each clone selected was expanded into triplicate
75cm2 tissue culture flasks. From these cells, total genomic DNA, total RNA and
soluble proteins were extracted for further analysis.

Determining Insertion Number in HEK293 Clones
To determine gene insertion number in each clone, a southern blot was
performed using luxA probes generated to both the wild type and codon optimized luxA
sequences. As shown in Figure 29, all of the cell lines tested had either one or two
copies of the gene inserted with the exception of the COA/COB3 clone. To simplify
further measurements, this clone was then disregarded for further bioluminescence
comparisons.

Determination of luxA Message Levels in HEK293 Clones
To determine transcript levels, total RNA was extracted and northern blot analysis
was performed. The same probes that were used for Southern blot analysis were used in
these experiments as well. Transcript levels were determined to be approximately
equal with the exception of the WTA/WTB1 clone that had a lower amount of luxA
transcript (Figure 30). The vector (NC) control had little to no background
hybridization (Figure 30). The ethidium bromide stained 28S was included as an RNA
loading reference.
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Figure 29. Southern blot analysis on the stable HEK293 clones harboring either wild
type luxA and luxB, codon optimized luxA and wild type luxB or codon
optimized luxA and luxB. The blot was probed with a 300 bp [32P] labeled
probe of both the wild type and codon optimized luxA sequence.
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Figure 30. Northern blot analysis of the stable HEK293 clones harboring either wild
type luxA and luxB, codon optimized luxA and wild type luxB or codon
optimized luxA and luxB. Ethidium bromide stained 28S rRNA was used to
ensure RNA quality and loading controls.
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Determination of LuxA Protein Levels in HEK293 Clones
Total soluble proteins from each clone were isolated by a series of freeze (liquid
N2) thaw (37°C) cycles. Two hundred fifty micrograms of total protein were run on an
SDS-PAGE gel and Western blot analysis was performed using a polyclonal luxA
antibody (Figure 31). LuxA protein was not detected in any of the wild type luxA and
luxB clones, only detected at very low levels in codon optimized luxA with wild type
luxB clones, but readily detectable when both genes were codon optimized (Figure 31).
This increase in LuxA protein concentration was observed despite the fact that the
levels of luxA mRNA transcript were relatively equivalent for all of the clones tested
(Figure 32).

Bioluminescence Levels from Wild Type Versus Codon Optimized Luciferase
Genes
Bioluminescence levels were evaluated on whole cell extracts upon the addition
of n-decanal and FMNH2. Each clone was tested in triplicate from individual 35cm2
wells. Bioluminescence values were found to be greater than two orders of magnitude
higher in cell lines harboring both a codon optimized luxA and luxB (COA/ COB) over
that of the cell lines harboring the wild type genes (WTA/WTB) (Figure 33). The
bioluminescence levels obtained increased in the order WTA/WTB < COA/WTB <
COA/COB. Based on these data it was determined that codon optimization had a
significant effect (p<0.05) on the bioluminescence potential from HEK293 cells.
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Figure 31. Western blot analysis of HEK293 clones harboring either wild type luxA
and luxB, codon optimized luxA and wild type luxB or codon optimized luxA
and luxB. The β-actin protein was used as a loading control.
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A
B

Figure 32. Comparison of mRNA levels and protein levels in each of the stable
HEK293 cell line clones. A. Northern blot of total RNA (20µg) from stably
transfected HEK293 cells probed with 32P labeled complimentary luxA
probes. B. Western blot of total soluble protein (250 µg) from stably
transfected HEK293 cells immunoblotted with a polyclonal luxA antibody.
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Figure 33. Average bioluminescence from individual HEK293 clones stably
transfected with WTA/IRES/WTB, COA/IRES/WTB or COA/IRES/COB.
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Discussion
Codon usage regulates gene expression at the level of translation and the usage
patterns between species are not conserved (Kurland, 1991). This is especially true
between genes derived from eukaryotes versus those from prokaryotes. Therefore, to
efficiently express the bacterial lux genes in mammalian cells, the nucleotide sequence
was altered in such a way as to create a “humanized” form of the gene without altering
the amino acid sequence. This approach has been used previously to optimize the
expression of both GFP and Renilla luciferase proteins for expression in mammalian
cells (Zhang et al., 2002 and Gruber and Wood, 2000). The design of this new
sequence was carefully determined, removing all potential splice sites and most
regulatory regions. After the final codon optimized sequence was determined, it was
evaluated using the GENSCAN prediction algorithm to determine the potential
expression efficiency in a human cell. According to the output from this program the
overall expression of the codon optimized lux genes would be significantly improved
versus the wild type. The increase in expression was predicted to be caused by an
increase in both transcription and translation efficiency. Furthermore, it was predicted
that the first sixty bases (20 amino acids) of the wild type luxA gene would be
completely eliminated when expressed in mammalian cells. Considering that this
region of the LuxA protein holds most of the catalytic properties (active site) for the
bacterial luciferase enzyme, this would be devastating for its expression. If this were
the case, the low expression levels observed for the LuxAB fusion protein, shown
earlier, may be better explained in part by a nonfunctional protein being formed rather
than inefficient folding or heat liability.
135

To test the expression of the codon optimized genes, modified versions were
required. However, because the necessary changes were to numerous to achieve by site
directed mutagenesis, a complete in vitro gene synthesis protocol was pursued. Large
oligonucleotides (80-106 bp) were designed with overlapping (18-22 bp) regions. The
original plan was to amplify all of the oligonucleotides together in one PCR reaction
according to methods set by Prodromou and Pearl (1992). However, because of the
larger size of the lux genes (approximately 1000 bp each), this was not possible. As an
alternative, the gene was synthesized in parts and the subsequently linked by a second
round of PCR. The two outside oligonucleotides were used as both template and
primers for each reaction. After some experimental effort, it was determined that for
optimal amplification the internal oligonucleotides (template) should be added at a
concentration that equaled 100 fold less than the outside oligos. Amplification products
of the correct size were cloned and sequenced. Unfortunately, sequence analysis
revealed several base substitution mutations within all clones tested. These mutations
were present despite the fact that care was taken by using a Pfu polymerase that has
proof reading abilities. This finding was disappointing while not surprising given that
two consecutive PCR reactions were required to obtain the final gene product resulting
in > 60 cycles of amplification. To eliminate these errors and produce the proper
sequence, site directed mutagenesis was performed.
It was determined previously through work accomplished in S. cerevisiae and
mammalian cells for the expression of the bacterial luciferase genes that IRES elements
may be an efficient way to express independent proteins as single bicistronic transcripts.
This expression format provides the most natural expression of the genes, most closely
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mimicking the polycistronic form found in the bacterial operon. Therefore, experiments
were set up to compare the codon optimized and wild type luxA and luxB genes in
mammalian cells using an IRES based expression vector. The expression vector used
was designed to highly express two independent genes under the control of a single
constitutive encephalomyocarditis virus (ECMV) promoter region by linking two
multicloning sites fused to either side of an internal ribosomal entry site (IRES). The
IRES element allows for the translation of two consecutive open reading frames from
one messenger RNA (Jang et al., 1990; Jackson et al., 1990; Rees et al., 1996). By
constructing plasmids with different combinations of the codon optimized luxA and
luxB with their wild type counterparts, a direct comparison of the genes was made.
To quickly determine if a difference in translation efficiency could be detected
between the optimized and wild type luxA genes, in vitro transcription and translation
analysis was performed. The codon optimized luxA gene (COA) was detected
approximately twenty fold over wild type (Figure 26). This finding supported the
results that shown earlier with the in vitro generation of the wild type LuxA protein.
Since the rabbit reticulocyte lysate translation system is used to mimic mammalian
translation machinery in vitro, these results indicated that the codon optimization would
indeed make a significant impact on the translation efficiency of the lux proteins in
mammalian systems.
HEK293 cells were transfected with the WTA/ WTB, WTA/ COB or COA/COB
constructs and stable cell line clones were selected by antibiotic resistance. Twenty
stable clones for each luxA and luxB combination were selected and bioluminescence
levels were determined upon the exogenous addition of n-decanal and FMNH2. The
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bioluminescence significantly increased in the order WTA/WTB < COA/WTB <
COA/COB. These data indicated that codon optimization had made a significant
impact on the potential bioluminescence levels obtained from mammalian cells. To
analyze this data further, the two or three brightest clones were chosen for further study.
From these cells, total genomic DNA, total RNA and total soluble proteins were
extracted.
Foreign gene integration in mammalian cells is a random event, therefore it is
possible to have more than one insertion of the construct occur during each transfection.
Since integration is fairly inefficient, the copy number per cell is generally very low.
However, because of this possibility, it was important to determine the copy number of
the inserted genes for at true comparison. To accomplish this, Southern blot analysis
was performed on each of the seven clones that produced the highest bioluminescence
levels. All of the cell lines tested had either one or two copies of the gene inserted with
the exception of the COA/COB3 clone which had three. To simplify further
measurements, this clone was then disregarded for further bioluminescence
comparisons. Nevertheless, it should be noted that increased copy number does not
correlate with increased expression levels. Numerous other factors have been shown to
impact from gene expression at a greater level.
The overall amount of luxA mRNA transcript was determined by Northern blot
analysis. Transcript levels were relatively equal with the exception of the WTA/WTB1
clone that produced significantly lower amounts of luxA mRNA. Since each construct
contained the same promoter (ECMV) element and initiation signals, it would be
expected that each clone would have approximately equal amounts of transcript for the
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introduced genes. However, cis acting regulatory elements could potentially interfere
with transcription initiation and overall transcript levels in vivo. These types of
interferences would vary based on where within the chromosome the genes were
integrated. Therefore, the position effect of various clones could explain the lower
amount of transcript detected with the WTA/WTB1 clone. Other factors that can
potentially impact the amount of RNA transcript would be a direct result of increased
RNA degradation of certain mRNA sequences that can occur. This type of RNA
instability would be less likely after codon optimization because of the removal of
several AU rich target degradation regions. However, because the lower amount of
transcript was not seen in both the WTA/WTB clones, this scenario is unlikely.
To evaluate the overall protein concentrations and determine translation
efficiency of each construct, Western blot analysis was performed. Total soluble
proteins from each clone were isolated and quantified. Western blot analysis was
performed using a polyclonal luxA antibody (Figure 31). The LuxA protein was not
detectable from WTA/WTB clones and faintly visible in the COA/WTB clones.
However, large amounts of LuxA protein were detected from the COA/COB clones
which harbored a construct carrying codon optimized versions of both genes. This
finding was intriguing and unexpected. Since the only available antibody was raised
against a polypeptide of LuxA, it was expected that the constructs harboring the
COA/WTB and COA/COB would produce equal amounts of LuxA protein. Since this
was not the case, these data indicated that the codon optimization of both genes might
infer stability on the heterodimeric complex that makes up the luciferase enzyme. This
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increased stability of the complex may have allowed the proteins to be detected in the
Western blot while the other construct was not detected.
Perhaps the most valuable measurement to determine if codon optimization was
a success is the amount of enzyme activity that could be obtained from each construct.
Bioluminescence levels were evaluated on whole cell extracts upon the addition of ndecanal and FMNH2. Average bioluminescence values were found to be greater than
two orders of magnitude higher in cell lines harboring both a codon optimized luxA and
luxB (COA/COB) over that of the cell lines harboring the wild type genes (WTA/WTB)
(Figure 33). While bioluminescence levels were significantly higher in clones
expressing COA and WTB versus WTA and WTB, the optimal bioluminescence was
obtained from clones harboring optimized versions of both genes (Figure 33). These
data further support the stabilization conclusion of the heterodimeric protein. Based on
these data it was determined that codon optimization had a significant effect on the
protein expression in HEK293 cells.
In conclusion, the codon optimization of the luxA and luxB genes was
successful in increasing the overall expression levels of the individual proteins. This
increase in protein quantities resulted in a significant increase in bioluminescence from
cell lines harboring these constructs. Furthermore, the bioluminescence levels from
codon optimized luxA and luxB provide adequate bioluminescence for the proof in
principle data needed for the future development of reliable reporter constructs for
analyte sensing in mammalian cells.
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CHAPTER 4
EVALUATION OF MAMMALIAN CELLS FOR FMNH2 AVAILABILITY AND
STABILITY OF BACTERIAL LUCIFERASE IN STABLE MAMMALIAN CELL
LINES

Introduction
The bacterial luciferase enzyme system has several advantages over other
bioreporter systems available. Of these advantages, the ability to directly measure in
vivo gene expression without the disruption of the reporter cell or loss of cell viability is
perhaps the most obvious benefit. This property has made the lux system sought out by
many for various research applications using prokaryotic cells. As a result, numerous
biosensor systems utilizing the bacterial luciferase system have been developed and are
currently in use. However, as discussed earlier, the bacterial luciferase system has not
yet been efficiently expressed in mammalian cell lines and therefore the full potential of
this technology is not yet realized. The obstacles encountered by researchers trying to
employ the bacterial lux system in eukaryotes have included low expression levels of
the Lux proteins and limited amounts of substrates and cofactors required for the
reaction within the cells.
The bacterial luciferase enzyme system consists of a multi-enzyme complex
encoded by five genes that provide the luciferase enzyme as well as the luciferin
(aldehyde) substrate for the reaction. However, this reaction additionally requires the
host cell metabolism to provide adequate amounts of molecular O2, the reducing power
of FMNH2 and the energy of ATP as co-factors and substrates. To produce
bioluminescence, the reaction goes through several intermediate steps. With a
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stoichiometry of 1:1:1, the α and β subunits bind with a reduced flavin molecule
(FMNH2) to form a C4a hydroxyflavin. As this hydroxyflavin becomes dehydrated to
FMN, a blue-green light is emitted (Baldwin et al., 1979). Because of the stoichiometry
of the reaction and its absolute requirement, the FMNH2 molecule is considered to be an
additional substrate for the bioluminescence reaction rather than a co-factor. On the
other hand, the luciferase reaction itself can proceed in the absence of the decalaldehyde substrate, but its presence significantly increases the light output kinetics and
therefore is required for bioreporter applications (Volkova et al., 1999).
In bacteria, the availability of FMNH2 is not a limiting factor for the
bioluminescence reaction. Nevertheless, in several bioluminescent strains of bacteria, a
flavin oxidoreductase gene (frp) has been identified in close proximity to the lux
operon. This enzyme has the ability to reduce pools of FMN within the cell to FMNH2
and then recycle itself to catalyze further reductions. Although the availability of
FMNH2 in yeast was shown to be a limiting substrate for the bioluminescence reaction
in these cells, it was subsequently shown that yeast could be further engineered to
express the flavin oxidoreductase gene (frp) from Vibrio harveyi to overcome this
limitation (Gupta et al., 2003). This was the first illustration of the use of a flavin
reductase enzyme to improve the bioluminescence output from an engineered lux
bioreporter cell. Although the availability of the FMNH2 substrate has not been
completely evaluated in mammalian cells, it has been hypothesized to be one of the
major problems leading to inefficient expression of the bacterial luciferase system in
eukaryotes. Furthermore, to this point, all mammalian cell line experiments have been
conducted with the exogenous addition of FMNH2 or the enzymes required to produce
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this substrate. In order to efficiently express the bacterial luciferase system in
mammalian cells, the availability of FMNH2 needs to be fully evaluated and the
possibilities available to overcome this limitation need to be explored.
For the future generation of a useful mammalian bioreporter cell line for gene
expression analysis or target analyte monitoring, the engineered cell line not only needs
to be able to efficiently express the lux genes but, it must also remain stable for long
periods of time in the absence of antibiotic selection. Some of the proposed
applications for this technology may require that the cells remain stable for extended
periods with very little to no intervention. Therefore, the overall stability of engineered
mammalian cell lines harboring the lux genes needs to be evaluated to completely
understand the limitations of this technology. Therefore, in this research effort, the
following objectives will be met:

•

Determine to what extent FMNH2 limits the bioluminescence reaction in
mammalian cell lines expressing the bacterial luciferase enzyme.

•

Obtain a bioluminescent cell line that can overexpress the flavin oxidoreductase
enzyme from Vibrio harveyi.

•

Evaluate the ability of this engineered cell line to produce adequate levels of
FMNH2 for the bioluminescence reaction.

•

Evaluate the overall stability of the constructs within stably integrated
mammalian cell lines engineered with the bacterial luciferase genes for long
term maintenance without antibiotic pressure.
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Materials and Methods
Cell Culture and Plasmid Maintenance
All relevant constructs and strains, bacterial and mammalian, used in this study
are outlined in Table 12. E. coli cells were routinely grown in Luria Bertani (LB)
(Fisher Scientific, Pittsburgh, PA) broth containing the appropriate antibiotic selection
with continuous shaking (200 rpm) at 37°C. Kanamycin and Ampicillin were used at a
final concentration of 50µg/ml and 100µg/ml, respectively.
All cell culture reagents and media were obtained from Sigma Aldrich (St.
Louis, MO) unless otherwise stated. Mammalian cells were grown in the appropriate
complete growth media containing 10% heat-inactivated horse serum, 0.01mM nonessential amino acids and a Dubelco’s minimal media base (DMEM) (M4655). Cells
were routinely grown at 37° C in a 5% CO2 atmosphere to confluency and split every
three to four days by trypsinization at 1:4 ratio and transferred into fresh complete
growth media. Appropriate concentrations of antibiotic were used to maintain
constructs after transfection according to susceptibility kill curve analysis. Kill curves
were completed for each lot of antibiotic. The range of typical concentrations used for
the selection of HEK293 cell line clones was between 450µg/ml and 650µg/ml of
Neomycin G418 and 250µg/ml and 400µg /ml of Zeocin (Invitrogen Corporation,
Carlsbad, CA).
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Table 12. Constructs and Strains used in this study.
Plasmid/Strain
Designation
Relevant Genotype/ Characteristics
Strains
E. coli

Source

DH5α

Φ80dlacZ∆M15, recA1, endA1, gyrA96, thi-1,
hsdR17 (rK-, mK+), supE44, relA1, deoR,
∆(lacZYA-argF)U169

Gibco, BRL

TOP 10

F-, mcrA ∆(mrr-hsdRMS-mcrBC) Φ80/lacZ
∆lacX74 deoR recA1 araD139 ∆(ara-leu) 7697
ga/K rpsL endA1 nupG

Invitrogen

Mammalian Cells
HEK293

Permanent line of primary human embryonal
kidney transformed by sheared human adenovirus
type 5 (Ad 5) DNA. ATCC# CRL-1573

ATCC

Plasmids

pCR4-TOPO

pIRES

pcDNAHISMAX

pcDNA3.1Zeo

pCR4frp

TOPO TA cloning vector for easy cloning of
PCR products generated with 3′ A overhangs
designed for sequencing Kmr, Ampr
Mammalian expression vector containing the
internal ribosomal entry site (IRES) of the
encephalomyocarditis virus between two multicloning sites which allows for the expression of
two genes under the control of a single
constitutive CMV promoter, Neomycin G418
antibiotic selection marker and a pUC ori and
Kmr for replication in E.coli
Mammalian expression vector allows for
constitutive expression under the control of a
constitutive CMV promoter contains a SPC163
translational enhancer, Zeocin antibiotic selection
marker and pUC ori and Ampr for replication in
E. coli.
Mammalian expression vector allows for
constitutive expression under the control of a
constitutive CMV promoter, Zeocin antibiotic
selection marker and pUC ori and Ampr for
replication in E. coli.
pCR4 TA cloning vector harboring the frp from
Vibrio harveyi.
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Invitrogen

Clontech

Invitrogen

Invitrogen

This Study

Table 12. Continued
Plasmid/Strain
Designation

Relevant Genotype/ Characteristics

Source

pMaxfrp

pcDNAHISMAX vector harboring the frp gene
from V. harveyi.

This Study

pcfrpZeo

pcDNA vector harboring the frp gene from V.
harveyi.

This Study

HEK293 cell lines stably transfected with the
pCOA-I-COB plasmid and selected by G418.

Chapter 3

COA/COB2 cell line stably transfected with the
pcDNAfrp plasmid and selected by G418 and
Zeocin.

This Study

Mammalian Cell Line
Constructs
COA/COB(2)
frp (1-9)
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Construction of a Mammalian Expression System for frp
To generate a strain to overexpress the flavin oxidoreductase enzyme in
mammalian cells, the frp gene was amplified from V. harveyi strain VHU08996 DNA.
The gene was then TA TOPO cloned into the pCR4-TOPO cloning vector according to
the manufacturer’s instructions to generate pCR4frp (Invitrogen Corporation, Carlsbad,
CA) and subsequently cut and ligated into the pcDNAHISMAX mammalian expression
vector using introduced unique 5`BamHI and 3` NotI restriction sites to generate
pMaxfrp (Figure 34A) (Invitrogen Corporation, Carlsbad, CA). This expression vector
possesses an SPC163 untranslated sequence upstream of the gene insert. This sequence
has been shown to enhance translation between four and five fold over expression
without the enhancer.
A second plasmid was generated to express the frp gene from V. harveyi by
cloning the gene via the introduced unique 5`BamHI and 3`NotI restriction sites into the
pcDNA3.1Zeo mammalian expression vector to generate pcfrpZeo (Figure 34B).

Ligation Reactions
Plasmid vectors and inserts were digested (2-6 h) with the appropriate enzymes
(Promega Corporation, Madison, WI). Linearized vectors were dephosphorylated using
a calf alkaline phosphatase enzyme according to the manufacturer’s instructions
(Promega Corporation, Madison, WI). Both vector and insert DNA were gel purified
from 1% agarose gels using the Geneclean gel extraction kit (Bio101, Carlsbad, CA).
The recovered DNA was then quantified using the Dyna Quant 200 fluorometer (Hoefer
Pharmacia Biotech Incorporated, San Francisco, CA) and ligations were set
147

Figure 34. Schematic diagram of the expression vectors used to express the flavin
oxidoreductase enzyme (frp) from V. harveyi in mammalian cells. A.
Expression in the pcDNAHISMAX that provides an SPC163 translational
enhancer region for enhanced translation and protein expression driven from
a constitutive CMV promoter region. B. Expression in the pcDNA3.1Zeo
provides high constitutive expression from a CMV promoter.
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up as 20µl reactions using a 3:1 molar ratio of insert to vector DNA. The ligation
reactions were then incubated at 17ºC overnight.

Electroporation
Electrocompetent cells were prepared as outlined by the manufacturer (BTX,
San Diego, CA). Electroporations were performed using the BTX Electroporator 600
with the following conditions: 40µl cells, 1-2µl ligation mixture, a 2.5kV pulse for 4.7
ms using a 2 mm gap cuvette. After the pulse, cells were immediately resuspended in 1
ml of sterile LB and allowed to recover for 1 h at 37ºC (200 rpm). Cells were then
plated on selective media containing the appropriate antibiotic.

Selection of Bacterial Clones
Resistant colonies were picked after 24 h and expanded to patches on grid
plates. To test for proper insert presence and orientation, rapid boil mini-preps were
done followed by the digestion of the plasmid with the appropriate restriction enzymes
according to the manufacturer’s instructions (Promega Corporation, Madison, WI).
Digestions products were run on 1% agarose gels to determine if the banding pattern
indicated the insert presence and proper orientation. Upon identification of correct
clones, the plasmids were further purified using the Wizard midiprep plasmid
purification system according to the manufacturer’s protocol (Promega Corporation,
Madison, WI) and sequenced.
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Sequencing
All constructs were sequenced to ensure their integrity. Sequencing was done in
the University of Tennessee Molecular Biology Service Facility using an Applied
Biosystems 3100 Genetic Analyzer sequencer (Foster City, CA).

Transfection of Mammalian Cells
Transfection of mammalian cell lines was done in six well poly-D-lysine coated
tissue culture plates (Fisher Scientific, Pittsburgh, PA). Cells were split from stock
cultures and inoculated into each well at approximately 1 X 105 cells per well in
complete growth media. The plate was then placed at 37ºC in a 5% CO2 atmosphere for
1-2 days until the cells became 80-90% confluent. The day of transfection, the media
was refreshed. DNA for transfections was purified from 100ml overnight E. coli
cultures using the Wizard Purefection plasmid purification kit to remove endotoxins
according to the manufacturer’s instructions (Promega Corporation, Madison, WI). For
chromosomal integration, the plasmid DNA was linearized before transfection to
increase proper integration.
HEK293 Cells
Purified plasmid DNA (3.2µg) was mixed into 200µl of serum free DMEM in a
1.5 ml tube. In a second tube, 8µl of Lipofectamine 2000 reagent (Invitrogen
Corporation, Carlsbad, CA) was added to a 200µl of serum free DMEM. The
lipofectamine mixture was added to the DNA mixture within 5 min and incubated at
room temperature for 20 min. The entire mixture (400µl total) was added directly to the
appropriate well on the plate and rocked back and forth to ensure adequate mixing.
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Twenty-four hours post transfection, the complexes were removed and the media was
replaced with fresh complete growth media supplemented with the appropriate
antibiotic for selection of the two co-transfected plasmids.

Selection of Mammalian Cell Clones
Twenty-four hours post transfection, selective media was added to all wells and
refreshed every three to four days. Because these transfections were conducted on a
cell line that already harbored a Neomycin G418 resistance plasmid, the G418 was
added at a concentration to maintain the plasmid and Zeocin was added to select for the
second plasmid. When the COA/COB2 clone was co-transfected with the pMaxfrp,
resistant clones never appeared within the transfected wells. Therefore, the pcfrp clone
was generated to determine if the overexpression of the gene was causing a lethal
product for the cells. Within two weeks after co-transfection with this plasmid
construct, all control wells were dead and the transfected cells were forming small
colonies on the plate surface. Colonies were separated from the rest of the well by
placing a sterile chamber around the cell mass and sealing it with silicon (Fisher
Scientific, Pittsburgh, PA). The media could then be removed and each colony could be
trypsinized and transferred to individual tissue culture flasks. To accomplish this, after
washing with a PBS solution, 200µl of a 1X Trypsin-EDTA solution (Sigma Aldrich,
St. Louis, MO) was added directly to the chamber and incubated at 37°C for 3 to 5 min.
The trypsin-EDTA solution was then replaced with complete growth media and the
cells were transferred to a 25cm2 tissue culture flask for propagation. Each clone was
given a number and expanded to individual cell lines. Each line was split and
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maintained as described earlier with the addition of selective media. Nine cell lines
were propagated in this manner.

In Vitro Bioluminescence Assays
To evaluate the bioluminescence potential from each cell line clone, total
proteins were extracted and in vitro enzyme (bioluminescence) assays were performed.
To extract the proteins, the cells were first trypsinized from the plate or flask surface
and resuspended into 2.0 ml Sarstedt tubes (Fisher Scientific, Pittsburgh, PA). The cells
were then spun down and washed two times in sterile phosphate buffered saline (PBS)
to remove any residual media (Sigma Aldrich, St. Louis, MO). Cell pellets were then
resuspended into 1 ml 0.1M potassium phosphate buffered pH 7.8 and disrupted by
three consecutive cycles of freeze (30 s liquid N2) thaw (5 min at 37ºC) extraction.
After disruption, the cell debris was pelleted by spinning the samples at 14,000 X g for
5 min and the supernatant was used in the bioluminescence assay. To determine light
intensity, the protein extract was mixed with 0.1mM NAD(P)H, 4µM FMN, 0.2% (w/v)
BSA, 0.002% (w/v) n-decanal. Bioluminescence was measured using the FB14
luminometer (Zylux Corporation, Pforzheim, Germany) at a 1 s integration and reported
as relative light units (RLU). To evaluate the limitation of FMNH2 for the
bioluminescence reaction, a flavin oxidoreductase enzyme (1U) isolated and purified
from V. harveyi (Roche Scientific, Indianapolis, IN) was added to the mixture and light
levels were measured again for comparison.
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Bioluminescence levels were determined by taking measurements from triplicate
35 cm2 wells and recording the values as relative light units (RLU) using a 1 s
integration time.

Whole Cell Bioluminescence Assays
To evaluate the bioluminescence levels from intact cells, the adherent cell lines
were first trypsinized from the flask or plate surface and resuspended in 2.0 ml
Sardstedt tubes (Fisher Scientific, Pittsburgh, PA). The cells were then spun down and
washed two times in sterile phosphate buffered saline (PBS) to remove any residual
media (Sigma Aldrich, St. Louis, MO). Cell pellets were resuspended into 1 ml 0.1M
potassium phosphate (pH 7.8). The cells were then mixed 1:1 volume of the enzyme
mix that consisted of: 0.2% BSA and 0.002% (w/v) n-decanal. Bioluminescence was
measured immediately using the FB14 luminometer (Zylux Corporation, Pforzheim,
Germany) at a 1 s integration and reported as relative light units (RLU).
Bioluminescence levels were normalized between samples and cell lines by
dividing the RLU measurement by the number of cells in the assay and reporting the
bioluminescence as relative light units (RLU) per 1 X 105 cells. The total cell count
was determined by direct counting the samples by standard methods. The cells were
first mixed with a Trypan Blue stain (Sigma Aldrich, St. Louis, MO) and individual
cells were counted under light microscopy with a hemocytometer.
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Stability of the Bacterial Luciferase Constructs
In order to determine the overall stability of the HEK293 cell line clones
expressing the bacterial luciferase genes, each line was grown in culture for > 40
passages in the presence and absence of antibiotic selection. Cell extract
bioluminescence measurements were taken every fifth passage to compare light levels
over time.

Statistics
Statistical analysis of the data presented here was conducted using either the
JMP (SAS Institute, Incorporated, Pacific Grove, CA) or Microsoft Excel (Microsoft,
Seattle, WA) statistical software packages. Graphs were made using Sigma Plot
software (SPSS, SAS Institute, Incorporated, Pacific Grove, CA) or Microsoft Excel
(Microsoft, Seattle, WA). All error bars on graphs indicate one standard deviation of
the mean. Significant differences were determined using either t-test or 1 way ANOVA
analysis at a level of α=0.05. Statistically different groups were indicated on graphs by
letter.

Results
Evaluation of FMNH2 Bioavailability in Mammalian Cells
To determine the overall bioavailability of the FMNH2 substrate in mammalian
cells, bioluminescence assays were performed and light measurements were taken
before and after the addition of a purified flavin oxidoreductase enzyme. This enzyme
in the presence of FMN and NAD(P)H reduces the FMN to the required FMNH2 for the
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reaction. Bioluminescence levels from each of the cell line clones increased at least an
order of magnitude after the addition of FMNH2 (Figure 35, maroon bars). These data
illustrated that FMNH2 was extremely limiting for the bioluminescence reaction from
these engineered human cell lines. However, in every case, the clones harboring the
luxA and luxB genes alone were able to produce bioluminescence levels above
background without the addition of the flavin oxidoreductase enzyme indicating that
some FMNH2 was available within the cells for the reaction (Figure 35, blue bars).
Nevertheless, to achieve optimal bioluminescence values and generate a useful
bioreporter, the lack of available FMNH2 within mammalian cells needs to be
addressed.

Expression of the Flavin Oxidoreductase Enzyme
In an attempt to overcome this limitation, the COA/COB2 clone (brightest
clone) was co-transfected with an frp gene that was isolated from V. harveyi and cloned
into a mammalian expression vector containing a translational enhancer region
upstream of the multi-cloning site. Unfortunately, when COA/COB2 clones were cotransfected with this plasmid, the HEK293 cells were not able to survive and as a result
no clones were obtained from this construct. As an alternative approach, the frp gene
was cloned into and expressed constitutively from the pcDNA3.1Zeo vector that allows
for high constitutive expression but does not contain the SPC163 enhancer region. Nine
stable cell line clones were obtained by resistance to toxic concentrations of both
Neomycin G418 and Zeocin antibiotics simultaneously. Resultant clones were
expanded to individual cell lines and tested for bioluminescence potential.
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Figure 35. Bioluminescence levels (RLU) from stable HEK293 clones before (blue bars) and after
(maroon bars) the addition of FMNH2.
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Bioluminescence levels were evaluated from total cell protein extracts and in whole
cell bioluminescence assays.

In Vitro Bioluminescence Assays
From in vitro bioluminescence assays (total protein extracts), the overall light
levels increased with the expression of the frp gene at least an order of magnitude in
both the absence and after the addition of exogenous flavin oxidoreductase versus the
COA/COB2 clone without the frp gene tested under the same conditions (Figure 36).
These data indicated that the expression of the frp gene was successful in producing an
excess of available FMNH2 within HEK293 cells. The further increase in
bioluminescence after the exogenous addition of the purified oxidoreductase enzyme
however, indicates that the system has yet to reach saturation.
The bioluminescence levels obtained from the cell extract, in vitro, assays
remained stable for several minutes before gradually declining to background levels.
The light intensity could be increased back to peak levels upon exogenous addition of
additional NAD(P)H to provide the reducing power for the flavin oxidoreductase
enzyme and generate more FMNH2. Thus the luciferase complex itself remained stable
throughout the assay and bioluminescence levels were correlated to availability or
decay of reduced FMN.

Whole Cell Bioluminescence Assays
Whole cell bioluminescence assays were performed to determine if these cell
lines could produce adequate bioluminescence levels for use in gene expression
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analysis, much in the same way that firefly luciferase (Luc) is currently used today in
several reporter applications. Average bioluminescence levels from the COA/COB2
clone were obtained that were at least two orders of magnitude greater than background
levels (4 X 104 RLU/s versus 380 RLU/s). The bioluminescence was further increased
at least another order of magnitude when the frp gene was co-expressed along with the
luciferase genes. All clones co-transfected to express the frp gene produced
significantly more light than without the enzyme being expressed (p<0.05).
Furthermore, there were significant differences between the nine frp clones as well
(Figure 37). However, unlike the relatively stable nature of the bioluminescence signal
from in vitro bioluminescence assays, the light levels from these whole cell clones
resulted in a flash bioluminescent response. The maximum light output was obtained
within 1 s of n-decanal addition and returned to background levels within five seconds.
These levels could not be induced with the further addition of n-decanal or FMNH2 to
achieve a second peak in bioluminescent activity.

In Vitro versus In Vivo Light Measurements
To better determine cytoplasmic concentrations of FMNH2, whole cell
bioluminescence measurements were compared to levels obtained from in vitro assays.
In the whole cell assays, the light levels were obtained immediately upon the addition of
n-decanal and recorded as relative light units (RLU) for 1 X 106 cells. The cells were
then lysed and bioluminescence was remeasured upon the addition of n-decanal and
FMNH2. The cell number was determined by direct counting. Overall, the light levels
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measurements were taken from triplicate 35cm2 wells.
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10
9

from whole cells were much lower (as much as 20 fold) than those obtained from
protein extracts (Table 13).

Stability of Bacterial Luciferase in Mammalian Cells Over Long Periods of Time
The stability of mammalian cell lines engineered to stably express the bacterial
luciferase genes was monitored by performing bioluminescence assays over time. The
bioluminescence levels remained relatively constant for forty passages, for every clone
except WTA/WTB2 where the level radically deteriorated after passage thirty (Figure
38). Although the light levels for the other clones remained relatively stable during this
time, other phenotypic changes occurred within the cells, including a lower binding
affinity to the flask surface.

Discussion
The expression of the bacterial luciferase enzyme system in eukaryotic cells has
long been desired. Unfortunately, several obstacles have been encountered that resulted
in only modest success when trying to employ this technology in eukaryotes. Among
the problems associated with the ultimate development of this technology, the lack of
available FMNH2, the reduced flavin molecule that is required for the bioluminescence
reaction is perhaps one of the most obvious. The FMNH2 limitation in mammalian
cells engineered with the luxA and luxB genes was shown to hamper potential light
outputs significantly (Figure 35). These data clearly showed that light levels were
significantly enhanced upon the exogenous addition of a flavin reductase enzyme.
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Table 13. Bioluminescence levels from HEK293 cells engineered to express luxA and
luxB genes with and without the co-expression of the flavin oxidoreductase
(frp) enzyme. Each bioluminescence measurement was made in triplicate
from approximately 1 X 106 cells and reported as relative light units (RLU).

In Vitro

In Vitro

Clone

Whole Cell
Assay

(without FMNH2)

(with FMNH2)

COA/COB2

4.3 X 104
(±7,913)

2.5 X 105
(±31,201)

6.77 X 106
(±170,098)

frp1

2.75 X 105
(±68,373)

2.42 X 106
(±161,278)

22.8 X 106
(±4,078,998)

frp2

3.06 X 105
(±16,526)

2.50 X 106
(±98,006)

31.0 X 106
(±3,909,260)

frp3

3.27 X 105
(±36,193)

2.46 X 106
(±101,456)

28.0 X 106
(±4,433,714)

frp4

2.5 X 105
(±23,355)

4.46 X 106
(±457,293)

33.4 X 106
(±5,975,079)

frp5

1.22 X 105
(±21,595)

7.86 X 105
(±36,862)

12.74 X 106
(±1,518,130)

frp6

1.37 X 105
(±9,004)

1.74 X 106
(±112,367)

12.96 X 106
(±912,574)

frp7

2.66 X 105
(±21,971)

3.65 X 106
(±346,997)

28.4 X 106
(±2,864,018)

frp8

3.62 X 105
(±16,907)

3.47 X 106
(±440,620)

18.02 X 106
(±2,286,558)

frp9

1.54 X 105
(±10,151)

5.64 X 106
(±381,295)

28.56 X 106
(±197,408)
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Therefore, efforts were explored to overcome the FMNH2 limitation by
attempting to express the reductase enzyme in vivo to provide adequate levels of this
substrate.
Recently, this approach was taken in yeast cells by the overexpression of an
NAD(P)H –dependent FMN reductase enzyme from V. harveyi (Gupta et al., 2003 and
Szittner et al., 2003). In these studies, the bioluminescence levels from whole yeast
cells were significantly increased by the expression of the frp gene. These data
illustrated that the limiting substrate in yeast was indeed a lack of the reduced FMNH2
and that the FMN and NAD(P)H precursors were available within cytoplasm of yeast
cells. Based on these results, it was hypothesized that the overexpression of the frp gene
in mammalian cells may also provide adequate pools of FMNH2 to catalyze
bioluminescence. Therefore, HEK293 cells harboring a codon optimized luxA and luxB
gene pair were co-transfected with the frp gene and stable cell lines obtained.
From in vitro bioluminescence assays of clones expressing frp, the overall light
levels increased at least an order of magnitude in both the absence and after the addition
of exogenous flavin oxidoreductase versus the COA/COB2 clone without the frp gene,
tested under the same conditions (Figure 36). These data indicated that the expression
of the frp gene was successful in producing higher concentrations of FMNH2 within
HEK293 cells. However, because the light levels increased further upon the addition of
exogenous flavin oxidoreductase, it was determined that FMNH2 remains the limiting
factor for the bioluminescence potential from these mammalian cells and has yet to
reach saturation.
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Furthermore, it is believed that much of the available FMNH2 within
mammalian cells would be found at much higher concentrations within the
mitochondria of the cell. As a result, the FMNH2 would remain sequestered from the
bioluminescence (Lux) proteins within the cytoplasm and not available for the reaction.
By monitoring light levels as total protein extracts, the location of available FMNH2
within the cytoplasm is unknown. To better determine cytoplasmic concentrations of
FMNH2, whole cell bioluminescence assays were performed. Overall, the light levels
from whole cells were much lower (as much as 20 fold) than those obtained from
protein extracts (Table 13). These data indicate that the cytoplasmic concentrations of
FMNH2 are limiting and that much of the cellular pool of the reduced flavin molecule is
compartmentalized within organelles, like the mitochondria. Therefore, future
experiments should be conducted to allow for the expression of the Lux proteins in the
mitochondria of the cell to allow for their interaction with other necessary substrates for
the reaction. Targeting of the Lux proteins can be easily accomplished with the
addition of a signaling peptide on the N- terminus of the proteins that will shuttle the
enzymes into the mitochondria of the cell.
The bioluminescence levels obtained from the cell extract, in vitro, assays
remained stable for several minutes before gradually declining to background levels.
The light intensity could be increased back to peak levels upon exogenous addition of
additional NAD(P)H to provide the reducing power for the flavin oxidoreductase
enzyme and generate more FMNH2. Thus, the luciferase complex itself remained stable
throughout the assay and the light output was directly correlated to the available
FMNH2. On the other hand, the whole cell in vivo assays provided a flash
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luminescence response that could not be induced further to give a second peak upon the
addition of n-decanal or FMNH2. These data indicate that the n-decanal substrate was
toxic to the cells. Once the cells were lysed and proteins extracted, high
bioluminescence levels could be obtained upon the addition of n-decanal and FMNH2.
These data further support the idea that the addition of n-decanal to whole cells resulted
in cell mortality and not the loss of stable Lux proteins.
The stability of mammalian cell lines engineered to express the bacterial
luciferase genes was monitored to determine if the constructs could maintain their
bioluminescence levels over time in the absence of antibiotics. Although the
bioluminescence outputs remained relatively constant for > 40 passages, one of the
clones (WTA/WTB2) bioluminescence levels radically deteriorated after passage thirty
(Figure 38). Furthermore, during this culture period, other phenotypic changes occurred
within the cells, including a lower binding affinity to the flask surface. It was further
determined that the loss of light from the WTA/WTB2 clone was not a result of the loss
of the genes within the cells and perhaps a change in the cell’s physiology or some
unknown regulatory mechanism that caused the loss of light. Even though the
WTA/WTB2 clone resulted in a complete loss of bioluminescence activity, PCR
analysis revealed that the luxA and luxB genes were still present. Nevertheless, the
bioluminescence levels did remain stable for more than five months in culture without
the need for antibiotic selection, indicating that these cell lines would be stable enough
for relatively long term monitoring projects and applications as long as the proper
control experiments were also included.
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CHAPTER 5
SUMMARY AND CONCLUSIONS
This investigation achieved optimized expression of the bacterial
luciferase enzyme in mammalian cells. Previous attempts to express this
heterodimeric enzyme complex in mammalian cells have been met with only
modest success. In this research effort, several vector formats were evaluated and a
novel approach to codon optimize the genes was performed. Additionally, the
limited availability of the FMNH2 substrate was evaluated and steps were taken to
overcome this limitation. The overall stability of the engineered cells was also
assessed to determine the persistence of the reporter for long-term monitoring
applications. Based on the findings of this study, the following conclusions were
drawn:

•

A translational fusion of the two luciferase subunits is not an efficient way to
express this enzyme in eukaryotes likely due to thermal instability and the
inability of the subunits to properly fold forming an active heterodimer.

•

Integrated expression of the luciferase provides a more stable expression
format for long-term persistence of the luciferase genes.
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•

The bacterial luciferase enzyme produced optimal bioluminescence in
mammalian cells when the individual genes were expressed as a bicistronic
transcript fused with an internal ribosomal entry site (IRES).

•

Codon optimization of the luxA and luxB genes significantly increased the
translation efficiency of the proteins in vitro and in vivo when expressed in
HEK293 cells. This increase in translation in turn resulted in significant
increases in bioluminescence output from the cells.

•

FMNH2 is a limiting substrate for the bioluminescence reaction in
mammalian cells.

•

The expression of a flavin oxidoreductase gene in HEK293 provides
additional FMNH2 for the bioluminescence reaction. However, this
substrate remains limiting for the reaction.

•

The available FMNH2 within mammalian cells may be compartmentalized in
organelles and not readily available to interact with the luciferase enzyme.

•

The expression of the bacterial luciferase genes in HEK293 cells remains
relatively stable for more than 40 passages (5 months) in culture without the
selective pressure of an antibiotic.
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Determining an Optimal Expression Format for Expression of the Bacterial
Luciferase Genes (luxA and luxB)
As a first attempt to express the bacterial luciferase enzyme in mammalian cells,
a LuxAB fusion protein was designed. Previous work by Escher et al. (1989) showed
that the luxAB fusion, using genes from Vibrio harveyi, was stable at elevated
temperatures if initially expressed in E. coli at 23°C. However, when the fused protein
was grown and expressed at 37°C there was a greater than 99% reduction in light.
These data suggest that the fused luxAB does not fold properly at elevated temperatures.
The luciferase from P. luminescens has a higher thermal stability (t1/2 >3 h at 45°C) than
V. harveyi (t1/2 5 min. at 45°C) (Meighen, 1991). Therefore, a translational fusion of
the P. luminescens luxA and luxB genes was generated in this work and evaluated.
Although the luxAB fusion was functional in E. coli, bioluminescence activity was
significantly reduced (70%) compared to the wild type unfused genes. In the unfused
luxAB the α and β subunits are individually translated and are free to fold into their
specific conformation (Tu and Mager, 1995). Therefore, the reduction in
bioluminescence may be due to steric hindrance involved in the way the subunits form
the heterodimer when expressed as a protein monomer.
The addition of a Kozak sequence further reduced the bioluminescence level to
approximately 5% of the wild type protein. Nevertheless, the Kazak sequence is a
mammalian ribosomal binding site and therefore to evaluate its true effectiveness the
construct was tested in HEK293 cells. The light levels were significantly reduced
(>90%) compared to HEK293 cells expressing the fusion protein without the Kazak
modifications. The addition of a Kozak sequence (G at the +4 position) specifically
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changes the second amino acid of luxA from Lysine to Glutamic acid. These two amino
acids have opposite net charges, which could result in a modification of the protein's
secondary structure ultimately altering the protein's function resulting in decreased
bioluminescence. Therefore, future studies were conducted in the absence of the Kazak
sequence or with the addition of an external Kazak for ribosomal binding.
To determine temperature effect on the folding of the fusion protein, the fused
and unfused versions of the luxAB were grown at 23˚C, 30˚C and 37˚C. In E. coli, there
was not a statistical difference (p = 0.05) associated with temperature on
bioluminescence as seen by Escher et al. (1989). This suggested and led us to believe
that the folding problems in the V. harveyi LuxAB fusion protein were not present in the
P. luminescens LuxAB fusion protein. However, when the fusion construct was
expressed in the yeast, S. cerevisiae the bioluminescence levels significantly decreased
as temperature increased to 37˚C. The differences seen in these two systems may be a
result of the bacterial system’s ability to transcribe the luxB independently due to the
ribosomal binding site and luxB start codon still present in the fusion. When the fusion
is expressed in the yeast system, the luxB is no longer independently expressed resulting
in a true fusion protein that is unable to properly fold at 37˚C. The independent
expression of the luxB in bacteria may have resulted in the unfused LuxB subunit
forming the heterodimeric conformation with the LuxA within the LuxAB fusion
resulting in the unaffected bioluminescence observed when the construct was expressed
in E. coli.
In an attempt to mimic mammalian translation machinery, in vitro transcription
and translation of the luxA, luxB and luxAB fusion were performed in a rabbit
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reticulocyte lysate system. Although the 77kDa fusion protein was easily detected, the
individual proteins, LuxA and LuxB, were not. This result was unexpected because
equal amounts of RNA transcript were added to each translation reaction. These data
suggest that the formation of the heterodimeric (α and β subunit) complex may be
required for not only efficient bioluminescence activity, but also for the overall stability
of the protein.
Although detectable amounts of bioluminescence were obtained from
mammalian cell lines harboring the LuxAB fusion protein, these levels were not
sufficient for the creation of a reliable biosensor. Therefore, other expression formats
were evaluated in an attempt to optimize bioluminescence activity. It was thought that
by expressing the lux genes separately, the subunits would be able to form a more
natural heterodimeric conformation. Human embryonic kidney cells (HEK293) were
used for these evaluations. Cells were transfected with a dual promoter vector construct
that that was developed to constitutively express each gene from a separate promoter or
co-transfected with two plasmids each harboring either the luxA or luxB gene.
Furthermore, to evaluate the differences in protein expression from genes integrated in
the host’s chromosome versus those constructs maintained as episomal plasmids, each
expression format (fusion, dual promoter and co-transfection) was constructed on a
plasmid backbone able to replicate episomally in HEK cells. The bioluminescence
levels from stable cell lines harboring each expression variation were determined.
Although there were slight variations in activity, the differences were not statistically
significant (p=0.05). The only exception was the reduced bioluminescence activity
obtained from cells harboring a dual promoter vector episomally. The low light levels
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from these clones were somewhat surprising considering that the average
bioluminescence from the fusion protein and from cells co-transfected with two
plasmids were slightly higher when the constructs were maintained as episomes. Upon
further analysis, it was determined that the mRNA levels from the individual lux genes
were not equal and therefore in this expression format, one promoter is inducing
transcription at a higher rate than the other. This type of promoter occlusion where the
transcription of one of the two promoters was significantly dampened has been seen
previously (Horlick et al., 2000). The unequal availability of one of the lux subunits at
a level higher than the other, may prevent the proper formation of the heterodimeric
active luciferase protein and may result in inactive homodimer formation.
In order for bacterial lux-based mammalian bioreporter to be useful, the
constructs need to remain stable in the absence of antibiotic selection for long periods of
time. Efficient maintenance and stability of foreign genes requires that the DNA
replicate once per cell cycle and be retained (integrated or episomally) in the nucleus.
Constructs harboring the luxA and luxB genes in three individual expression formats
were created on both the traditional integration vectors and on Epstein-Barr virus (ori-P)
based episomal plasmid vectors. To determine the stability of these constructs in
HEK293 cells, the cell line clones were grown for twenty passages in complete growth
media without antibiotic.

In general, all clones (chromosomal and episomal) were

stable for at least five passages after the antibiotic removal. However, the constructs
that were maintained as episomes began to lose bioluminescence activity by passage ten
with episomal co-transfected cells resulting in the fastest bioluminescence decline rate.
Although there was a significant decline in bioluminescence activity from episomally
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based constructs over time, the light was not completely lost from any of the cells lines.
Therefore, this reduction in bioluminescence may be the result of natural plasmid loss
and generation of a plasmid equilibrium within the cells. Immediately following
transfection the DNA molecules within each cell can be very high and a natural decline
in this concentration occurs to a steady state for plasmid maintenance (Middleton and
Sugen, 1994 and Horlick et al.,1997). This number can vary, but the average is between
50 and 100 copies per cell with the further loss of approximately 5% per generation in
the absence of selection (Yates and Guan, 1991). The constructs that were integrated
into the host’s chromosome remained relatively stable throughout the twenty passages
(approximately 2.5 months) evaluation. These data indicate that integration of the lux
genes within the host’s chromosome may be the most suitable way to express the genes
in mammalian cells for long-term gene maintenance and stable bioluminescence
activity.
In order to optimize the bioluminescence potential from mammalian cells the lux
genes need to be processed and expressed much in the way they are in bacteria. To
establish a more natural expression format for the heterodimeric luciferase protein, the
luxA and luxB genes were cloned into a bicistronic mammalian expression vector. This
vector was developed to allow for the expression of two genes of interest under the
control of a single constitutive promoter with the use of an internal ribosomal entry site
(IRES). IRES elements can be defined as specific nucleotide sequences that allow for
ribosomal entry and translation initiation directly at the start codon (AUG) rather than
requiring scanning from the 5′ end, cap structure, of the mRNA (Pestova et al., 2001
and Kozak, 2001). Since the lux genes are naturally found in a polycisitronic operon, it
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was thought that by expressing the genes in this format a more natural production and
formation of the heterodimer could be obtained. From each of the stable cell line
clones obtained harboring lux genes expressed as a bicistronic transcript, the
bioluminescence (RLU/mg total protein) was at least an order of magnitude greater than
levels obtained with any of the other expression formats tested. On average, there was
no significant difference between bioluminescence levels obtained from HEK293 cells
expressing the luxAB fusion, the luxA and luxB in a dual promoter format or as cotransfected separate plasmids. However, the bioluminescence levels from HEK293
cells harboring the luxA and luxB as a single bicistronic transcript constitutively
produced significantly higher light levels.
Based on these data it was determined that of the four expression formats
evaluated that the bicistronic expression of the luxA and luxB genes was by far the best
choice. Furthermore, although in general, the bioluminescence levels were slightly less,
the stability of the construct when integrated into the host’s chromosome makes this a
more suitable choice for the development of bacterial lux-based mammalian biosensors.
Therefore, the first hypothesis set forth in this research can be accepted which stated
that the expression of the bacterial luciferase (lux) subunits as individual proteins rather
than as a monomeric translational fusion will result in more efficient folding and
thermostability resulting in a higher bioluminescent signal in mammalian cells.
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Codon Optimization of the Bacterial Luciferase for Expression in Mammalian
Cells
Codon usage regulates gene expression at the level of translation and the usage
patterns between species are not conserved (Kurland, 1991). This is especially true
between genes derived from eukaryotes versus those from prokaryotes. Therefore, to
efficiently express the bacterial lux genes in mammalian cells, the nucleotide sequence
was altered in such a way as to create a “humanized” form of the gene without altering
the amino acid sequence. This approach has been used previously to optimize the
expression of both GFP and Renilla luciferase proteins for expression in mammalian
cells (Zhang et al., 2002 and Gruber and Wood, 2000). The design of this new
sequence was carefully determined, removing all potential splice sites and most
regulatory regions. After the final codon optimized sequence was determined, it was
evaluated using the GENSCAN prediction algorithm to determine the potential
expression efficiency in a human cell. According to the output from this program the
overall expression of the codon optimized lux genes would be significantly improved
versus the wild type. The increase in expression was predicted to be caused by an
increase in both transcription and translation efficiency. Furthermore, it was predicted
that the first sixty bases (20 amino acids) of the wild type luxA gene would be
completely eliminated when expressed in mammalian cells. Considering that this
region of the LuxA protein holds most of the catalytic properties (active site) for the
bacterial luciferase enzyme, this would be devastating for its expression. If this were
the case, the low expression levels observed for the LuxAB fusion protein, shown
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earlier, may be better explained in part by a nonfunctional protein being formed rather
than inefficient folding or heat liability.
To test the expression of the codon optimized genes, modified versions were
required. However, because the necessary changes were to numerous to achieve by site
directed mutagenesis, a complete in vitro gene synthesis protocol was pursued. Large
oligonucleotides (80-106 bp) were designed with overlapping (18-22 bp) regions. The
original plan was to amplify all of the oligonucleotides together in one PCR reaction
according to methods set by Prodromou and Pearl (1992). However, because of the
larger size of the lux genes (approximately 1000 bp each), this was not possible. As an
alternative, the gene was synthesized in parts and the subsequently linked by a second
round of PCR. The two outside oligonucleotides were used as both template and
primers for each reaction. After some experimental effort, it was determined that for
optimal amplification the internal oligonucleotides (template) should be added at a
concentration that equaled 100 fold less than the outside oligos. Amplification products
of the correct size were cloned and sequenced. Unfortunately, sequence analysis
revealed several base substitution mutations within all clones tested. These mutations
were present despite the fact that care was taken by using a Pfu polymerase that has
proof reading abilities. This finding was disappointing while not surprising given that
two consecutive PCR reactions were required to obtain the final gene product resulting
in > 60 cycles of amplification. To eliminate these errors and produce the proper
sequence, site directed mutagenesis was performed.
It was determined previously through work accomplished in S. cerevisiae and
mammalian cells for the expression of the bacterial luciferase genes that IRES elements
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may be an efficient way to express independent proteins as single bicistronic transcripts.
This expression format provides the most natural expression of the genes, most closely
mimicking the polycistronic form found in the bacterial operon. Therefore, experiments
were set up to compare the codon optimized and wild type luxA and luxB genes in
mammalian cells using an IRES based expression vector. The expression vector used
was designed to highly express two independent genes under the control of a single
constitutive encephalomyocarditis virus (ECMV) promoter region by linking two
multicloning sites fused to either side of an internal ribosomal entry site (IRES). The
IRES element allows for the translation of two consecutive open reading frames from
one messenger RNA (Jang et al., 1990; Jackson et al., 1990; Rees et al., 1996). By
constructing plasmids with different combinations of the codon optimized luxA and
luxB with their wild type counterparts, a direct comparison of the genes was made.
To quickly determine if a difference in translation efficiency could be detected
between the optimized and wild type luxA genes, in vitro transcription and translation
analysis was performed. The codon optimized luxA gene (COA) was detected
approximately twenty fold over wild type. This finding supported the results that
shown earlier with the in vitro generation of the wild type LuxA protein. Since the
rabbit reticulocyte lysate translation system is used to mimic mammalian translation
machinery in vitro, these results indicated that the codon optimization would indeed
make a significant impact on the translation efficiency of the lux proteins in mammalian
systems.
HEK293 cells were transfected with the WTA/ WTB, WTA/ COB or COA/COB
constructs and stable cell line clones were selected by antibiotic resistance. Twenty
178

stable clones for each luxA and luxB combination were selected and bioluminescence
levels were determined upon the exogenous addition of n-decanal and FMNH2. The
bioluminescence significantly increased in the order WTA/WTB < COA/WTB <
COA/COB. These data indicated that codon optimization had made a significant
impact on the potential bioluminescence levels obtained from mammalian cells. To
analyze this data further, the two or three brightest clones were chosen for further study.
From these cells, total genomic DNA, total RNA and total soluble proteins were
extracted.
Foreign gene integration in mammalian cells is a random event, therefore it is
possible to have more than one insertion of the construct occur during each transfection.
Since integration is fairly inefficient, the copy number per cell is generally very low.
However, because of this possibility, it was important to determine the copy number of
the inserted genes for at true comparison. To accomplish this, Southern blot analysis
was performed on each of the seven clones that produced the highest bioluminescence
levels. All of the cell lines tested had either one or two copies of the gene inserted with
the exception of the COA/COB3 clone which had three. To simplify further
measurements, this clone was then disregarded for further bioluminescence
comparisons. Nevertheless, it should be noted that increased copy number does not
correlate with increased expression levels. Numerous other factors have been shown to
impact from gene expression at a greater level.
The overall amount of luxA mRNA transcript was determined by Northern blot
analysis. Transcript levels were relatively equal with the exception of the WTA/WTB1
clone that produced significantly lower amounts of luxA mRNA. Since each construct
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contained the same promoter (ECMV) element and initiation signals, it would be
expected that each clone would have approximately equal amounts of transcript for the
introduced genes. However, cis acting regulatory elements could potentially interfere
with transcription initiation and overall transcript levels in vivo. These types of
interferences would vary based on where within the chromosome the genes were
integrated. Therefore, the position effect of various clones could explain the lower
amount of transcript detected with the WTA/WTB1 clone. Other factors that can
potentially impact the amount of RNA transcript would be a direct result of increased
RNA degradation of certain mRNA sequences that can occur. This type of RNA
instability would be less likely after codon optimization because of the removal of
several AU rich target degradation regions. However, because the lower amount of
transcript was not seen in both the WTA/WTB clones, this scenario is unlikely.
To evaluate the overall protein concentrations and determine translation
efficiency of each construct, Western blot analysis was performed. Total soluble
proteins from each clone were isolated and quantified. Western blot analysis was
performed using a polyclonal luxA antibody. The LuxA protein was not detectable from
WTA/WTB clones and faintly visible in the COA/WTB clones. However, large
amounts of LuxA protein were detected from the COA/COB clones which harbored a
construct carrying codon optimized versions of both genes. This finding was intriguing
and unexpected. Since the only available antibody was raised against a polypeptide of
LuxA, it was expected that the constructs harboring the COA/WTB and COA/COB
would produce equal amounts of LuxA protein. Since this was not the case, these data
indicated that the codon optimization of both genes might infer stability on the
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heterodimeric complex that makes up the luciferase enzyme. This increased stability of
the complex may have allowed the proteins to be detected in the Western blot while the
other construct was not detected.
Perhaps the most valuable measurement to determine if codon optimization was
a success is the amount of enzyme activity that could be obtained from each construct.
Bioluminescence levels were evaluated on whole cell extracts upon the addition of ndecanal and FMNH2. Average bioluminescence values were found to be greater than
two orders of magnitude higher in cell lines harboring both a codon optimized luxA and
luxB (COA/COB) over that of the cell lines harboring the wild type genes
(WTA/WTB). While bioluminescence levels were significantly higher in clones
expressing COA and WTB versus WTA and WTB, the optimal bioluminescence was
obtained from clones harboring optimized versions of both genes. These data further
support the stabilization conclusion of the heterodimeric protein. Based on these data it
was determined that codon optimization had a significant effect on the protein
expression in HEK293 cells.
In conclusion, the codon optimization of the luxA and luxB genes was
successful in increasing the overall expression levels of the individual proteins. This
increase in protein quantity resulted in a significant increase in bioluminescence from
cell lines harboring these constructs. Furthermore, the bioluminescence levels from
codon optimized luxA and luxB provide adequate bioluminescence for the proof in
principle data needed for the future development of reliable reporter constructs for
analyte sensing in mammalian cells. Based on these data, the second hypothesis
statement proposed in this research that stated that codon optimization of the bacterial
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luciferase (lux) genes will significantly enhance translation of the proteins and
ultimately result in greater bioluminescence levels from mammalian cells harboring
these optimized genes is accepted.

FMNH2 Availability
Among the problems associated with the ultimate development of a mammalian
lux bioreporter cell line, the lack of available FMNH2, the reduced flavin molecule that
is required for the bioluminescence reaction is perhaps one of the most obvious. The
FMNH2 limitation in mammalian cells engineered with the luxA and luxB genes was
shown to hamper potential light outputs significantly. These data clearly showed that
light levels were significantly enhanced upon the exogenous addition of a flavin
reductase enzyme. Therefore, efforts were explored to overcome the FMNH2 limitation
by attempting to express the reductase enzyme in vivo to provide adequate levels of this
substrate.
Recently, this approach was taken in yeast cells by the overexpression of an
NAD(P)H –dependent FMN reductase enzyme from V. harveyi (Gupta et al., 2003 an
Szittner et al., 2003). In these studies, the bioluminescence levels from whole yeast
cells were significantly increased by the expression of the frp gene. These data
illustrated that the limiting substrate in yeast was indeed a lack of the reduced FMNH2
and that the FMN and NAD(P)H precursors were available within cytoplasm of yeast
cells. Based on these results, it was hypothesized that the overexpression of the frp gene
in mammalian cells may also provide adequate pools of FMNH2 to catalyze
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bioluminescence. Therefore, HEK293 cells harboring a codon optimized luxA and luxB
gene pair were co-transfected with the frp gene and stable cell lines obtained.
From in vitro bioluminescence assays of clones expressing frp, the overall light
levels increased at least an order of magnitude in both the absence and after the addition
of exogenous flavin oxidoreductase versus the COA/COB2 clone without the frp gene,
tested under the same conditions. These data indicated that the expression of the frp
gene was successful in producing higher concentrations of FMNH2 within HEK293
cells. However, because the light levels increased further upon the addition of
exogenous flavin oxidoreductase, it was determined that FMNH2 remains the limiting
factor for the bioluminescence potential from these mammalian cells and has yet to
reach saturation. Based on these data, further experiments will be necessary to accept
or reject the third hypothesis set forth in this work, but at this point FMNH2 remains the
limiting substrate for bioluminescence.
Nevertheless, it is believed that much of the available FMNH2 within
mammalian cells would be found at much higher concentrations within the
mitochondria of the cell. As a result, the FMNH2 would remain sequestered from the
bioluminescence (Lux) proteins within the cytoplasm and not available for the reaction.
By monitoring light levels as total protein extracts, the location of available FMNH2
within the cytoplasm is unknown. To better determine cytoplasmic concentrations of
FMNH2, whole cell bioluminescence assays were performed. Overall, the light levels
from whole cells were much lower (as much as 20 fold) than those obtained from
protein extracts. These data indicate that the cytoplasmic concentrations of FMNH2 are
limiting and that much of the cellular pool of the reduced flavin molecule is
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compartmentalized within organelles, like the mitochondria. Therefore, future
experiments should be conducted to allow for the expression of the Lux proteins in the
mitochondria of the cell to allow for their interaction with other necessary substrates for
the reaction. Targeting of the Lux proteins can be easily accomplished with the
addition of a signaling peptide on the N- terminus of the proteins that will shuttle the
enzymes into the mitochondria of the cell.
The bioluminescence levels obtained from the cell extract, in vitro, assays remained
stable for several minutes before gradually declining to background levels. The light
intensity could be increased back to peak levels upon exogenous addition of additional
NAD(P)H to provide the reducing power for the flavin oxidoreductase enzyme and
generate more FMNH2. Thus, the luciferase complex itself remained stable throughout
the assay and the light output was directly correlated to the available FMNH2. On the
other hand, the whole cell in vivo assays provided a flash luminescence response that
could not be induced further to give a second peak upon the addition of n-decanal or
FMNH2. These data indicate that the n-decanal substrate was toxic to the cells. Once
the cells were lysed and proteins extracted, high bioluminescence levels could be
obtained upon the addition of n-decanal and FMNH2. These data further support the
idea that the addition of n-decanal to whole cells resulted in cell mortality and not the
loss of stable Lux proteins.

Stability of the Luciferase Constructs in Mammalian Cells
The stability of mammalian cell lines engineered to express the bacterial
luciferase genes was monitored to determine if the constructs could maintain their
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bioluminescence levels over time in the absence of antibiotics. Although the
bioluminescence outputs remained relatively constant for > 40 passages, one of the
clones (WTA/WTB2) bioluminescence levels radically deteriorated after passage thirty.
Furthermore, during this culture period, other phenotypic changes occurred within the
cells, including a lower binding affinity to the flask surface. It was further determined
that the loss of light from the WTA/WTB2 clone was not a result of the loss of the
genes within the cells and perhaps a change in the cell’s physiology or some unknown
regulatory mechanism that caused the loss of light. Even though the WTA/WTB2 clone
resulted in a complete loss of bioluminescence activity, PCR analysis revealed that the
luxA and luxB genes were still present. Nevertheless, the bioluminescence levels did
remain stable for the other five clones tested for more than five months in culture
without the need for antibiotic selection, indicating that these cell lines would be stable
enough for relatively long term monitoring projects and applications given that the
proper control experiments were also included to ensure the integrity of the reporter
strain.
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